<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">67587</article-id><article-id pub-id-type="doi">10.7554/eLife.67587</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Traumatic injury compromises nucleocytoplasmic transport and leads to TDP-43 pathology</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-228412"><name><surname>Anderson</surname><given-names>Eric N</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228413"><name><surname>Morera</surname><given-names>Andrés A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228414"><name><surname>Kour</surname><given-names>Sukhleen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228415"><name><surname>Cherry</surname><given-names>Jonathan D</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228416"><name><surname>Ramesh</surname><given-names>Nandini</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228417"><name><surname>Gleixner</surname><given-names>Amanda</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228418"><name><surname>Schwartz</surname><given-names>Jacob C</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-78154"><name><surname>Ebmeier</surname><given-names>Christopher</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7940-6190</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-78161"><name><surname>Old</surname><given-names>William</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-96258"><name><surname>Donnelly</surname><given-names>Christopher J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2383-9015</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228419"><name><surname>Cheng</surname><given-names>Jeffrey P</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228420"><name><surname>Kline</surname><given-names>Anthony E</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228421"><name><surname>Kofler</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-228422"><name><surname>Stein</surname><given-names>Thor D</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-131290"><name><surname>Pandey</surname><given-names>Udai Bhan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6267-0179</contrib-id><email>udai@pitt.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Chemistry and Biochemistry, University of Arizona</institution><addr-line><named-content content-type="city">Tucson</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Pathology and Laboratory Medicine, Boston University School of Medicine</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Boston VA Healthcare System</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Neurobiology, University of Pittsburgh School of Medicine</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>LiveLike Lou Center for ALS Research, Brain Institute, University of Pittsburgh School of Medicine</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Molecular, Cellular &amp; Developmental Biology, University of Colorado</institution><addr-line><named-content content-type="city">Boulder</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Physical Medicine &amp; Rehabilitation; Safar Center for Resuscitation Research, University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>Center for Neuroscience; Center for the Neural Basis of Cognition; Critical Care Medicine, University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution>Department of Pathology, University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution>Department of Human Genetics, University of Pittsburgh School of Public Health</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Verstreken</surname><given-names>Patrik</given-names></name><role>Reviewing Editor</role><aff><institution>KU Leuven</institution><country>Belgium</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zoghbi</surname><given-names>Huda Y</given-names></name><role>Senior Editor</role><aff><institution>Texas Children's Hospital</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic">
                <day>01</day>
                <month>06</month>
                <year>2021</year>
            </pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e67587</elocation-id><history><date date-type="received" iso-8601-date="2021-02-16"><day>16</day><month>02</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-05-14"><day>14</day><month>05</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Anderson et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Anderson et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-67587-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-67587-figures-v1.pdf"/><abstract><p>Traumatic brain injury (TBI) is a predisposing factor for many neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), Parkinson’s disease (PD), and chronic traumatic encephalopathy (CTE). Although defects in nucleocytoplasmic transport (NCT) is reported ALS and other neurodegenerative diseases, whether defects in NCT occur in TBI remains unknown. We performed proteomic analysis on <italic>Drosophila</italic> exposed to repeated TBI and identified resultant alterations in several novel molecular pathways. TBI upregulated nuclear pore complex (NPC) and nucleocytoplasmic transport (NCT) proteins as well as alter nucleoporin stability. Traumatic injury disrupted RanGAP1 and NPC protein distribution in flies and a rat model and led to coaggregation of NPC components and TDP-43. In addition, trauma-mediated NCT defects and lethality are rescued by nuclear export inhibitors. Importantly, genetic upregulation of nucleoporins in vivo and in vitro triggered TDP-43 cytoplasmic mislocalization, aggregation, and altered solubility and reduced motor function and lifespan of animals. We also found NUP62 pathology and elevated NUP62 concentrations in postmortem brain tissues of patients with mild or severe CTE as well as co-localization of NUP62 and TDP-43 in CTE. These findings indicate that TBI leads to NCT defects, which potentially mediate the TDP-43 pathology in CTE.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>neurodegeneration</kwd><kwd>amyotrophic lateral sclerosis</kwd><kwd>chronic traumatic encephalopathy</kwd><kwd>TDP-43</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>D. melanogaster</italic></kwd><kwd>Human</kwd><kwd>Rat</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>R21 AG064940</award-id><principal-award-recipient><name><surname>Donnelly</surname><given-names>Christopher J</given-names></name><name><surname>Pandey</surname><given-names>Udai Bhan</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>R01 NS081303</award-id><principal-award-recipient><name><surname>Pandey</surname><given-names>Udai Bhan</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>R21 NS098379</award-id><principal-award-recipient><name><surname>Donnelly</surname><given-names>Christopher J</given-names></name><name><surname>Pandey</surname><given-names>Udai Bhan</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>U54 NS115266</award-id><principal-award-recipient><name><surname>Stein</surname><given-names>Thor</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>R01 NS084967</award-id><principal-award-recipient><name><surname>Kline</surname><given-names>Anthony E</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>R56 NS113810</award-id><principal-award-recipient><name><surname>Kline</surname><given-names>Anthony E</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>1R00 NS082376</award-id><principal-award-recipient><name><surname>Schwartz</surname><given-names>Jacob</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012312</institution-id><institution>Robert Packard Center for ALS Research, Johns Hopkins University</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Pandey</surname><given-names>Udai Bhan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Traumatic injury leads to functional defects in nucleocytoplasmic transport and TDP-43 pathology in multiple model systems.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Traumatic brain injury (TBI) is one of the most common causes of death and disability worldwide (<xref ref-type="bibr" rid="bib101">Zaninotto et al., 2018</xref>). Indeed, secondary injuries resulting from TBI can lead to long-term neurological and neuropsychiatric sequalae, including neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) (<xref ref-type="bibr" rid="bib20">Chen et al., 2007</xref>; <xref ref-type="bibr" rid="bib74">Peters et al., 2013</xref>), Alzheimer’s disease (AD) (<xref ref-type="bibr" rid="bib56">Lye and Shores, 2000</xref>; <xref ref-type="bibr" rid="bib82">Sivanandam and Thakur, 2012</xref>), and Parkinson’s disease (<xref ref-type="bibr" rid="bib38">Goldman et al., 2006</xref>; <xref ref-type="bibr" rid="bib40">Harris et al., 2013</xref>; <xref ref-type="bibr" rid="bib89">Taylor et al., 2016</xref>). TBI is also linked with development of chronic traumatic encephalopathy (CTE), a progressive neurodegenerative syndrome associated with repeated head trauma (<xref ref-type="bibr" rid="bib19">Chauhan, 2014</xref>; <xref ref-type="bibr" rid="bib33">Gardner and Yaffe, 2015</xref>; <xref ref-type="bibr" rid="bib85">Stern et al., 2011</xref>). Postmortem brain tissues from repeated trauma patients such as CTE as well as animal models of TBI show microtubule-associated protein (TAU) and TAR DNA/RNA binding protein (TDP-43) pathology (<xref ref-type="bibr" rid="bib11">Blennow et al., 2012</xref>; <xref ref-type="bibr" rid="bib43">Huang et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Mckee et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">McKee et al., 2010</xref>; <xref ref-type="bibr" rid="bib88">Tan et al., 2018</xref>; <xref ref-type="bibr" rid="bib95">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib96">Wiesner et al., 2018</xref>). TDP-43 pathology is a hallmark of neurodegeneration and is present in ~97 % of ALS cases, ~45 % of cases with frontotemporal dementia (FTD) (<xref ref-type="bibr" rid="bib55">Ling et al., 2013</xref>), and ~60 % of AD cases (<xref ref-type="bibr" rid="bib1">Amador-Ortiz et al., 2007</xref>; <xref ref-type="bibr" rid="bib4">Arai et al., 2009</xref>; <xref ref-type="bibr" rid="bib92">Uryu et al., 2008</xref>). Despite evidence of TDP-43 pathology as a biomarker of neurodegeneration, it remains unclear how repeated trauma promotes TDP-43 proteinopathy.</p><p>TDP-43 is a predominantly nuclear DNA/RNA-binding protein that shuttles between the nucleus and cytoplasm (<xref ref-type="bibr" rid="bib6">Ayala et al., 2008</xref>). TDP-43 regulates RNA processing such as gene transcription, mRNA splicing, mRNA stability, and mRNA transport and localization, and pathological mutations disrupt RNA metabolism (<xref ref-type="bibr" rid="bib5">Arnold et al., 2013</xref>; <xref ref-type="bibr" rid="bib13">Bose et al., 2008</xref>; <xref ref-type="bibr" rid="bib15">Buratti and Baralle, 2001</xref>; <xref ref-type="bibr" rid="bib75">Polymenidou et al., 2012</xref>). In many neurodegenerative diseases, TDP-43 mislocalizes from the nucleus and aggregate in the cytoplasm of cells. Cytoplasmic TDP-43 aggregates are proposed to be an important mechanistic link to neurodegeneration because these aggregates are abnormally phosphorylated and ubiquitinated (<xref ref-type="bibr" rid="bib4">Arai et al., 2009</xref>; <xref ref-type="bibr" rid="bib3">Arai et al., 2006</xref>; <xref ref-type="bibr" rid="bib67">Neumann et al., 2006</xref>). Multiple mechanisms have been proposed to explain abnormal cytoplasmic accumulation of TDP-43 and progressive spreading of TDP-43 pathology in the context of neurodegenerative diseases.</p><p>TDP-43 contains a prion-like low complexity domain and has an intrinsically disordered region (IDR) that renders TDP-43 aggregation-prone (<xref ref-type="bibr" rid="bib16">Calabretta and Richard, 2015</xref>; <xref ref-type="bibr" rid="bib47">Johnson et al., 2009</xref>; <xref ref-type="bibr" rid="bib58">Mann et al., 2019</xref>). IDRs in RNA binding proteins (RBPs) are thought to play key roles in assembly of ribonuclear protein granules such as P-bodies, stress granules, and neuronal granules (<xref ref-type="bibr" rid="bib7">Bakthavachalu et al., 2018</xref>; <xref ref-type="bibr" rid="bib45">Jain et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Kedersha et al., 2013</xref>), suggesting that mutations or abnormal aggregation of RBPs may disrupt dynamics of these granules (<xref ref-type="bibr" rid="bib65">Molliex et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Murakami et al., 2015</xref>; <xref ref-type="bibr" rid="bib73">Patel et al., 2015</xref>). Further, IDRs in RBPs such as TDP-43 undergo liquid-liquid phase separation, and pathological mutations in TDP-43 alter liquid-liquid phase separation, which may contribute to disease processes (<xref ref-type="bibr" rid="bib25">Conicella et al., 2016</xref>; <xref ref-type="bibr" rid="bib47">Johnson et al., 2009</xref>; <xref ref-type="bibr" rid="bib59">McGurk et al., 2018</xref>). Alteration in RBPs such as TDP-43 could therefore be an important indicator of neurodegeneration. However, although these mechanisms potentially explain the role of pathological mutations of TDP-43 in the context of neurodegenerative disease, how TDP-43 aggregates form and lead to neurodegeneration in the absence of mutations, such as in the brains of repeated trauma patients, is unclear.</p><p>TDP-43 aggregates in ALS/FTD were recently reported to sequester nucleoporins, transport proteins, and other factors, suggesting that TDP-43 aggregation strongly impairs nucleocytoplasmic transport (NCT) and nucleopore complexes (<xref ref-type="bibr" rid="bib24">Chou et al., 2018</xref>). Moreover, NCT is also disrupted in AD (<xref ref-type="bibr" rid="bib30">Eftekharzadeh et al., 2018</xref>), ALS (<xref ref-type="bibr" rid="bib104">Zhang et al., 2015</xref>), and Huntington’s disease (HD) (<xref ref-type="bibr" rid="bib34">Gasset-Rosa et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Grima et al., 2017</xref>), suggesting a common dysfunctional pathway in these neurodegenerative diseases. However, the mechanism of TDP-43 pathology in neurodegeneration resulting from repeated head trauma is unknown. We previously demonstrated that repetitive trauma leads to ubiquitin, p62, and TDP-43 inclusion as well as stress granule pathology in <italic>Drosophila</italic> brains (<xref ref-type="bibr" rid="bib2">Anderson et al., 2018</xref>). Here, we performed proteomic analysis on <italic>Drosophila</italic> brains to identify the molecular pathways that were altered in response to traumatic injury.</p><p>In this manuscript, we found that repeated trauma upregulates nuclear pore proteins, alter nucleoporin stability, and NCT proteins as well as alters RanGAP1 and nucleoporins distribution, and NCT in vivo. In addition, pharmacological inhibition of nuclear export protects against TBI-mediated lethality and NCT defects. Intriguingly, upregulation of nucleoporins in vivo and in vitro leads to TDP-43 mislocalization, aggregation, phosphorylation, and alteration in solubility, and decreased motor function as well as lifespan. Our findings of NUP62 pathology and increased NUP62 concentrations in brain tissues from patients with CTE suggest that NCT defects are linked with traumatic injury, which potentially mediates TDP-43 pathology.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>TBI alters the <italic>Drosophila</italic> brain proteome, perturbs NCT proteins, and Nup protein level</title><p>To examine the mechanism of TBI, we used a well-characterized <italic>Drosophila</italic> model of TBI that exhibits robust phenotypes such as TDP-43 homolog (Tbph), p62, stress granules, and ubiquitin pathology (<xref ref-type="bibr" rid="bib2">Anderson et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Katzenberger et al., 2015</xref>; <xref ref-type="bibr" rid="bib48">Katzenberger et al., 2013</xref>) to identify and investigate changes in the brain proteome post-TBI (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). An unbiased proteomics analysis of 2000 proteins from third instar control (<italic>w<sup>1118</sup>) Drosophila</italic> larval brains exposed to repeated TBI identified 361 proteins that were significantly changed in response to traumatic injury (p ≤ 0.05, student’s T-test). Complex network analysis based on gene ontology (GO) association analysis in BiNGO (Cytoscape 3) of the TBI-associated brain proteome compared to non-TBI controls identified distinct categories of altered proteins, with the majority upregulated (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A-E</xref>; <xref ref-type="supplementary-material" rid="supp1 supp3">Supplementary files 1 and 3</xref>). Top categories that were upregulated after TBI were microtubule cytoskeleton, protein folding, and the proteasome. In addition, we also identified proteins involved in the ribonuclear protein complex and spliceosome. Components of the nuclear pore complex (NPC) and NCT pathway were a major subset of proteins upregulated post-TBI (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>). The NPC pathway has not previously been linked to trauma-mediated neurodegeneration but has been reported to be disrupted in ALS/FTD, AD, HD, and other neurodegenerative diseases (<xref ref-type="bibr" rid="bib24">Chou et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Eftekharzadeh et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Grima et al., 2017</xref>; <xref ref-type="bibr" rid="bib104">Zhang et al., 2015</xref>). Therefore, we decided to further examine the NPC alteration in mediating TDP-43 pathology in TBI.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Proteomic analysis of <italic>Drosophila</italic> brains identifies novel components of the nucleocytoplasmic transport machinery that are disrupted in response to TBI.</title><p>(<bold>A</bold>) Schematic flow of <italic>Drosophila</italic> larval brain traumatic injury, dissection, and proteomics analysis. (<bold>B</bold>) Volcano plot showing fold-change and <italic>p</italic>-values for all detected proteins (student’s t-test, assuming equal variances). (<bold>C</bold>) Heat map showing change in protein expression for 2000 detected proteins. Proteins with a significant change (p &lt; 0.05) are indicated. (<bold>D</bold>) Volcano plot showing fold change and <italic>p</italic>-values of all nucleoporins and nuclear transport proteins. Traumatic injury upregulates components of the nuclear pore and nucleocytoplasmic transport. (<bold>E</bold>) Heat map and p-values for proteins with more than ±1.4-fold change with the indicated nucleoporins. (<bold>F–I</bold>) Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) analysis of nucleoporins identified in the proteomics analysis showed significant increases in (<bold>F</bold>) <italic>Nup93-2</italic>, (<bold>G</bold>) <italic>Nup54</italic>, (<bold>H</bold>) <italic>Nup62</italic>, and (<bold>I</bold>) <italic>Nup214</italic> mRNA levels in <italic>w<sup>1118</sup> Drosophila</italic> larval brains exposed to trauma (eight hits @ 50° angle) compared to control animals (n = 3, *p &lt; 0.05, **p &lt; 0.01, ****p &lt; 0.0001). (<bold>J–L</bold>) qPCR analysis of <italic>Nup62</italic> (<bold>J</bold>, **p &lt; 0.01), <italic>Nup214</italic> (<bold>K</bold>, **p &lt; 0.01), and <italic>Nup54</italic> (<bold>L</bold>, **p &lt; 0.001) mRNA levels in adult <italic>Drosophila</italic> brains showed a significant increase in response to trauma as compared to control brains (n = 3). (<bold>M</bold>) qRT-PCR analysis of nuclear export factor <italic>Emb</italic> (exportin) mRNA post-trauma compared to non-trauma controls (n = 3, ***p &lt; 0.001). (<bold>N</bold>) Western blot of <italic>Drosophila</italic> larval brains exposed to trauma (one or eight hits @ 50° angle) and controls (0 hits) probed for Nup214 protein. <italic>Drosophila</italic> Gapdh is shown as a loading control. (<bold>O</bold>) Quantification of western blots of <italic>Drosophila</italic> Nup214 protein levels compared to controls (n = 3, **p &lt; 0.01, ***p &lt; 0.001, n.s. = not significant). (<bold>P</bold>) Western blot of Nup214 protein level in larval brains at 0, 2, 4, and 6 hr post-injury or controls. (<bold>Q</bold>) Quantification of Nup214 protein levels in larval brains of trauma and control at 0, 2, 4, and 6 hr (n = 3). (<bold>R</bold>) Western blot of Nup214 protein level in adult brains at 0, 2, 4, 24, and 72 hr post-injury or controls. (<bold>S</bold>) Quantification of Nup214 level levels in adult brains of trauma and control at 0, 2, 4, 24, and 72 hr (n = 3). All qRT-PCR and western blot analysis were done in triplicate using biological replicates. One-tailed t-test was used in panels F–L and O. One-way ANOVA with Tukey’s multiple comparisons tested was used for panel N. All quantification represents mean ± s.e.m.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Proteomic analysis of other altered proteins in response to traumatic injury.</title><p>(A–E) Volcano plots showing fold-change and p-values of altered pathways. (F) p-Values for gene ontology (GO) association of proteins detected during mass spectrometry and using the Bonferroni corrected method. Green arrow indicates GO associations for proteins with increased abundance, while red arrow indicates GO associations for proteins with decreased abundance following trauma (p &lt; 0.01, student’s T-test). (G) qRT- PCR analysis of Nup44A mRNA in brains exposed to traumatic brain injury (Trauma) and non- TBI controls (n = 3, *p &lt; 0.05). (H) qRT-PCR analysis of the microtubule binding protein Futsch in brains exposed to TBI and non-TBI controls (n = 3, n.s. = not significant).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig1-figsupp1-v1.tif"/></fig></fig-group><p>NPC is a large multi-protein complex that spans the nuclear envelope and mediates NCT. In vertebrates, NPC comprises multiple copies of ~30 proteins called nucleoporins (Nups) with highly conserved function between species (<xref ref-type="bibr" rid="bib68">Nofrini et al., 2016</xref>). Our proteomics analysis revealed that several Nups were upregulated in response to TBI in <italic>Drosophila</italic> brains (<xref ref-type="fig" rid="fig1">Figure 1D and E</xref>). Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) analysis of these Nups confirmed that TBI significantly upregulated <italic>Nup93-2</italic> (p &lt; 0.01), <italic>Nup54</italic> (p &lt; 0.001), <italic>Nup62</italic> (p &lt; 0.01), <italic>Nup44A</italic> (p &lt; 0.05), and <italic>Nup214</italic> (p &lt; 0.05) mRNA levels in <italic>Drosophila</italic> larval (<xref ref-type="fig" rid="fig1">Figure 1F–I and</xref> − <xref ref-type="fig" rid="fig1s1">Figure 1 − Figure Supplement 1G</xref>) and adult brains (<xref ref-type="fig" rid="fig1">Figure 1J–L</xref>; <italic>Nup62,</italic> p &lt; 0.01; <italic>Nup214</italic>, p &lt; 0.01; <italic>Nup54, p &lt; 0.001</italic>). In addition, mRNA levels of nuclear export gene <italic>Emb</italic> (<italic>Exportin</italic>) were significantly increased post-TBI (<xref ref-type="fig" rid="fig1">Figure 1M</xref>, p &lt; 0.001), while the microtubule-associated protein <italic>Futsch</italic> showed no change in mRNA levels compared to controls (<xref ref-type="fig" rid="fig1s1">Figure 1 − Figure Supplement 1H</xref>), consistent with proteomics analysis. Western blotting further confirmed a TBI-dependent increase in <italic>Drosophila</italic> Nup214 protein levels in larval brains (<xref ref-type="fig" rid="fig1">Figure 1N and O</xref>).</p><p>We next asked if trauma alter endogenous nucleoporin protein levels overtime. To address this, we measured Nup214 protein levels in trauma and control larval and adult brains. We performed time-course analysis on larval (0, 2, 4, and 6 hr) or adult (0, 2, 4, 24, and 72 hr) animals’ post-injury to assess Nup214 protein level by Western blot analysis. Interestingly, we found that Nup214 protein level remains upregulated in both larval and adult brains over the time point examined (<xref ref-type="fig" rid="fig1">Figure 1P,Q,R,S</xref>), suggesting that trauma probably disrupts Nup214 levels and possibly turnover in vivo.</p></sec><sec id="s2-2"><title>TBI disrupts NPC and RanGAP1 distribution and leads to TBPH/NPC coaggregation</title><p>To test whether repeated trauma disrupts NPC, we examined the distribution on the nuclear membrane of TBI <italic>Drosophila</italic> brains. Using the NPC marker Mab414, which recognizes the FG domains of several Nups including Nup62, we found a predominantly homogenous rim-like labeling of the nuclear membrane in non-TBI control <italic>Drosophila</italic> brains. NPC staining in the ventral nerve cord (VNC) in non-TBI control brains appeared distributed evenly. In contrast, nuclear membrane NPC staining in VNCs exposed to TBI was irregular and revealed a disturbed nuclear morphology. We observed gaps in the nuclear membrane and the appearance of aggregation (Mab414 clumps) in brains post-TBI (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Quantitatively, the percentage of cells with abnormal Mab414 staining was significantly higher in TBI brains than non-TBI controls (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, p &lt; 0.001), suggesting that traumatic injury disrupts NPC morphology. Next, we asked whether Tbph aggregation identified in our <italic>Drosophila</italic> larval and adult model of trauma (<xref ref-type="bibr" rid="bib2">Anderson et al., 2018</xref>) co-aggregate with NPC (Mab414). We found perinuclear and cytoplasmic coaggregation of Tbph and Mab414 in TBI-exposed VNCs, while control brains showed little to no coaggregation (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Quantification showed that the percentage of Mab414–Tbph-positive cells with coaggregation was significantly higher in TBI-exposed VNCs compared to controls (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, p &lt; 0.001).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Nuclear pore complex morphology and RanGAP1 distribution defects as well as TBPH/NPC coaggregation after traumatic injury in vivo.</title><p>(<bold>A</bold>) Immunofluorescence images of the ventral nerve cord (VNC) of trauma brain injury (Trauma) and non-TBI control <italic>w<sup>1118</sup> Drosophila</italic> larvae stained with the nuclear pore complex (NPC) marker (Mab414, red) marker and nuclei (DAPI, blue). TBI NPCs show gaps in membranes (arrows) with signs of aggregation (arrow heads). Scale bar = 15 µM. (<bold>B</bold>) Quantification of percentage of VNC cells with abnormal (Gaps and aggregation) Mab414 staining after TBI compared to non-TBI controls (n = 7–9 larval VNCs, ***p &lt; 0.001). (<bold>C</bold>) Representative images of larval VNCs in TBI and control brains stained for the <italic>Drosophila</italic> homolog of TDP-43, TAR DNA-binding protein-43 homolog (Tbph, red), and Mab414 (green), showing perinuclear as well as cytoplasmic coaggregation (arrows, yellow). Scale bar = 20 µM. (<bold>D</bold>) Percentage of cells with Tbph/Mab414 coaggregation in the VNCs of TBI and control brains (n = 8 larval VNCs, ***p&lt; 0.001). (<bold>E</bold>) Immunofluorescence of RanGAP1 (gray) and Lamin (red) in TBI and control VNCs shows aberrant RanGAP1 staining in TBI brains (intense nuclear and cytoplasmic staining, arrows). Scale bar = 15 µM. (<bold>F</bold>) Percentage of cells with abnormal RanGAP1 staining in TBI VNCs compared to controls (n = 6 larval VNCs, ***p &lt; 0.001). (<bold>G</bold>) Schematic of control cortical impact (CCI) model of TBI (adopted from <xref ref-type="bibr" rid="bib99">Xiong et al., 2013</xref>). (<bold>H</bold>) Immunohistochemical staining of RanGAP1 in rat hippocampal region (granule cell layer and subgranular zone) underlying the cortex in TBI animals or controls shows intense nuclear staining (arrow heads) and cytoplasmic aggregation (arrows). Inset box shows ×40 magnification (scale bar = 50 µM). (<bold>I</bold>) Percentage of cells with RanGAP1 pathology (cytoplasmic/nuclear aggregate or intense nuclear/cytoplasmic mislocalization) in TBI brains and controls (n = 4, **p &lt; 0. 01). (<bold>J</bold>) Immunohistochemical staining of Nup62 in rat hippocampal regions shows intense nuclear staining (arrow heads) and cytoplasmic aggregation (arrows). Inset box shows ×40 magnification (scale bar = 50 µM). (<bold>K</bold>) Percentage of cells with Nup62 pathology (cytoplasmic/nuclear aggregate or intense nuclear/cytoplasmic mislocalization) in TBI brains and controls (n = 4, **p &lt; 0.01). One-tailed t-tested was used in panel B, D, F, I, and K. Data represent mean ± s.e.m.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Repeated traumatic injury does not lead to cell death immediately following injury.</title><p>(<bold>A</bold>) TUNEL assay of apoptotic cells (green) in <italic>w<sup>1118</sup> Drosophila</italic> brains with or without trauma. Scale bar = 25 µM. (<bold>B</bold>) Quantification of TUNEL-positive cells in <italic>Drosophila</italic> brains immediately after TBI compared to non-TBI controls (n = 8, n.s. = not significant). One-tailed t-tested was used in panel B. Quantification represents± s.e.m.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>RanGAP1 and NUP62 distribution is mildly altered in the contralateral hemisphere in a CCI trauma rat model.</title><p>(<bold>A</bold>) Immunohistochemical staining of RanGAP1 in rat hippocampal region contralateral hemisphere of trauma and control (sham) animals from <xref ref-type="fig" rid="fig2">Figure 2G</xref>. Inset box corresponds to ×40 magnification. Scale bar = 50 µM. (<bold>B</bold>) Quantification of the percent of cells with RanGAP1 pathology (intense nuclear/cytoplasmic mislocalization) in trauma brains compared to controls (n = 3, n.s. = not significant). (<bold>C</bold>) Immunohistochemical staining of NUP62 in rat hippocampal region (contralateral hemisphere of control and trauma animals illustrated in <xref ref-type="fig" rid="fig2">Figure 2I</xref>) showing intense staining and aggregation. Inset box corresponds to ×40 magnification. Scale bar = 50 µM. (<bold>D</bold>) Quantification of percent of cells with NUP62 pathology (cytoplasmic/nuclear aggregation) in trauma brains cells contralateral to the site of injury compared to controls (n = 3, *p &lt; 0.05). One-tailed t-tested was used in panels B and D. Data represent mean ± s.e.m.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig2-figsupp2-v1.tif"/></fig></fig-group><p>Ran GTPase-activating protein 1 (RanGAP1), which is located on cytoplasmic filaments of the NPC, is required for Ran-dependent nuclear import and export (<xref ref-type="bibr" rid="bib10">Bischoff et al., 1995</xref>). GTP hydrolysis of Ran-GTP by RanGAP1 is essential for cargo release into the cytoplasm during nuclear export (<xref ref-type="bibr" rid="bib32">Floch et al., 2014</xref>). RanGAP1 maintains the nuclear/cytoplasmic Ran gradient, and its loss causes cell death (<xref ref-type="bibr" rid="bib41">Hetzer et al., 2002</xref>). Intriguingly, RanGAP1 gradient is disrupted in neurodegenerative diseases including ALS (<xref ref-type="bibr" rid="bib104">Zhang et al., 2015</xref>) and HD (<xref ref-type="bibr" rid="bib39">Grima et al., 2017</xref>). Therefore, we examined whether repeated trauma influences RanGAP1 distribution in the VNCs of <italic>Drosophila</italic> larvae. RanGAP1 in non-TBI control brains appeared mostly uniform in distribution within the nuclear membrane, with few cells showing intense nuclear signals. However, TBI-exposed brains had aberrant distribution of RanGAP1 staining, with intense nuclear and cytoplasmic intensity (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, arrows). The percentage of cells with abnormal RanGAP1 distribution was significantly higher in brains post-TBI compared to controls (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, p &lt; 0.001), suggesting that repeated traumatic injury disturbs RanGAP1 localization in the brain. TBI-mediated disruption in NPCs or RanGAP1 was not due to apoptosis, as TUNEL assays showed no elevation in cell death immediately after injury (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A,B</xref>).</p><p>To further determine whether RanGAP1 and Nup mislocalization and/or aggregation occurs in mammals, we assessed distribution in a control cortical impact (CCI) rat model of TBI (<xref ref-type="bibr" rid="bib99">Xiong et al., 2013</xref>; <xref ref-type="fig" rid="fig2">Figure 2G</xref>). Brain cells in hippocampal regions underlying the injured cortex (ipsilateral hemisphere) of rats with TBI exhibited either mislocalization and/or aggregation (arrows) or intense nuclear staining (arrow heads) of RanGAP1, compared to predominantly smooth perinuclear staining in sham controls (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). Quantitatively, the percentage of cells with mislocalization and/or aggregation of RanGAP1 was significantly higher in TBI brains than controls (<xref ref-type="fig" rid="fig2">Figure 2I</xref>, p &lt; 0.01). In contrast, RanGAP1 pathology in the contralateral hemisphere of trauma brains showed a mild increase that was not significant compared to controls (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A,B</xref>).</p><p>We also evaluated whether nucleoporins exhibited mislocalization and/or aggregation by staining for NUP62. Although we did not detect many instances of NUP62 aggregation, NUP62 showed dramatic cytoplasmic (arrows) and nuclear (arrow heads) mislocalization in TBI rats compared to sham controls, which showed few instances of cytoplasmic but no nuclear mislocalization (<xref ref-type="fig" rid="fig2">Figure 2J</xref>). Quantitatively, the percentage of cells with NUP62 pathology was significantly higher in TBI brains compared to sham controls (<xref ref-type="fig" rid="fig2">Figure 2K</xref>, p &lt; 0.01). Similarly, the percentage of cells with NUP62 pathology contralateral to the injury site was significantly higher in TBI brains compared to controls (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C,D</xref>, p &lt; 0.05).</p></sec><sec id="s2-3"><title>TBI-mediated NCT defects and lethality are suppressed by nuclear export inhibitors in vivo</title><p>To determine whether TBI impairs nucleocytoplasmic transport in vivo, we overexpressed a GFP protein tagged with a nuclear localization sequence (NLS) and nuclear export sequence (NES) (NLS-NES-GFP) (<xref ref-type="bibr" rid="bib51">Kusano et al., 2001</xref>) in <italic>Drosophila</italic> motor neurons (OK371-gal4). GFP signals in NLS-NES-GFP-expressing brains appeared distributed in both the nucleus and cytoplasm (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). However, quantitative analysis showed that the percentage of cells with reduced nuclear GFP signals in NLS-NES-GFP-expressing VNCs exposed to TBI was significantly increased while nuclear GFP intensity was significantly reduced (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>, p &lt; 0.001), suggesting that nuclear import of GFP was inhibited and/or nuclear export of GFP was increased. We next expressed a GFP protein tagged with an NLS and mutated NES (ΔNES) without nuclear export activity (<xref ref-type="bibr" rid="bib51">Kusano et al., 2001</xref>) in motor neurons. Brain cells of non-TBI animals expressing NLS-ΔNES-GFP showed robust GFP localization to the nucleus (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), whereas TBI animal VNCs showed significantly increased number of cells with reduced nuclear GFP (p &lt; 0.01) and decreased nuclear GFP intensity (p &lt; 0.001) (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). Together, these data strongly suggest that traumatic injury impair nuclear import.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Pharmacological suppression of nuclear export rescues trauma-mediated nucleocytoplasmic transport defects and lethality in vivo.</title><p>(<bold>A</bold>) Representative immunofluorescence images of larval ventral nerve cord (VNC) cells expressing NLS-NES-GFP or NLS-ΔNES-GFP in motor neurons (OK371-gal4) exposed to traumatic brain injury (TBI) or controls (non-TBI) were co-stained for anti-GFP (green) and nuclear envelope marker Lamin (red). Scale bar = 15 µM. (<bold>B</bold>) Percentage of cells with reduced nuclear GFP signal in animals expressing NLS-NES-GFP (n = 10–11) or NLS-ΔNES-GFP GFP (n = 6–10) exposed to TBI or non-TBI controls (**p &lt; 0.01, ***p &lt; 0.001). (<bold>C</bold>) Quantification of nuclear GFP signal intensity in TBI and non-TBI NLS-NES-GFP (n = 15) or NLS-ΔNES-GFP (n = 6) expressing animals (***p &lt; 0.001). (<bold>D, E</bold>) Quantification of eclosion assay of trauma <italic>Drosophila</italic> larvae treated with DMSO only compared to those treated with (<bold>D</bold>) KPT-350 (0.05, 0.1, or 0.5 mM) or (<bold>E</bold>) KPT-276 (50, 200, or 1000 nM). Treatment with KPT-350 or KPT-276 shows a dose-dependent rescue of trauma-mediated lethality (n = 3; *p &lt; 0.05, **p &lt; 0.01). Results indicate one-way ANOVA with Tukey’s multiple comparisons. All quantifications represent mean ± s.e.m. (n = 15 animals per experiment). (<bold>F</bold>) Representative immunofluorescence confocal images of <italic>Drosophila</italic> VNCs expressing NLS-NES-GFP or NLS-ΔNES-GFP in motor neurons exposed to TBI and fed KPT-350 (0.5 mM) or DMSO alone for 24 hr show that KPT-350 protects against trauma-mediated depletion of nuclear GFP signal. Scale bar = 15 µM. (<bold>G</bold>) Quantification of nuclear GFP signal intensity in animals expressing NLS-NES-GFP or NLS-ΔNES-GFP exposed to TBI or non-TBI controls (n = 5–6, ***p &lt; 0.001).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Pharmacological suppression of nuclear export rescues trauma mediated Tbph aggregation.</title><p>(<bold>A</bold>) Representative immunofluorescence images of <italic>w<sup>1118</sup></italic> adult <italic>Drosophila</italic> exposed to traumatic injury and treated with DMSO or KPT-350 (0.05 mM or 0.5 mM) for 10 days and untreated (no trauma control) stained with anti-Tbph (red) and Lamin (gray). Scale bar = 25 μM. (<bold>B</bold>) Quantification of Tbph puncta in the treated and untreated conditions showed significant reduction with 0.5 mM KPT-350 compared to DMSO treated animals (n = 4–5, p = 0.0142). One-way ANOVA with Tukey’s multiple comparisons tested was used for panel B.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig3-figsupp1-v1.tif"/></fig></fig-group><p>Previously, we showed that repeated trauma in <italic>Drosophila</italic> larvae leads to lethality (<xref ref-type="bibr" rid="bib2">Anderson et al., 2018</xref>). To assess whether pharmacological inhibition of trauma-mediated NCT defects protects against lethality, we fed selective inhibitors of nuclear export (SINE) compounds KPT-350 or KPT-276 to <italic>Drosophila</italic> larvae post-injury. KPT-350 and KPT-276 show neuroprotection in C9orf72 mediated ALS neurons and <italic>Drosophila</italic> models <xref ref-type="bibr" rid="bib87">Tamir et al., 2017</xref>; <xref ref-type="bibr" rid="bib104">Zhang et al., 2015</xref>; KPT-350 reduce cell death in rodent primary cortical neurons expressing HD protein <xref ref-type="bibr" rid="bib39">Grima et al., 2017</xref>; and KPT-350 protect cortical circuit function and survival of inhibitory interneurons as well as reduce TBI-induced behavioral and histological deficits in a CCI model of TBI (<xref ref-type="bibr" rid="bib17">Cantu et al., 2016</xref>; <xref ref-type="bibr" rid="bib86">Tajiri et al., 2016</xref>). <italic>Drosophila</italic> larvae were exposed to TBI and raised on either DMSO alone, KPT-350 (0.05, 0.1, or 0.5 mM), or KPT-276 (50, 200, or 1000 nM). Eclosion assays on <italic>Drosophila</italic> larvae that experienced TBI showed a significant dose-dependent suppression of lethality in animals treated with KPT-350 (<xref ref-type="fig" rid="fig3">Figure 3D</xref>, **p &lt; 0.01) or KPT-276 (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, *p &lt; 0.05, ***p &lt; 0.001). Because KPT-350 and KPT-276 rescue aberrant NCT in <italic>Drosophila</italic> models of C9 ALS/FTD (<xref ref-type="bibr" rid="bib87">Tamir et al., 2017</xref>), we examined whether administration of these compounds also protected <italic>Drosophila</italic> against TBI-mediated NCT defects. <italic>Drosophila</italic> larvae expressing NLS-NES-GFP or NLS-ΔNES-GFP in motor neurons, exposed to TBI, and fed KPT-350 (0.5 mM) for 24 hr showed strong nuclear GFP intensity compared to DMSO-treated controls (<xref ref-type="fig" rid="fig3">Figure 3F</xref>, ***p &lt; 0.001). Quantitatively, nuclear GFP signals in KPT-350-treated flies were significantly higher than DMSO-treated controls (<xref ref-type="fig" rid="fig3">Figure 3G</xref>, p &lt; 0.001). KPT-350 treatment in adult <italic>Drosophila</italic> exposed to TBI showed a dose-dependent suppression of Tbph puncta post-trauma (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A,B</xref>, p &lt; 0.05). Taken together, these results suggest that suppression of trauma mediated NCT defects and/or Tbph cytoplasmic puncta via inhibition of nuclear export correlate with increased survival.</p></sec><sec id="s2-4"><title>NUPs upregulation causes TDP-43/TBPH mislocalization and aggregation in vivo and in vitro</title><p>Upregulation of Nups in our proteomics analysis and TDP-43 aggregation post-TBI (<xref ref-type="bibr" rid="bib2">Anderson et al., 2018</xref>) prompted us to investigate whether Nup upregulation can directly lead to TDP-43 mislocalization. Previous studies report TDP-43 pathology in postmortem brain tissues of patients who experience repeated trauma (<xref ref-type="bibr" rid="bib63">Mckee et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">McKee et al., 2010</xref>) as well as in animal models of TBI (<xref ref-type="bibr" rid="bib43">Huang et al., 2017</xref>; <xref ref-type="bibr" rid="bib88">Tan et al., 2018</xref>; <xref ref-type="bibr" rid="bib96">Wiesner et al., 2018</xref>). Consistent with this, we recently showed that repeated traumatic injury in larval and adult <italic>Drosophila</italic> leads to stress granule induction, ubiquitin, p62 (Ref2(P)), and Tbph pathology (<xref ref-type="bibr" rid="bib2">Anderson et al., 2018</xref>). Moreover, TDP-43 droplets were recently shown to recruit <italic>NUP62</italic> and induce mislocalization of RanGAP1 and Nup107 (<xref ref-type="bibr" rid="bib35">Gasset-Rosa et al., 2019</xref>), suggesting that NUPs might be important modulators of TDP-43 proteinopathy. To test the impact of Nup upregulation on Tbph (<italic>Drosophila</italic> TDP-43) pathology, we generated a site-specific <italic>Nup62</italic> overexpression (Nup62 OE) fly line and stained for endogenous Tbph. The distribution of Tbph in eGFP control (henceforth referred to as control) expressing <italic>Drosophila</italic> larval VNC appeared predominantly nuclear, while Nup62 OE larval VNC had dramatically altered Tbph localization with cytoplasmic aggregation (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Quantitative analysis revealed a significant increase in Tbph puncta in Nup62 OE <italic>Drosophila</italic> larvae or adult brains compared to controls (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, p &lt; 0.001; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A,B</xref>, p &lt; 0.001). The Tbph puncta in Nup62 OE VNCs congregated with NPC/Mab414 (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). We further showed that nuclear Tbph intensity in Nup62 OE VNCs was significantly reduced compared to controls (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, p &lt; 0.01). Moreover, nuclear-cytoplasmic (N/C) fractionation further confirmed a significantly reduced Tbph N/C ratio in Nup62 OE animals compared to controls (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>, p &lt; 0.01), suggesting that <italic>Nup62</italic> upregulation alters the subcellular localization of Tbph in vivo. Mislocalization and aggregation of Tbph caused by Nup62 expression also led us to examine if Tbph solubility was affected by Nup62 expression. Soluble-insoluble fractionation of Nup62 OE or control <italic>Drosophila</italic> brains showed that upregulation of Nup62 expression in motor neurons shifted Tbph solubility by significantly increasing insolubility compared to controls (<xref ref-type="fig" rid="fig4">Figure 4F and G</xref>, p &lt; 0.01), suggesting that Nup62 levels are an important determinant of Tbph solubility. Overexpression of <italic>Nup62</italic> was confirmed by qPCR (<xref ref-type="fig" rid="fig4">Figure 4H</xref>, p &lt; 0.001).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Nup62 expression promotes TDP-43 mislocalization and aggregation in vivo and in vitro.</title><p>(<bold>A</bold>) <italic>Drosophila</italic> larval brain overexpressing Nup62 (<italic>Nup62</italic> OE) in motor neurons (Ok371-gal4) and controls (eGFP) stained for the <italic>Drosophila</italic> homolog of TDP-43, TAR DNA-binding protein-43 homolog (Tbph), and the nuclear envelope marker Lamin, showing Tbph accumulation. Scale bar = 25 µM. Zoom image represents inset box. (<bold>B</bold>) Quantification of the number of Tbph puncta in Nup62 OE flies compared to controls (n = 5–7, ***p&lt; 0.001). (<bold>C</bold>) Nuclear Tbph intensity in Nup62 OE flies compared to controls (n = 5–7 brains, **p &lt; 0.01). (<bold>D</bold>) Western blots of cytoplasmic (<bold>C</bold>) and nuclear (<bold>N</bold>) fractions from <italic>Drosophila</italic> expressing <italic>Nup62</italic> OE in motor neurons and control probed for Tbph, lamin, and tubulin. (<bold>E</bold>) Nuclear-cytoplasmic (N/C) ratio quantification of Tbph in Nup62 OE and control animals (n = 3 blots, **p &lt; 0.01). (<bold>F</bold>) Western blots of soluble (<bold>S</bold>) and insoluble (I/S) fractions <italic>Drosophila</italic> expressing <italic>Nup62</italic> OE in motor neurons and controls probed for Tbph and tubulin. (<bold>G</bold>) Percentage of Tbph solubility in Nup62 OE and control motor neurons (n = 3 blots, **p &lt; 0.01). (<bold>H</bold>) qRT-PCR analysis of <italic>Nup62</italic> mRNA in Nup62 OE animals compared to controls (n = 3, ***p &lt; 0.001). (<bold>I</bold>) Representative immunofluorescence images of human embryonic kidney 293T (HEK293T) cells transfected with mRuby alone (red) and NUP62-mRuby show endogenous TDP-43 (green) coaggregation with NUP62. NUP62-mRuby co-localizes with endogenous TDP-43 (merge, yellow). Scale bar = 25 µM. (<bold>J</bold>) Western blots of soluble and insoluble fractions from HEK293T cells transfected with mRuby alone or NUP62-mRuby probed for TDP-43 and tubulin. (<bold>K</bold>) Quantification of TDP-43 solubility in HEK293T cells transfected with mRuby alone or NUP62-mRuby (n = 3 blots, **p &lt; 0.01). (<bold>L</bold>) Representative immunofluorescence images of HEK293T cells transfected with NUP62 show phosphorylated TDP-43 accumulation (green) that co-localizes with NUP62 (merged, yellow). Scale bar = 25 µM. qRT-PCR and western blot analysis were done in triplicate using biological replicates. One-tailed t-test was used in panel B, C, E, G, H, and K. All quantification represent mean ± s.e.m.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Nup62 expression modulates TBPH and TDP-43 aggregation as well as mislocalization.</title><p>(<bold>A</bold>) Representative immunofluorescence images of adult <italic>Drosophila</italic> brain overexpressing Nup62 (Nup62 OE) in motor neurons show Tbph (red) aggregation compared to eGFP controls. Lamin was used as a nuclear envelope marker. Inset box corresponds to zoom image. Scale bar = 20 µM. (<bold>B</bold>) Quantification of Tbph puncta in Nup62 OE and eGFP control brains (n = 4, ***p &lt; 0.001). (<bold>C</bold>) Representative immunofluorescence images of CRISPR/Cas9 FLAG-tagged human wild-type TDP-43 (TDP-43<sup>WT</sup>) <italic>Drosophila</italic> larval brains overexpressing Nup62 (Nup62 OE) in motor neurons stained with anti-FLAG and DAPI. Scale bar = 20 µM. (<bold>D</bold>) Quantification of TDP-43 puncta (anti-FLAG) in control, Nup62 OE, TDP-43<sup>WT</sup>, and Nup62 OE; TDP-43<sup>WT</sup> brains (n = 3, **p &lt; 0.01). (<bold>E</bold>) Quantification of nuclear TDP-43 (anti-FLAG) intensity in TDP-43<sup>WT</sup> and Nup62 OE; TDP-43<sup>WT</sup> brains (n = 3, *p &lt; 0.05). One-way ANOVA with Tukey’s multiple comparisons test was used for panel D, and t-test was used for panel B and E. All quantifications represent mean ± s.e.m.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Expression of Nup62 but not Nup214 or Nup43 leads to NPC/TBPH coaggregation.</title><p>(<bold>A</bold>) Larval VNCs overexpressing Nup62, Nup214, or eGFP control in motor neurons stained with Tbph (red) and NPC/Mab414 (green). Tbph colocalized with NPC/Mab414 (merge) in Nup62 OE but not Nup214 animals. (<bold>B</bold>) Larval VNCs expressing HA-tagged Nup43 (Nup43 OE) or eGFP control in motor neurons stained with Tbph (red) and Anti-HA (green). Scale bar = 20 µM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Increased Nup93-2 but not Nup44A expression partially leads to TBPH mislocalization and aggregation in vivo.</title><p>(<bold>A</bold>) Larval brains expressing Nup93-2 or Nup44A and <italic>w<sup>1118</sup></italic> control stained for Tbph and the nuclear envelope marker Lamin show Tbph accumulation. Scale bar = 25 µM. Inset box corresponds with zoom image. (<bold>B</bold>) Quantification of number of Tbph puncta in Nup93-2 or Nup44A overexpressing animals compared to controls (n = 5–7, ***p &lt; 0.001, n.s. = not significant). (<bold>C</bold>) Quantification of nuclear Tbph intensity in Nup93-2 or Nup44A expressing animals compared to controls (n = 5–7, n.s. = not significant). (<bold>D</bold>) qPCR analysis of <italic>Nup44A</italic> mRNA levels in expressing animals compared to controls (***p &lt; 0.001). (<bold>E</bold>) qPCR analysis of <italic>Nup93-2</italic> mRNA levels in expressing animals compared to controls (***p &lt; 0.001). One-way ANOVA with Tukey’s multiple comparisons tested was used for panels B and C; t-test was used for panels D and E. All quantifications represent mean ± s.e.m.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig4-figsupp3-v1.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title><italic>Nup</italic>214 and <italic>Nup</italic>43 expression leads TDP-43 mislocalization and aggregation.</title><p>(<bold>A</bold>) <italic>Drosophila</italic> larval brain overexpressing Nup214 (Nup214 OE), HA-tagged Nup43 (Nup43 OE), or eGFP controls (controls) in motor neurons (OK371-gal4) stained for the Tbph (red), and the nuclear envelope marker Lamin, show Tbph accumulation. Scale bar = 20 µM. (<bold>B</bold>) Quantification of the number of Tbph puncta in Nup214 OE or Nup43 OE flies compared to controls (n = 7, ***p&lt; 0.001). (<bold>C</bold>) Western blots of cytoplasmic (<bold>C</bold>) and nuclear (<bold>N</bold>) fractions from Nup214 OE, Nup43 OE, and control motor neurons probed for Tbph, Lamin, and tubulin. (<bold>D</bold>) Nuclear-cytoplasmic (N/C) ratio quantification of Tbph in Nup214 OE, Nup43 OE and control animals (n = 3 blots, **p &lt; 0.05). (<bold>E</bold>) qRT-PCR analysis of <italic>Nup214</italic> mRNA in Nup214 OE animals compared to controls (n = 3, ***p &lt; 0.001). (<bold>F</bold>) qRT-PCR analysis of <italic>Nup43</italic> mRNA in Nup43 OE animals compared to controls (n = 3, ***p &lt; 0.001). One-way ANOVA with Tukey’s multiple comparisons tested was used for panels B and D; t-test was used for panels E and F. All quantifications represent mean ± s.e.m.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig4-figsupp4-v1.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 5.</label><caption><title>NUP54 expression does not alter TDP-43 localization.</title><p>Representative immunofluorescence images of HEK293T cells expressing HA-eGFP or NUP54-HA-EGFP and stained for endogenous TDP-43 (red). Inset box corresponds to zoom image. Scale bar = 25 µM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig4-figsupp5-v1.tif"/></fig><fig id="fig4s6" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 6.</label><caption><title>Expression of other upregulated proteins in the top five categories does not alter TDP-43 localization.</title><p>Representative immunofluorescence images of HEK293T cells expressing: (<bold>A</bold>) nucleoside diphosphate kinase 1 (NME1, green), the human homolog of <italic>Drosophila</italic> awd; (<bold>B</bold>) heat-shock protein family B (small) member 2 (HSPB2), the human homolog of <italic>Drosophila</italic> heat-shock protein 27 (HSP27); (<bold>C</bold>) peptidyl-prolyl cis-trans isomerase (FKBP1A), the human homolog of <italic>Drosophila</italic> Fkbp12; or (<bold>D</bold>) SRSF1, the human homolog of <italic>Drosophila</italic> SF2. TDP-43 (red) localization was not altered in any of these conditions. Scale bar = 15 µM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig4-figsupp6-v1.tif"/></fig></fig-group><p>We further evaluated the impact of Nup62 overexpression on human TDP-43 protein in <italic>Drosophila</italic>. We crossed Nup62 OE flies to a previously published line made using CRISPR/Cas9 genome editing that removed the endogenous Tbph gene and replaced it with FLAG-tagged wild-type human TDP43 (hTDP-43WT) (<xref ref-type="bibr" rid="bib18">Chang and Morton, 2017</xref>). FLAG staining in CRISPR hTDP-43WT control <italic>Drosophila</italic> brains appeared nuclear, with few puncta. However, Nup62 OE; CRISPR hTDP-43WT brains had significantly increased FLAG puncta (p &lt; 0.01) and reduced nuclear TDP-43 intensity (p &lt; 0.05) compared to controls (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C,D,E</xref>), further suggesting that Nup62 overexpression disrupts TDP-43 subcellular localization.</p><p>We also expressed four additional Nups that were upregulated in our proteomic analysis, EP (Enhancer-promoter) overexpression Nup93-2 and Nup44A lines, Nup214 OE, and HA-tagged Nup43 OE, to determine the contribution of other Nups on Tbph subcellular distribution. There was a significant increase in Tbph puncta in flies overexpressing Nup93-2 (p &lt; 0.001) but not Nup44A (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A,B</xref>). Further, Nup93-2 and Nup44A overexpressing flies showed a trend of decreasing nuclear Tbph intensity that was not significant (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3C</xref>). qPCR analysis validated that flies significantly overexpressed <italic>Nup93-2</italic> and <italic>Nup44A</italic> mRNA (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3D,E</xref>, p &lt; 0.001). Nup214 or Nup43 overexpression led to Tbph aggregation (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A,B</xref>, p &lt; 0.001) and decreased N/C Tbph ratio (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4C,D</xref>, p &lt; 0.05), although the Tbph aggregates in Nup214 and Nup43-expressing animals did not localize with Mab414 (<italic>Nup214</italic>) or Anti-HA (<italic>Nup43</italic>) (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A,B</xref>). qPCR analysis showed significant increase <italic>Nup214</italic> and <italic>Nup43</italic> mRNA levels (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4E,F</xref>, p &lt; 0.001). Together, these data suggest that alteration in multiple Nups may contribute to Tbph mislocalization and/or aggregation, albeit with a more pronounced effect by Nup62.</p><p>We next assessed the effects of NUP62 expression on endogenous TDP-43 localization and aggregation in human embryonic kidney cells (HEK293T). HEK293T cells were transfected with mRuby alone or mRuby tagged NUP62 (Nup62-mRuby). Expression of NUP62 in HEK293T led to aggregation of the mRuby reporter (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). FG-Nups such as NUP62, NUP214, and NUP54 are predicted to contain prion-like domain and a low complexity domain, which is suggested to mediate cytoplasmic coaggregation with the C-terminal fragment of TDP-43 (TDP-CTF) (<xref ref-type="bibr" rid="bib24">Chou et al., 2018</xref>). Interestingly, NUP62 co-aggregated with endogenous TDP-43 (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). Moreover, expression of NUP62 in HEK293T cells led to a significant shift in TDP-43 solubility compared to mRuby alone (<xref ref-type="fig" rid="fig4">Figure 4J and K</xref>, p &lt; 0.01), similar to the <italic>Drosophila</italic> Nup62 overexpression model. TDP-43 aggregates are phosphorylated and are toxic in vitro and in vivo (<xref ref-type="bibr" rid="bib4">Arai et al., 2009</xref>; <xref ref-type="bibr" rid="bib23">Choksi et al., 2014</xref>; <xref ref-type="bibr" rid="bib103">Zhang et al., 2009</xref>),. Therefore, we assessed whether NUP62-mediated TDP-43 aggregates were phosphorylated in HEK293T cells. Endogenous TDP-43 aggregates that co-localized with NUP62-mRuby were phosphorylated (<xref ref-type="fig" rid="fig4">Figure 4L</xref>), suggesting that TDP-43 aggregates might be pathological and toxic. Interestingly, expression of NUP54 in HEK293T cells did not show endogenous TDP-43 aggregation (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5</xref>), although proteomic analysis showed an increase in <italic>Drosophila</italic> Nup54 protein levels, suggesting that TDP-43 localization and/or aggregation may be influenced by a subset of Nups, specifically NUP62. Expression of human NME1 [<italic>Drosophila</italic> Awd], HSPB2 [<italic>Drosophila</italic> heat shock protein 27 (HSP27)], FKBP1A (<italic>Drosophila</italic> Fkbp12), and SRSF1 (<italic>Drosophil</italic>a SF2), which were upregulated as part of the microtubule cytoskeleton, protein folding, and spliceosome component post-TBI (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), in HEK293T cells did not alter TDP-43 localization (<xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6A,B,C,D</xref>), suggesting that expression of a subset of proteins within the top four upregulated pathways does not disrupt TDP-43 distribution.</p></sec><sec id="s2-5"><title>Nucleoporin’s expression leads to motor dysfunction and reduced lifespan in <italic>Drosophila</italic> that is partially rescued by nucleoporins knockdown</title><p>To determine whether Nup upregulation, which leads to Tbph aggregation and mislocalization, is toxic in <italic>Drosophila,</italic> we assessed the effect of Nup62, Nup214, and Nup43 expression on motor function and lifespan. Overexpression of Nup62, Nup214, or Nup43 in motor neurons significantly reduced motor function and climbing velocity (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>, p &lt; 0.01; p &lt; 0.001, and p &lt; 0.05, respectively) in <italic>Drosophila</italic> compared to controls<italic>,</italic> suggesting that genetic upregulation of Nups alters motor function. Further, Nup62 OE, Nup214 OE, and Nup43 OE animals had a significantly reduced lifespan compared to control animals—controls had a median survival of 55 days when raised at 29°C, while Nup62 OE, Nup214 OE, and Nup43 animals had a median survival of 33, 40, and 43 days respectively. Overexpression of Nup62 and Nup214 or Nup62 and Nup43 together was further shown to significantly reduce lifespan compared to their respective Nup controls or control animals - Nup62/Nup214 OE and Nup62/Nup43 OE median survival was 23 days and 21 days, respectively (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, p &lt; 0.0001, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Nups expression reduces motor function and lifespan, and knockdown partially rescues trauma-mediated motor dysfunction in <italic>Drosophila</italic>.</title><p>(<bold>A</bold>) Percentage of flies that climbed 4 cm in 20 seconds for Nup62, Nup214, and Nup43-overexpressing (Nup62 OE, Nup214 OE and Nup43 OE) animals compared to eGFP control (n = 3 trials, 10 animals per trials; ***p &lt; 0.001, *p &lt; 0.01, *p &lt; 0.05). (<bold>B</bold>) Quantification of climbing velocity (cm/s) of Nup62 OE, Nup214 OE, and Nup43 OE flies compared to eGFP controls (n = 3 trials, 10 animals per trials, ***p &lt; 0.001, **p &lt; 0.01, *p &lt; 0.05). (<bold>C</bold>) Kaplan-Meier survival curve of flies expressing Nup62 OE, Nup214 OE, Nup43 OE, Nup62/Nup214 OE, Nup62/Nup43 OE or eGFP control in motor neurons. (n = 60–80, ****p &lt; 0.0001). (<bold>D, E</bold>) qPCR analysis of <italic>Nup62</italic> and <italic>Nup214</italic> mRNA levels in flies expressing Nup62 RNAi, Nup214 RNAi or eGFP controls (n = 3, **p &lt; 0.01, ***p &lt; 0.001). (<bold>F, G</bold>) Adult <italic>Drosophila</italic> expressing Nup62 RNAi or Nup214 RNAi in neuronal cells exposed to repeated traumatic brain injury (TBI) were raised on RU486 (+ RU486) or ethanol (-RU486) treated food for 20 days before motor assays. Quantification of (<bold>F</bold>) percentage of flies that climbed 4 cm in 20 s (n = 3 trials, *<italic>*</italic>p &lt; 0.01, ***p &lt; 0.001) and (<bold>G</bold>) climbing velocity (cm/s) (n = 3 trials, *p &lt; 0.05, **p &lt; 0.01). Log-rank with Grehan-Breslow-Wilcoxon tests were performed to determine significance for panel C, while one-tailed t-tested was used in panel D, E, F, and G. All quantifications represent mean ± s.e.m.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Knockdown of Nup62/Nup214 together extends lifespan.</title><p>(<bold>A, B</bold>) Kaplan-Meier survival curve of Nup62 RNAi (<bold>A</bold>) or Nup214 RNAi (<bold>B</bold>) exposed to repeated traumatic brain injury (TBI) were raised on RU486 (+ RU486) or ethanol (-RU486) showed no change (n = 85–90, p = NS). (<bold>C</bold>) Kaplan-Meier survival curve <italic>of</italic> Nup62 RNAi/Nup214 RNAi flies exposed to trauma were raised on RU486 (+ RU486) or ethanol (-RU486) showed that+ RU486-treated animals significantly increase survival (n = 80–90, ***p &lt; 0.001). (<bold>D</bold>) Table showing the median survival of control Nup62 OE, Nup214 OE, Nup43 OE, Nup62/Nup214 OE, Nup62/Nup43 OE, and control animals. Log-rank with Grehan-Breslow-Wilcoxon tests were performed to determine significance for panels A-C.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Enhanced Nup levels post-TBI coupled with Nup-mediated alteration in motor function in <italic>Drosophila</italic> prompted us to evaluate whether RNAi-mediated knockdown of Nups post-trauma was protective in vivo. We used the Elav-GeneSwitch (ElavGS) system to conditionally express Nup62 RNAi or Nup214 RNAi in neuronal cells by feeding adult flies RU486, as reported (<xref ref-type="bibr" rid="bib2">Anderson et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">Osterwalder et al., 2001</xref>). Adult RNAi (Nup62 or Nup214) flies were exposed to repeated traumatic injuries and motor function as well as lifespan were examined. <italic>Nup62</italic> mRNA (p &lt; 0.01) and <italic>Nup214</italic> mRNA (p &lt; 0.001) levels were significantly reduced in Nup62 and Nup214 RNAi-treated animals compared to controls (<xref ref-type="fig" rid="fig5">Figure 5D and E</xref>). Interestingly, Nup62 RNAi and Nup214 RNAi animals treated with RU486 post-trauma had a significant improvement in climbing (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, p &lt; 0.01 and p &lt; 0.001, respectively) and velocity (<xref ref-type="fig" rid="fig5">Figure 5F</xref>, p &lt; 0.05 and p &lt; 0.01, respectively) compared to ethanol-treated animals, suggesting that genetically modulating <italic>Nup62</italic> and <italic>Nup214</italic> levels post-TBI may partially improve motor function in <italic>Drosophila</italic>. Knockdown of <italic>Nup62</italic> or <italic>Nup214</italic> individually did not significantly extend life-span post-injury (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A,B</xref>, <italic>P</italic> = NS). However, RNAi knockdown Nup62/Nup214 together significantly increase lifespan of trauma animals (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>,p &lt; 0.001).</p></sec><sec id="s2-6"><title>Nuclear pore pathology is present in repetitive TBI patient brain tissues and co-aggregates with TDP-43 pathology</title><p>TBI can be categorized as mild, moderate, or severe based on clinical factors such as duration and severity, amnesia and neurological symptoms, and structural brain imaging (Management of Concussion/mTBI <xref ref-type="bibr" rid="bib57">Management of Concussion/mTBI Working Group, 2009</xref>). We examined postmortem brain tissue from patients with mild (nine cases) and severe CTE (nine cases) and aged-matched controls (eight control cases) without neurodegenerative disease for NUP62 pathology in the frontal cortex (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). All mild and severe CTE subjects were involved in sports, specifically American Football with one severe case played Hockey, and control cases played no sports. The mild subjects played an average of 12.222 ± 6.438 years (mean ± SD), while severe subject played an average of 18.333 ± 4.610 (mean ± SD). Interestingly, tissues from mild and severe CTE but not age-matched controls showed widespread and intense NUP62 immunoreactivity (<xref ref-type="fig" rid="fig6">Figure 6A,B,C</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Brain tissues from mild and severe CTE cases also showed cytoplasmic and nuclear mislocalization of Nup62 as well as perinuclear accumulation. Cytoplasmic NUP62 aggregates were present in brain tissue from patients with severe CTE, suggesting increased NUP62 aggregation with more severe CTE neuropathology. Enzyme-linked immunosorbent assay (ELISA) on postmortem brain tissues from eleven subjects with mild CTE showed an increasing trend in NUP62 levels, although they were not significantly different from controls cases. However, NUP62 levels in twenty-one severe CTE patient brain tissues were significantly higher than controls (<xref ref-type="fig" rid="fig6">Figure 6D</xref>, p &lt; 0.05), suggesting that repetitive TBI is associated with altered NUP62 in CTE.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>NUP62 pathology is present in brain tissue of patients with mild and severe CTE and coaggregates with pTDP-43 inclusion.</title><p>(<bold>A</bold>) NUP62 immunohistochemical staining in human frontal cortex tissue from a control individual without neurodegenerative disease, showing faint perinuclear staining for NUP62 (arrow). (<bold>B</bold>) NUP62 immunohistochemical staining in human frontal cortex tissue from a participant with mild CTE (mCTE), showing more neurons with diffuse cytoplasmic staining as well as perinuclear aggregates of NUP62 (arrowhead). (<bold>C</bold>) NUP62 immunohistochemical staining in human frontal cortex tissue from a participant with severe CTE (sCTE), showing more intense Nup62 staining in the nucleus and cytoplasm (arrowheads). Scale bar = 20 µm. (<bold>D</bold>) Quantification of enzyme-linked immunosorbent assay (ELISA) results for human NUP62 in control (n = 6), mCTE (n = 11), and sCTE (n = 21) subjects (*p &lt; 0.05, n.s. = not significant). (<bold>E</bold>) Representative immunofluorescence images of a control, and two mCTE and sCTE cases stained for NUP62 (green) and phosphorylated TDP-43 (red) in the frontal cortex (Scale bar = 25 µm), showing pTDP-43 co-localization with NUP62 (arrows head, merge) in two patients. DAPI was used as a nuclear marker. One-way ANOVA with Tukey’s multiple comparisons tested was used for panel D. All quantification represent mean ± s.e.m.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Control NUP62 immunohistochemistry cases.</title><p>(<bold>A, B</bold>) NUP62 immunohistochemical staining in human frontal cortex tissue from two control individual without neurodegenerative disease.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67587-fig6-figsupp1-v1.tif"/></fig></fig-group><p>To investigate the connection between Nups and TDP-43 pathology in CTE, we stained the dorsolateral prefrontal cortex at the depth of the cortical sulcus (approximately Broadman area 9) from two subject with mild and severe CTE as well as an aged-matched control. CTE brain tissue exhibited abnormal NUP62 staining in the prefrontal cortex. Interestingly, we found that mild CTE cases showed limited NUP62 coaggregation with pTDP-43, whereas the severe CTE cases showed a more pronounced coaggregation (arrows) of NUP62 and pTDP-43-positive inclusions in the frontal cortex (<xref ref-type="fig" rid="fig6">Figure 6E</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Evidence suggests that TBI is a predisposing factor for the development of neurodegenerative diseases (<xref ref-type="bibr" rid="bib20">Chen et al., 2007</xref>; <xref ref-type="bibr" rid="bib33">Gardner and Yaffe, 2015</xref>; <xref ref-type="bibr" rid="bib38">Goldman et al., 2006</xref>; <xref ref-type="bibr" rid="bib56">Lye and Shores, 2000</xref>; <xref ref-type="bibr" rid="bib74">Peters et al., 2013</xref>; <xref ref-type="bibr" rid="bib82">Sivanandam and Thakur, 2012</xref>; <xref ref-type="bibr" rid="bib89">Taylor et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Vanacore et al., 2006</xref>), and repeated trauma to the head is also associated with CTE (<xref ref-type="bibr" rid="bib61">McKee et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Omalu et al., 2010</xref>; <xref ref-type="bibr" rid="bib70">Omalu et al., 2005</xref>; <xref ref-type="bibr" rid="bib85">Stern et al., 2011</xref>). Further, CTE postmortem brain tissues and animal models of TBI show TDP-43 and TAU pathology (<xref ref-type="bibr" rid="bib11">Blennow et al., 2012</xref>; <xref ref-type="bibr" rid="bib43">Huang et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Mckee et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">McKee et al., 2010</xref>; <xref ref-type="bibr" rid="bib88">Tan et al., 2018</xref>; <xref ref-type="bibr" rid="bib95">Wang et al., 2015</xref>),, although the underlying mechanism that promotes this pathology has remained unexplored. Interestingly, although TBI causes nuclear dysfunction (<xref ref-type="bibr" rid="bib86">Tajiri et al., 2016</xref>), it has remained unknown whether TBI leads to NCT defects that might be linked to TDP-43 pathology in CTE. Here, we uncovered that TBI disrupts NPC proteins and NCT in models of trauma, postmortem brain tissues form CTE patients, and leads to TDP-43/Tbph coaggregation with components of the NPC. Of note, our study provides evidence of alteration in nucleoporins proteins, defects in NPC morphology and RanGAP1 distributions, coaggregation of NPC components with TDP-43/Tbph, overexpression of nucleoporins lead to TDP-43 mislocalization and/or aggregation, alter motor function and lifespan, and pharmacological inhibition of nuclear export or modulating nucleoporins post-injury is protective. Taken together, these results suggest that TBI can disrupt NCT machinery. These defects may account for the nuclear depletion and cytoplasmic accumulation of TDP-43 widely seen in CTE and/or TBI-related conditions.</p><p>Trafficking of protein and RNA between the nucleus and cytoplasm is important for proper cellular function—NCT of macromolecules is essential for signaling, neuronal plasticity, and overall cellular survival (<xref ref-type="bibr" rid="bib28">Dickmanns et al., 2015</xref>; <xref ref-type="bibr" rid="bib80">Schachtrup et al., 2015</xref>). NCT dysfunction has been reported in AD (<xref ref-type="bibr" rid="bib30">Eftekharzadeh et al., 2018</xref>), HD (<xref ref-type="bibr" rid="bib34">Gasset-Rosa et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Grima et al., 2017</xref>), and ALS/FTD (<xref ref-type="bibr" rid="bib24">Chou et al., 2018</xref>; <xref ref-type="bibr" rid="bib104">Zhang et al., 2015</xref>), and mutation in NUP62 causes autosomal recessive infantile bilateral striatal necrosis (<xref ref-type="bibr" rid="bib8">Basel-Vanagaite et al., 2006</xref>), suggesting a common disrupted pathway. Our study provides evidence that TBI directly alters NPC and NCT components in vivo. Nups mRNA and protein levels were increased post-TBI (<xref ref-type="fig" rid="fig1">Figure 1</xref>) and NUP62 protein levels were elevated in postmortem brain tissues from CTE patients (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Nups that were significantly upregulated include cytoplasmic FG Nups and filaments (Nup214), central channel FG Nups (Nup62 and Nup54), nuclear FG Nups and basket (TPR), linker Nups (Nup93), and outer ring Nups (Nup44A/SEH1, Nup43, and Nup75). In mammals, NUP93 forms an adaptor complex with NUP155, NUP35, NUP205, and NUP188, while NUP214 and other Nups constitute NPC cytoplasmic filaments that provide key interaction sites for NCT machinery (<xref ref-type="bibr" rid="bib54">Lin and Hoelz, 2019</xref>; <xref ref-type="bibr" rid="bib83">Solmaz et al., 2011</xref>). On the other hand, NUP62 and NUP54, in addition to NUP58, are suggested to constitute the channel (termed channel Nups) that undergoes large-scale reversible expansions to regulate NCT (<xref ref-type="bibr" rid="bib28">Dickmanns et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Lin and Hoelz, 2019</xref>) suggesting that alteration in these components by TBI might impact NCT of critical components in and out of the nucleus.</p><p>It is tempting to speculate that upregulation in Nups protein post-trauma (<xref ref-type="fig" rid="fig1">Figure 1</xref>) may be linked to post-transcriptional modifications. NPC components are extensively modified by nucleocytoplasmically disposed <italic>N</italic>-acetyglucosamine (GlcNAc) residues <italic>O</italic>-linked to serine and threonine residues (<italic>O-</italic>GlcNAc) (<xref ref-type="bibr" rid="bib42">Holt et al., 1987</xref>; <xref ref-type="bibr" rid="bib53">Li and Kohler, 2014</xref>). Indeed, 18 of the 30 Nups are modified by <italic>O-</italic>GlcNAc, and FG-Nups in the central scaffold of the NPC are heavily <italic>O-</italic>GlcNAcylated (<xref ref-type="bibr" rid="bib106">Zhu et al., 2016</xref>). Nups such as Nup62, Nup153, Nup214, Nup93, and Nup358 as well as scaffold Nups are targeted by <italic>O-</italic>GlcNAc (<xref ref-type="bibr" rid="bib14">Boyce et al., 2011</xref>; <xref ref-type="bibr" rid="bib37">Gloster et al., 2011</xref>; <xref ref-type="bibr" rid="bib106">Zhu et al., 2016</xref>). Further, genetic and pharmacological reduction of <italic>O-</italic>GlcNAc levels lead to decreased Nup levels and accelerated degradation, suggesting that <italic>O-</italic>GlcNAc might modulate Nup stability (<xref ref-type="bibr" rid="bib106">Zhu et al., 2016</xref>). Collectively, these studies imply that repeated trauma can directly or indirectly upregulate components of the NPC and that <italic>O</italic>-GlcNAcylation may have an important role in this process. However, further studies are needed to assess the role of trauma in modulating Nup <italic>O</italic>-GlcNacylation. Alternatively, Nups protein upregulation post-trauma may occur at the transcriptional level. Our results showed significant upregulation in Nups mRNA (<xref ref-type="fig" rid="fig1">Figure 1</xref>). It is plausible that both transcriptional and translational events may contribute to Nups upregulation in traumatic injury, but the exact sequence of events and factors involve require additional work. Intriguingly, Nups such as Pom121 and Nup107 are long-lived proteins in post-mitotic cells and are susceptible to oxidative damage. The slow turnover of damaged Nups and aged-associated reduction of nuclear protein import and NPC may result in neuronal dysfunction and death (<xref ref-type="bibr" rid="bib29">D’Angelo et al., 2009</xref>; <xref ref-type="bibr" rid="bib76">Pujol et al., 2002</xref>). In support, our data showed the Nup214 protein levels remains elevated overtime in larval and adult brains. It is possible that the slow turnover of Nup214 protein might be due to dysfunction in protein clearance pathways. Our lab and others have shown that traumatic brain injury impaired autophagy (<xref ref-type="bibr" rid="bib2">Anderson et al., 2018</xref>; <xref ref-type="bibr" rid="bib79">Sarkar et al., 2014</xref>; <xref ref-type="bibr" rid="bib102">Zeng et al., 2018</xref>) and ubiquitin proteosome components (<xref ref-type="bibr" rid="bib91">Tylicka et al., 2014</xref>; <xref ref-type="bibr" rid="bib100">Yao et al., 2008</xref>), suggesting that the impairments in these pathways might be important in mediating Nups slow turnover which potentially contribute to neurodegeneration.</p><p>Although strong evidence exists for NCT dysfunction in neurodegenerative disease, this evidence is centered around how pathological mutations in disease proteins influence this process, while many neurodegenerative diseases are mostly sporadic. Factors such as heavy metal exposure, pesticides, smoking, and head trauma have been link to development of neurodegenerative disease. Repeated head trauma is one of the most consistent risk factors for developing diseases such as ALS (<xref ref-type="bibr" rid="bib74">Peters et al., 2013</xref>) and AD (<xref ref-type="bibr" rid="bib31">Fann et al., 2018</xref>). However, the role of repeated head trauma in NCT dysfunction and its relation to neurodegeneration are unknown. To address this question, we used a well-characterized <italic>Drosophila</italic> trauma model (<xref ref-type="bibr" rid="bib49">Katzenberger et al., 2015</xref>; <xref ref-type="bibr" rid="bib48">Katzenberger et al., 2013</xref>) that shows a strong correlation between the amount of trauma and lethality as well as pathology in larval and adult <italic>Drosophila</italic> (<xref ref-type="bibr" rid="bib2">Anderson et al., 2018</xref>). Our results show that repeated trauma altered several molecular pathways including NPC and NCT. The NPC tightly regulates transport in and out of the nucleus, suggesting that trauma-mediated alteration in NPC components may disrupt NCT. Indeed, trauma disrupt the NPC morphology resulting in gaps and/or aggregation of nucleoporins on the membrane (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Trauma was shown to disrupt RanGAP1 distribution, Ran-dependent nuclear import and export regulator (<xref ref-type="bibr" rid="bib10">Bischoff et al., 1995</xref>), as well as nuclear import of GFP containing a classic NLS and NES in vivo (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Studies in multiple model systems of neurodegenerative diseases suggest that defects in the NCT pathway can manifest as ‘leaky pores’, impaired NCT, reduced NPC density, and irregular nuclear envelope morphology (<xref ref-type="bibr" rid="bib44">Hutten and Dormann, 2020</xref>). Studies also show that overexpression of NUP214 leads to NCT defects (<xref ref-type="bibr" rid="bib12">Boer et al., 1998</xref>). Conversely, depletion of NUP214 in mouse embryonic stem cells is reported to impair NLS-mediated protein import and lead to nuclear accumulation of polyadenylated RNA (<xref ref-type="bibr" rid="bib93">van Deursen et al., 1996</xref>), while knockout of NUP98 in mice disrupts nuclear import of proteins with an NLS (<xref ref-type="bibr" rid="bib98">Wu et al., 2002</xref>). Together, these data implicate repeated traumatic injury as a disruptor of the NPC and suggest that altering nucleoporins might possibly disrupt NCT by either disrupting the NPC morphology or creating ‘leaky pores’ but further work is needed to address this.</p><p>Our data further support a role for Nup62 upregulation in transport defects of NLS-containing protein, TDP-43. Targeted upregulation of Nup62 in <italic>Drosophila</italic> and in HEK293T cells caused nuclear depletion of TDP-43. In addition, expression Nup214, Nup43, and Nup93 also caused TDP-43 mislocalization, albeit to a lesser extent. Our in vivo and in vitro data further support that Nup62 upregulation leads to TDP-43 cytoplasmic aggregation and phosphorylation as well as increased levels of insoluble TDP-43. TDP-43 contains a classic NLS sequence, and its aggregation and phosphorylation are reported to be toxic (<xref ref-type="bibr" rid="bib47">Johnson et al., 2009</xref>; <xref ref-type="bibr" rid="bib103">Zhang et al., 2009</xref>). TDP-43 is considered a pathological hallmark of ALS/FTD (<xref ref-type="bibr" rid="bib52">Lattante et al., 2013</xref>) and is also found in CTE postmortem brain tissues (<xref ref-type="bibr" rid="bib60">McKee et al., 2010</xref>). Further, our results show that mild and severe CTE cases also have NUP62 pathology that coaggregated with pTDP-43, and its extent is related to disease severity. Importantly, repeated trauma in <italic>Drosophila</italic> led to TDP-43/Tbph accumulation with NPC components in the brain and this is recapitulated by overexpressing Nup62 but not Nup214 or Nup43 in <italic>Drosophila</italic>. We speculate that the TDP-43 pathology observed post-trauma is likely due to NPC dysfunction via upregulated NPC proteins. Our recent work have demonstrated that cytoplasmic Nup62 droplets exhibit characteristics of proteins that undergo liquid-liquid phase separation, and it is likely that these interaction through the classical NLS promotes deleterious phase transition of cytoplasmic TDP-43 causing it to mature into insoluble inclusions (<xref ref-type="bibr" rid="bib36">Gleixner et al., 2021</xref> <bold>PREPRINT</bold>), providing a mechanism for how Nups might promote TDP-43 pathology in traumatic injury. On the other hand, evidence in vitro and in vivo demonstrate that TDP-43 aggregation/demixing promotes NPC deficits that sequesters NPC components with TDP-43 aggregates (<xref ref-type="bibr" rid="bib24">Chou et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Cook et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Gasset-Rosa et al., 2019</xref>; <xref ref-type="bibr" rid="bib105">Zhang et al., 2018</xref>), suggesting that the TBI-mediated NCT deficits could be a consequence of cytoplasmic TDP-43 pathology. However, further research is needed to address whether NPC dysfunction is a cause or consequence of TDP-43 pathology in trauma-related conditions to fully decipher the exact mechanism. Moreover, the synergistic effects of both mechanisms cannot be ruled out as cause of neurodegeneration in traumatic injury.</p><p>Here, we also show that overexpression of Nups is toxic in <italic>Drosophila</italic>. Overexpression of Nup62, Nup214, or Nup43 reduces motor function and lifespan of <italic>Drosophila</italic> (<xref ref-type="fig" rid="fig5">Figure 5</xref>)<italic>,</italic> suggesting that altered NPC proteins may mediate toxicity. Interestingly, RNAi-mediated knockdown of <italic>Nup62</italic> or <italic>Nup214</italic> partially rescued the motor dysfunction but not lifespan in adult <italic>Drosophila</italic> exposed to TBI. However, knockdown of Nup62 and Nup214 together post-trauma partially extend lifespan. Importantly, pharmacological inhibition of nuclear export via administration of KPT compounds rescued the trauma-mediated NCT defect of GFP-tagged NLS-NES and Tbph aggregation, which correlates with rescue of trauma-mediated lethality (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Similarly, KPT-350 and KPT-276 are protective in models of ALS/FTD (<xref ref-type="bibr" rid="bib87">Tamir et al., 2017</xref>; <xref ref-type="bibr" rid="bib104">Zhang et al., 2015</xref>) and TBI (<xref ref-type="bibr" rid="bib17">Cantu et al., 2016</xref>; <xref ref-type="bibr" rid="bib86">Tajiri et al., 2016</xref>), suggesting a potential therapeutic application in TBI cases. While we did not observe a complete rescue of lifespan by RNAi knockdown of Nups post-injury, we speculate that it might be due to upregulation of multiple Nups post-trauma that might contribute to the overall phenotypes. We cannot exclude the possibility that Nups upregulation or a combination of other upregulated Nups might mediate toxicity by altering NCT balance, leading to NLS-containing proteins such as TDP-43 mislocalization and aggregation. Thus, further work is needed to assess whether modulating the levels of multiple Nups post-trauma or in conjunction with NCT inhibitors might be protective. In all cases, modulating Nups and/or nuclear export post-injury might provide some level of protection following repeated head trauma.</p><p>Taken together, our data suggest that disruption of NPC and NCT function may be a common pathogenesis in repetitive TBI diseases such as CTE. Based on our findings, we propose that trauma-mediated cytoplasmic aggregation of NLS-containing proteins such as TDP-43 is potentially caused by NCT defects and that cytoplasmic aggregation of NPC components such as Nup62 may sequester TDP-43 in aggregates that lead to toxicity. Further understanding of the role of repeated trauma in NCT and TDP-43 pathology will help develop therapeutic strategies for CTE and trauma-related diseases.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom">w<sup>1118</sup></td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC:3605; FLYB: FBst000360; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_3605">BDSC_3605</ext-link></td><td align="left" valign="bottom">w[1,118]</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom">w<sup>1118</sup>; P{UAS-NLS-NES<sup>+</sup>-GFP}5A</td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC:7032; FLYB: FBst0007032; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_7032">BDSC_7032</ext-link></td><td align="left" valign="bottom">w[1,118]; P{w[+ mC] = UAS-NLS-NES[+]-GFP}5A</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom">y<sup>1</sup> w*; P{UAS-NLS-NES<sup>P12</sup>-GFP}2A</td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC:7033; FLYB: FBst0007033; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_7033">BDSC_7033</ext-link></td><td align="left" valign="bottom">y (<xref ref-type="bibr" rid="bib1">Amador-Ortiz et al., 2007</xref>) w[*]; P{w[+ mC] = UAS-NLS-NES[P12]-GFP}2A</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom">w<sup>1118</sup>; P{EP}Nup44A<sup>EP2417</sup></td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC:17053; FLYB: FBst0017053; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_17053">BDSC_17053</ext-link></td><td align="left" valign="bottom">w[1,118]; P{w[+ mC] = EP}Nup44A[EP2417]</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom">w<sup>1118</sup>; P{EPg}Nup93-2<sup>HP35056</sup></td><td align="left" valign="bottom">Bloomington <italic>Drosophila</italic> Stock Center</td><td align="left" valign="bottom">BDSC:21975; FLYB: FBst0021975; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:BDSC_21975">BDSC_21975</ext-link></td><td align="left" valign="bottom">w[1,118]; P{w[+ mC] = EPg}Nup93-2[HP35056]</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom">P{VSH330104}attP40</td><td align="left" valign="bottom">Vienna <italic>Drosophila</italic> Resource Center</td><td align="left" valign="bottom">VDRC:v330104; FLYB: FBst0491076; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:FlyBase_FBst0491076">FlyBase_FBst0491076</ext-link></td><td align="left" valign="bottom">P{VSH330104}attP40</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom">P{KK108318}VIE-260B</td><td align="left" valign="bottom">Vienna <italic>Drosophila</italic> Resource Center</td><td align="left" valign="bottom">VDRC: v100588; FLYB: FBst0472461; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:FlyBase_FBst0472461">FlyBase_FBst0472461</ext-link></td><td align="left" valign="bottom">P{KK108318}VIE-260B</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom">UAS-Nup62</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Created at BestGene</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom">M{UAS-Nup214.ORF}ZH-86Fb</td><td align="left" valign="bottom">FLYORF</td><td align="left" valign="bottom">FLYORF: F001467; FLYB: FBst0500182; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:FlyBase_FBst0500182">FlyBase_FBst0500182</ext-link></td><td align="left" valign="bottom">M{UAS-Nup214.ORF}ZH-86Fb</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom">M{UAS-Nup43.ORF.3xHA.GW}ZH-86Fb</td><td align="left" valign="bottom">FLYORF</td><td align="left" valign="bottom">FLYORF: F003133; FLYB: FBst0502466; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:FlyBase_FBst050246">FlyBase_FBst050246</ext-link></td><td align="left" valign="bottom">M{UAS-Nup43.ORF.3xHA.GW}ZH-86Fb</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. melanogaster</italic>)</td><td align="left" valign="bottom">CRISPR/Cas9 hTDP43-WT</td><td align="left" valign="bottom">Gift from David B. Morton <xref ref-type="bibr" rid="bib18">Chang and Morton, 2017</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Human Embryonic Kidney cells (HEK 293T)</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0063">CVCL_0063</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">mRFP-FKBP1A Plasmid</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">(Cat #: 67514); RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_67514">Addgene_67514</ext-link></td><td align="left" valign="bottom">transfected construct (human)</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">Frt-V5-HspB2 Plasmid</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">(Cat #: 63103); RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_63103">Addgene_63103</ext-link></td><td align="left" valign="bottom">transfected construct (human)</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">FLAG NM23-H1/NME1 Plasmid</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">(Cat #: 25000); RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_25000">Addgene_25000</ext-link></td><td align="left" valign="bottom">transfected construct (human)</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">pEGFP SF2/SRSF1 Plasmid</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">(Cat #: 17990); RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_17990">Addgene_17990</ext-link></td><td align="left" valign="bottom">transfected construct (human)</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">Nup54-HA-eGFP Plasmid</td><td align="left" valign="bottom">VectorBuilder</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">transfected construct (human)</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">HA-eGFP Plasmid</td><td align="left" valign="bottom">VectorBuilder</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">transfected construct (human)</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">mRuby Plasmid</td><td align="left" valign="bottom">Gift from Dr. Christopher Donnelly</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">transfected construct (human)</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">NUP62-mRuby Plasmid</td><td align="left" valign="bottom">Gift from Dr. Christopher Donnelly</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">transfected construct (human)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Nup214 (Guinea Pig polyclonal)</td><td align="left" valign="bottom">Gift from Dr. Christos Samakovlis <xref ref-type="bibr" rid="bib77">Roth et al., 2003</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Lamin Dm0 (Mouse monoclonal)</td><td align="left" valign="bottom">DSHB</td><td align="left" valign="bottom">Cat# ADL84.12; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_528338">AB_528338</ext-link></td><td align="left" valign="bottom">IF(1:200)WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-α-Tubulin (Mouse monoclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#: T5168; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_477579">AB_477579</ext-link></td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Tbph (Rabbit polyclonal)</td><td align="left" valign="bottom">Gift from Dr. Frank Hirth <xref ref-type="bibr" rid="bib27">Diaper et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">IF (1:1500)WB (1:3000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-FLAG (Mouse monoclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#: F1804; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_259529">AB_259529</ext-link></td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-GFP (Chicken polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat#: ab13970; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_300798">AB_300798</ext-link></td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-TDP43 (Rabbit polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat#: 10782–2-AP; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_615042">AB_615042</ext-link></td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-phospho-TDP43 (Rat monoclonal)</td><td align="left" valign="bottom">Millipore SIGMA</td><td align="left" valign="bottom">Cat#: MABN14; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11212279">AB_11212279</ext-link></td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Mab414 (Mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat#: ab24609; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_448181">AB_448181</ext-link></td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-RanGAP1 (Rabbit polyclonal)</td><td align="left" valign="bottom">Millipore SIGMA</td><td align="left" valign="bottom">Cat#: ABN1674</td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Nup62 (Mouse polyclonal)</td><td align="left" valign="bottom">BD Transduction Laboratories</td><td align="left" valign="bottom">Cat#: 610497; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_397863">AB_397863</ext-link></td><td align="left" valign="bottom">IHC/IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-pTDP-43 (Rabbit polyclonal)</td><td align="left" valign="bottom">Cosmo Bio</td><td align="left" valign="bottom">Cat#:NC0877946; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1961899">AB_1961899</ext-link></td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Nup62 (Mouse polyclonal)</td><td align="left" valign="bottom">Roche Applied Science</td><td align="left" valign="bottom">Cat#: 610497; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_397863">AB_397863</ext-link></td><td align="left" valign="bottom">IHC (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-RanGAP1 (Rabbit polyclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat#: sc-28322; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2176987">AB_2176987</ext-link></td><td align="left" valign="bottom">IHC (1:1000)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Futsch</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers (5'–3'):</td><td align="left" valign="bottom">Forward: CAAAGCCCACTCACCTTTCReverse: CTGCTCCTGCCAACATCTProbe: AGTCTCTGGAAATGCAGCACCACT</td></tr><tr><td align="left" valign="bottom">Sequenced-based reagent</td><td align="left" valign="bottom"><italic>dNup93-2</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers (5'–3'):</td><td align="left" valign="bottom">Forward: ACACCGTCCGCGAAATACReverse: ACTCAACCGCCACCTTAACProbe: ATGGCCGCTGGTTTACTACGGATT</td></tr><tr><td align="left" valign="bottom">Sequenced-based reagent</td><td align="left" valign="bottom"><italic>dNup214</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers (5'–3'):</td><td align="left" valign="bottom">Forward: CCTAAGTGAGGACAAGGATGAGReverse: GGCATAGTCTGCAGCTTCTTProbe: TGCCTTCGACACTTCTACAACGCA</td></tr><tr><td align="left" valign="bottom">Sequenced-based reagent</td><td align="left" valign="bottom"><italic>dNup54</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers (5'–3'):</td><td align="left" valign="bottom">Forward: GAGTGAGCTGACAGAACTCAAGReverse: CTCGGCCAGTTTCCGTTTATProbe: CCACTGCCACAGCGAAGATACTTGA</td></tr><tr><td align="left" valign="bottom">Sequenced-based reagent</td><td align="left" valign="bottom"><italic>dNup44A</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers (5'–3'):</td><td align="left" valign="bottom">Forward: AAGGTATCCTCCACCAATACCCReverse: TTGGGTGCAAACTCCACATCProbe: TTGTAGACTCGCGGACCAGTGTCA</td></tr><tr><td align="left" valign="bottom">Sequenced-based reagent</td><td align="left" valign="bottom"><italic>dNup62</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers (5'–3'):</td><td align="left" valign="bottom">Forward: CTTGCTGTTGTCTGCATCTCReverse: CAGCACCAGCTTCAGGAProbe: ACATTCTCTTTCGGAACACCGGCA</td></tr><tr><td align="left" valign="bottom">Sequenced-based reagent</td><td align="left" valign="bottom"><italic>Emb (Exportin)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers (5'–3'):</td><td align="left" valign="bottom">Forward: GGTCACGCGTATGTCATTCAReverse: GTTCACATTGACGCCATTCACProbe: AGCATGTCCAGATATATGCGGCCC</td></tr><tr><td align="left" valign="bottom">Sequenced-based reagent</td><td align="left" valign="bottom"><italic>dNup43</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers (5'–3'):</td><td align="left" valign="bottom">Forward: TTGCATCTGATCCTCCTCCACReverse: ACCGCCATGGAGTTCGTProbe: TGGACGTTAAACACGCTGAGATGACC</td></tr><tr><td align="left" valign="bottom">Sequenced-based reagent</td><td align="left" valign="bottom"><italic>dGapdh</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers (5'–3'):</td><td align="left" valign="bottom">Forward: CAACAGTGATTCCCGACCAGReverse: TTCGTCAAGCTAATCTCGTGGProbe: CCAAAACTATCGTACAAACCCGGCG</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">3,3'-diaminobenzidine (DAB)</td><td align="left" valign="bottom">Vector Laboratories</td><td align="left" valign="bottom">Cat: #SK-4100; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2336382">AB_2336382</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NE-PER nuclear-cytoplasmic extraction kit</td><td align="left" valign="bottom">ThermoFisher Scientific</td><td align="left" valign="bottom">Cat #: 78,833</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Nup62 ELISA</td><td align="left" valign="bottom">LSBio</td><td align="left" valign="bottom">Cat #: LS-F22196</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">KPT-350</td><td align="left" valign="bottom">Karyopharm</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">KPT-276</td><td align="left" valign="bottom">Selleck Chem</td><td align="left" valign="bottom">Cat #: S7251</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism 6</td><td align="left" valign="bottom">GraphPad Prism 6</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title><italic>Drosophila</italic></title><sec id="s4-1-1"><title>Fly lines</title><p>w<sup>1118</sup>, P{EP}Nup44A<sup>EP2417</sup>, P{EPg}Nup93-2<sup>HP35056</sup>, P{UAS-NLS-NES-GFP}, P{UAS-NLS-ΔNES-GFP}, Ok371-gal4, and UAS-eGFP were obtained from the Bloomington <italic>Drosophila</italic> stock center (<ext-link ext-link-type="uri" xlink:href="http://www.flystocks.bio.indiana.edu">http://www.flystocks.bio.indiana.edu</ext-link>). UAS-Nup214 (F001467) and UAS-Nup43 (F003133) were obtained from FlyORF. Nup62 RNAi (100588) and Nup214 <italic>RNAi</italic> (41964) were obtained from Vienna <italic>Drosophila</italic> Resource Center. The previously described CRISPR/Cas9 human TDP-43 wild-type (hTDP-43WT) was a kind gift from David B. Morton (Oregon Health and Science University) (<xref ref-type="bibr" rid="bib18">Chang and Morton, 2017</xref>). UAS-Nup62 overexpression lines (UAS-Nup62 OE) were generated through site-specific integration of the transgene at BestGene Inc To generate UAS-Nup62 OE lines, we used the pUAST-attB vector. We subcloned the Nup62 cDNA (<italic>Drosophila</italic> Genomic Research Center) into the pUAST-attB vector.</p></sec><sec id="s4-1-2"><title>Proteomics of <italic>Drosophila</italic> brains</title><p>Larvae (three biological replicate) that were subjected to repeated whole-body trauma, 8 hits @ 50° angles with 20 s interval between hits (<xref ref-type="bibr" rid="bib2">Anderson et al., 2018</xref>), and non-TBI controls brains were extracted immediately following trauma and flash-frozen. For protein extraction, frozen brains were thawed on ice with 50 µL of chilled MS lysis buffer (6 M urea, 0.4 M NaCl, 20 mM HEPES [pH 7.9], 5 % glycerol, 0.2 mM EDTA, 0.5 mM DTT) with 1 X protease inhibitors. Brains were crushed by 20 strokes with a plastic pestle and centrifuged at 19,000 <italic>g</italic> for 30 min to pellet debris. Supernatants was passed through a 0.45 µm microcentrifuge filter and quantified for mass spectrometry by BCA assay. Filtered protein was reduced and alkylated with 10 mM TCEP and 40 mM chloroacetamide, respectively. Lysates were digested into tryptic peptides using the filter-aided sample prep (FASP) method (<xref ref-type="bibr" rid="bib97">Wisniewski et al., 2009</xref>) by diluting to 4 M urea, adding LysC (Wako), and rocking at ambient temperature for 4 hr. Lysates were further diluted to ~1 M urea for trypsin digestion (Pierce), rocking overnight at ambient temperature. Digested peptides were desalted using an Oasis HLB cartridge (Waters) according to the manufacturer’s instructions.</p><p>Samples were suspended in 7 µL of 3 % (v/v) acetonitrile/0.1 % (v/v) trifluoroacetic acid, and 1 µL was directly injected on a C18 1.7 µm, 130 Å, 75 µm X 250 mm M-class column (Waters), using a Waters M-class UPLC. Tryptic peptides were eluted at 300 nL/min using a gradient from 3–20% acetonitrile over 100 min into an Orbitrap Fusion mass spectrometer (Thermo Scientific). Precursor mass spectra (MS1) were acquired at a resolution of 120,000 from 380 to 1500 m/z with an AGC target of 4.0 × 10<sup>5</sup> and a maximum injection time of 60 ms. Dynamics exclusion was set for 30 s with a mass tolerance of ±10 ppm. Precursor peptide ion isolation width for MS2 fragment scans was 1.6 Da using the quadrupole, and the most intense ions were sequenced using Top Speed with a 3 s cycle time. All MS2 sequencing was performed using higher energy collision dissociation (HCD) at 35 % collision energy and scanning in the linear ion trap. An AGC target of 1.0 × 10<sup>4</sup> and 35 s maximum injection time was used. Raw files were searched against the Uniprot <italic>Drosophila</italic> database using Maxquant version 1.6.0.16 with cysteine carbamidomethylation as a fixed modification (<xref ref-type="bibr" rid="bib9">Bateman, 2019</xref><xref ref-type="bibr" rid="bib69">Old et al., 2005</xref>; <xref ref-type="bibr" rid="bib90">Tyanova et al., 2015</xref>). Methionine oxidation and protein N-terminal acetylation were searched as variable modifications. All peptides and proteins were thresholded at a 1% false discovery rate (FDR).</p></sec><sec id="s4-1-3"><title>Quantification of AE-MS data and gene ontology</title><p>Of the 4696 <italic>Drosophila</italic> proteins detected, the top 2000 ranking proteins were selected for further analysis with &gt;4 label-free quantified (LFQ) values averaged across all samples and biological replicates. The average fold-change between TBI samples and controls (n = 2 or 6 biological replicates, respectively) was determined, and significance was determined by student’s t-test. Proteins were selected for GO analysis if they had a log-2 fold-change after TBI of ≥0.7 or ≤–0.7. The 361 proteins are just those whose p-value between TBI and non-TBI is ≤0.05. When we did both &gt;1.6 fold up or down and p ≤ 0.05, there were 246 proteins (<xref ref-type="supplementary-material" rid="supp1 supp3">Supplementary files 1 and 3</xref>) that were altered and present “TBI Proteome”. The GO analysis accepted all genes changed &gt;1.6 fold and p ≤ 0.1 to get enough genes to do GO analysis on. These proteins were consistently observed in all replicates. GO analysis was performed using Cytoscape v.3.7.1 and the BiNGO tool set v.3.0.3 (<xref ref-type="bibr" rid="bib78">Saito et al., 2012</xref>). Associated GO terms were determined with the hypergeometric test with Benjamini and Hochberg FDR correction. Volcano plots were generated using all proteins associated with the selected GO terms and in the top 2000 ranked proteins detected. Additional proteins were included in volcano plots by manual curation and indicated in recent literature to associate with factors listed under the GO term (e.g. nuclear pore proteins).</p></sec><sec id="s4-1-4"><title>Western blotting</title><p>Fly heads were collected from each genetic cross and snap-frozen on dry ice. Heads were crushed on dry ice and incubated in RIPA buffer (150 mM NaCl, 1% NP40, 0.1% SDS, 1% sodium deoxycholate, 50 mM NaF, 2 mM EDTA, 2 mM DTT, 0.2 mM Na orthovanadate, 1 X Roche protease inhibitor #11836170001). Lysates were sonicated and centrifuged to remove debris. Supernatants were boiled in Laemmli buffer (Boston Bioproducts, #BP-111R) for 5 min and loaded onto 4%–12% Nupage Bis-Tris gels (Novex/Life Technologies). Proteins were transferred using the iBlot2 (Life Technologies, #13120134) onto nitrocellulose (iBlot 2 NC regular Stacks, Invitrogen, #IB23001). Western blots were blocked with milk solution (BLOT-QuickBlocker reagent, EMB Millipore, #WB57-175GM) and incubated with primary antibody overnight: guinea pig DNup214, 1:5000 (a kind gift from Christos Samakovlis [<xref ref-type="bibr" rid="bib77">Roth et al., 2003</xref>]); anti-lamin Dm0 (ADL84.12), 1:1000 (Developmental Studies Hybridoma Bank); mouse anti-tubulin, 1:10,000 (Sigma-Aldrich); rabbit GAPDH, 1:1000 (GeneTex). Blots were washed and incubated in secondary antibody for one hour [anti-mouse IRDye 680D, 1:10,000 (LI-COR Biosciences); anti-rabbit DYLight 800, 1:10,000 (Invitrogen)] and imaged on a Licor imager (Odyssey CLx). All western blots were run in triplicate using biological replicates. Protein levels were quantified using NIH Image J software, and statistical analysis was performed with GraphPad Prism six software.</p></sec><sec id="s4-1-5"><title>Soluble-insoluble fractionation</title><p>Ten adult fly heads were collected for each genotype, crushed on dry ice, incubated in NP40 lysis buffer (10 mM Tris HCl pH 7.8, 10 mM EDTA, 150 mM NaCl, protease inhibitor cocktail, 0.5% NP40), sonicated, and centrifuged (21,000 <italic>g</italic> for 20 min), and supernatants (soluble fractions) were collected. Pellets were washed in 1 mL washing buffer (50 mM Tris HCl pH 7.4, 150 mM NaCl), vortexed, and centrifuged (21,000 <italic>g</italic> for 5 min). Supernatants were discarded, and pellets were resuspended in resolubilization buffer (50 mM Tris HCl pH 6.8, 5% SDS, 10% glycerol) and sonicated. Similarly, transfected HEK293T cells were harvested 24 h after transfection, and the above protocol was followed. Western blotting was performed as described above.</p></sec><sec id="s4-1-6"><title>Nuclear-cytoplasmic fractionation</title><p>A total of 50 adult fly heads were harvested, and nuclear-cytoplasmic fractionation was done using a NE-PER Nuclear-Cytoplasmic extraction kit per manufacturer’s protocol (Thermo Fisher Scientific).</p></sec><sec id="s4-1-7"><title>Larval preparations, immunohistochemistry, and quantification</title><p>Third instar larvae or adult <italic>Drosophila</italic> brains were dissected, fixed, and immunostained as previously described (<xref ref-type="bibr" rid="bib2">Anderson et al., 2018</xref>). Briefly, animals were dissected in ice-cold phosphate buffered saline (PBS) (Lonza, #17–516 F), fixed in 4% formaldehyde, washed three times in PBS, incubated in 5% Triton X-100/PBS for 20 min, washed three times in 0.1% PBST (0.1 % Triton X-100/PBS), and incubated overnight with primary antibodies: mouse anti-Lamin Dm0, 1:200 (Developmental Studies Hybridoma Bank); rabbit anti-Tbph, 1:3000 generous gift from Dr. Frank Hirth <xref ref-type="bibr" rid="bib27">Diaper et al., 2013</xref>; mouse anti-FLAG, 1:1,000 (Sigma-Aldrich); chicken anti-GFP, 1:1000 (Abcam); Rabbit Anti-RanGAP1, 1:200 (Millipore Sigma) or mouse anti-nuclear pore complex (Mab414), 1:1000 (Abcam). Larvae were washed three times in 0.1% PBST and incubated with secondary antibodies: anti-rabbit Alexa Flour 568, 1:100 (Invitrogen, #651727); anti-mouse Alexa Flour 647, 1:100 (Invitrogen, #28181); anti-rabbit Alexa Flour 405, 1:100 (Invitrogen, #157554); anti-rabbit Alexa Flour 647, 1:100 (Invitrogen, #1660844); or anti-chicken Alexa Flour 647, 1:100 (Invitrogen, #2010133). Stained larvae were mounted using DAPI Fluoroshield (Sigma-Aldrich, #F6182). Images were collected on a Nikon A1 eclipse T<sub>i</sub> confocal microscope. Relative Tbph puncta and staining intensity were quantified in 100–150 VNC cells from four to seven animals using the Image J threshold function, and average intensity (subtracted from background) was used for analysis. All IF image quantification were done single-blinded.</p></sec><sec id="s4-1-8"><title>Eclosion assay</title><p>For eclosion percentages, a total of 15 <italic>w<sup>1118</sup></italic> larvae were subjected to trauma, 8hits @ 50° angles with 20 sec interval between hits, as previously described (<xref ref-type="bibr" rid="bib2">Anderson et al., 2018</xref>). Briefly, larvae were exposed to trauma and directly transferred to food vials supplemented with DMSO only, KPT-350 (0.05, 0.1, or 0.5 mM; Karyopharm), or KPT-276 (50, 200, or 1,000 nM; Selleck Chem). Eclosion percentages were calculated as: (total number of eclosed adults) / (total number of pupal cases) x 100. Each condition was analyzed in triplicate using biological replicates. Statistical analysis was performed with GraphPad Prism six software.</p></sec><sec id="s4-1-9"><title>Climbing assay</title><p>OK371-gal4 (motor neuron specific driver) was used to overexpress Nups (Nup62 OE, Nup214 OE, Nup43 OE) or eGFP (control), and climbing assays were performed as previously described (<xref ref-type="bibr" rid="bib2">Anderson et al., 2018</xref>). Additionally, Elav-GeneSwitch (ElavGS) was used to conditionally express <italic>Nup62</italic> RNAi or <italic>Nup214</italic> RNAi in neuronal cells on normal cornmeal food. Adult progeny were subjected to repeated trauma as described (<xref ref-type="bibr" rid="bib2">Anderson et al., 2018</xref>), and flies that survived after 24 hr were placed on food treated with ethanol (-RU486) or RU486 (+ RU486, Cayman Chemical) for 20 days before motor assay. Adult flies were anesthetized with CO<sub>2</sub> after 20 days, transferred to vials, and allowed to recover for 30 min. Flies were knocked to the bottom of vials by tapping against the bench three times, and a video camera was used to record flies climbing up the walls. The percentage of flies that climbed 4 cm in 20 s as well as the velocity (cm/s) of each individual fly was quantified and analyzed using GraphPad Prism six software. Three experimental replicates were performed for each group.</p></sec><sec id="s4-1-10"><title>Lifespan assay</title><p>Nup62 OE, Nup214 RNAi or Nup43 RNAi or eGFP adult 2-day-old flies (20 flies per vial, 60–80 flies) were collected for each experimental group. Flies were transferred to fresh food twice a week. Number of dead flies was counted every day, and survival functions were calculated and plotted as Kaplan-Meier survival curves. Log-rank with Grehan-Breslow-Wilcoxon tests were performed to determine significance of differences in survival data between samples using GraphPad Prism six software.</p></sec><sec id="s4-1-11"><title><italic>Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR</italic>)</title><p>RNA was extracted in triplicate from TBI or non-TBI <italic>w<sup>1118</sup></italic> larval brains (10 brains per extraction) as well as Nup62 RNAi, Nup214 RNAi, Nup62 RNAi, eGFP, Nup214 OE, Nup43 OE, or Nup62 OE, flies using Trizol (Ambion, #15596026) in 1-bromo-3-chloropropane (BCP; Sigma-Aldrich, #MKCB0830V), as previously described (<xref ref-type="bibr" rid="bib46">Jensen et al., 2013</xref>). Brains were dissected from larvae, snap frozen on dry ice, ground in Trizol, and centrifuged to pellet. BCP was added, and samples were centrifuged again. The upper aqueous layer was used to precipitate RNA with isopropanol, followed by pelleting RNA through centrifugation. RNA pellets were washed with 70% ethanol and allowed to air-dry prior to resuspending in RNase-free water. RNA samples were quantified on a NanoDrop ND-1000 spectrophotometer, and purity was assessed using 260/280 and 260/230 ratios. Samples were run on a 1% agarose gel with ethidium bromide to rule out RNA degradation. cDNA was then generated from RNA samples with the BioRad iScript Select cDNA Synthesis Kit (#170–8897) in a Thermo Hybaid Omn-E PCR machine. All cDNA samples were run on a 96-well plate (Applied Biosystems, #4306737) on an Applied Biosystems 7,300 Real-Time PCR system with BioRad iQ Supermix (#170–8862). cDNA-specific PrimeTime qPCR Assay primers (Integrated DNA Technologies) were used for qPCR reactions (<ext-link ext-link-type="uri" xlink:href="http://www.idtdna.com">http://www.idtdna.com</ext-link>). <italic>Drosophila</italic> GAPDH (<italic>dGapdh</italic>) was used as a housekeeping control. The comparative C(T) method was used to analyze results, as previously described (<xref ref-type="bibr" rid="bib81">Schmittgen and Livak, 2008</xref>). GraphPad Prism six software was used for statistical analyses.</p><p>Primers (5'–3'):</p></sec><sec id="s4-1-12"><title>Futsch</title><list list-type="bullet"><list-item><p>Forward: <named-content content-type="sequence">CAAAGCCCACTCACCTTTC</named-content></p></list-item><list-item><p>Reverse: <named-content content-type="sequence">CTGCTCCTGCCAACATCT</named-content></p></list-item><list-item><p>Probe: <named-content content-type="sequence">AGTCTCTGGAAATGCAGCACCACT</named-content></p></list-item></list></sec><sec id="s4-1-13"><title>dNup93-2</title><list list-type="bullet"><list-item><p>Forward: <named-content content-type="sequence">ACACCGTCCGCGAAATAC</named-content></p></list-item><list-item><p>Reverse: <named-content content-type="sequence">ACTCAACCGCCACCTTAAC</named-content></p></list-item><list-item><p>Probe: <named-content content-type="sequence">ATGGCCGCTGGTTTACTACGGATT</named-content></p></list-item></list></sec><sec id="s4-1-14"><title>dNup214</title><list list-type="bullet"><list-item><p>Forward: <named-content content-type="sequence">CCTAAGTGAGGACAAGGATGAG</named-content></p></list-item><list-item><p>Reverse: <named-content content-type="sequence">GGCATAGTCTGCAGCTTCTT</named-content></p></list-item><list-item><p>Probe: <named-content content-type="sequence">TGCCTTCGACACTTCTACAACGCA</named-content></p></list-item></list></sec><sec id="s4-1-15"><title>dNup54</title><list list-type="bullet"><list-item><p>Forward: <named-content content-type="sequence">GAGTGAGCTGACAGAACTCAAG</named-content></p></list-item><list-item><p>Reverse: <named-content content-type="sequence">CTCGGCCAGTTTCCGTTTAT</named-content></p></list-item><list-item><p>Probe: <named-content content-type="sequence">CCACTGCCACAGCGAAGATACTTGA</named-content></p></list-item></list></sec><sec id="s4-1-16"><title>dNup44A</title><list list-type="bullet"><list-item><p>Forward: <named-content content-type="sequence">AAGGTATCCTCCACCAATACCC</named-content></p></list-item><list-item><p>Reverse: <named-content content-type="sequence">TTGGGTGCAAACTCCACATC</named-content></p></list-item><list-item><p>Probe: <named-content content-type="sequence">TTGTAGACTCGCGGACCAGTGTCA</named-content></p></list-item></list></sec><sec id="s4-1-17"><title>dNup62</title><list list-type="bullet"><list-item><p>Forward: <named-content content-type="sequence">CTTGCTGTTGTCTGCATCTC</named-content></p></list-item><list-item><p>Reverse: <named-content content-type="sequence">CAGCACCAGCTTCAGGA</named-content></p></list-item><list-item><p>Probe: <named-content content-type="sequence">ACATTCTCTTTCGGAACACCGGCA</named-content></p></list-item></list></sec><sec id="s4-1-18"><title>Emb (Exportin)</title><list list-type="bullet"><list-item><p>Forward: <named-content content-type="sequence">GGTCACGCGTATGTCATTCA</named-content></p></list-item><list-item><p>Reverse: <named-content content-type="sequence">GTTCACATTGACGCCATTCAC</named-content></p></list-item><list-item><p>Probe: <named-content content-type="sequence">AGCATGTCCAGATATATGCGGCCC</named-content></p></list-item></list></sec><sec id="s4-1-19"><title>dNup43</title><list list-type="bullet"><list-item><p>Forward: <named-content content-type="sequence">TTGCATCTGATCCTCCTCCAC</named-content></p></list-item><list-item><p>Reverse: <named-content content-type="sequence">ACCGCCATGGAGTTCGT</named-content></p></list-item><list-item><p>Probe: <named-content content-type="sequence">TGGACGTTAAACACGCTGAGATGACC</named-content></p></list-item></list></sec><sec id="s4-1-20"><title>dGapdh</title><list list-type="bullet"><list-item><p>Forward: <named-content content-type="sequence">CAACAGTGATTCCCGACCAG</named-content></p></list-item><list-item><p>Reverse: <named-content content-type="sequence">TTCGTCAAGCTAATCTCGTGG</named-content></p></list-item><list-item><p>Probe: <named-content content-type="sequence">CCAAAACTATCGTACAAACCCGGCG</named-content></p></list-item></list></sec></sec><sec id="s4-2"><title>Rat CCI TBI model</title><sec id="s4-2-1"><title>Subjects and presurgical procedures</title><p>Ten adult male Sprague-Dawley rats (Envigo RMS) were pair-housed in standard rat individual ventilated cages under a 12 hr light/dark cycle and maintained at a temperature of 21°C ± 1°C with ad libitum access to food and water. All experimental procedures were approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh. Every attempt was made to limit the number of rats used and to minimize suffering.</p></sec><sec id="s4-2-2"><title>Surgery</title><p>TBI was conducted on rats weighing 300–325 g, as previously described (<xref ref-type="bibr" rid="bib84">Sozda et al., 2010</xref>). Briefly, following induction of surgical anesthesia with 4% isoflurane and 2:1 N<sub>2</sub>O:O<sub>2</sub>, rats were intubated, maintained on 2% isoflurane, and mechanically ventilated. A controlled cortical impact (CCI) of moderate severity (2.8 mm tissue deformation at a velocity of 4 m/s) was produced. Immediately after CCI, anesthesia was removed, and the incision was promptly sutured. Rats were returned to home cages, where they remained until being euthanized at 24 hr post-injury.</p></sec><sec id="s4-2-3"><title>Immunohistochemistry</title><p>CCI and sham rats were anesthetized intraperitoneally with Fatal-Plus (0.25 mL) and perfused transcardially with 200 mL 0.1 M PBS (pH 7.4), followed by 300 mL 4% paraformaldehyde (PFA) 24 h post-injury. Calvaria were immersion-fixed an additional 24 h in 4% PFA, and brains were subsequently extracted and post-fixed in 4% PFA until dehydration for immunohistochemical staining. Serial dehydrations (increasing concentrations of ethanol, then embedded in paraffin wax) were performed on all brain tissues. After embedding, 5-mm-thick tissues were sectioned at ~1 mm interval.</p><p>Slides were selected based on region of interest (ROI), deparaffinized, and rehydrated. ROIs were determined <italic>a priori</italic> as hippocampal regions underlying the injured cortex. Endogenous peroxide was blocked with 3% H<sub>2</sub>O<sub>2</sub>, and slides were subjected to an antigen retrieval step with 1 X Decloaking solution (BioCare Medical, #CB910M). Primary antibody incubation was then performed on all sections for 12 hr at 4°C using mouse anti-Nup62 (IgG), 1:400 (Roche Applied Sciences) or rabbit anti-RanGAP1 (IgG), 1:1000 (Santa Cruz Biotechnology). Slides were washed in 1 X TBS automation buffer (BioCare Medical, #TWB945M) and incubated for 2 hr with secondary goat anti-mouse IgG (1:750, Vector Laboratories, #PK-6102) or anti-rabbit IgG (1:750, Vector Laboratories, #PK-6101). Immunostaining was visualized using a 3,3'-diaminobenzidine (DAB) staining kits (Vector Laboratories, #SK-4100) for ~5 min. Slides were counterstained with aqueous Hematoxylin QS (Vector Laboratories, #H-3404), dehydrated, and cover-slipped using Permount mounting medium (Thermo Fisher Scientific, #SP15-500). Sections were imaged on a Nikon i90 microscope with NS-elements software (Nikon). Nup62 and RanGAP1 pathology was quantified as previously described (<xref ref-type="bibr" rid="bib39">Grima et al., 2017</xref>).</p></sec></sec><sec id="s4-3"><title>Human neuropathology</title><sec id="s4-3-1"><title>Subjects</title><p>Cases were ascertained from the VA-BU-CLF Brain Bank at Boston University. Detailed inclusion criteria have been described previously (<xref ref-type="bibr" rid="bib64">Mez et al., 2015</xref>). An authorized legal representative provided written consent from brain donation. IRB approval for the brain donation program was obtained through Boston University Alzheimer’s Disease &amp; CTE Center and the Edith Nourse Rogers Memorial Veterans Hospital. Neuropathologic evaluation has been described previously (<xref ref-type="bibr" rid="bib22">Cherry et al., 2017</xref>). CTE neuropathologic stage was determined using McKee staging criteria (<xref ref-type="bibr" rid="bib62">McKee et al., 2016</xref>). CTE Stage I or II cases were grouped as mild CTE, and Stage III or IV cases were grouped as severe CTE, as previously published (<xref ref-type="bibr" rid="bib21">Cherry et al., 2016</xref>).</p></sec><sec id="s4-3-2"><title>ELISA</title><p>Frozen tissue was collected from identical regions in Broadman area 8/9, as previously described (<xref ref-type="bibr" rid="bib21">Cherry et al., 2016</xref>). Briefly, freshly prepared, ice-cold 5 M guanidine hydrochloride in Tris-buffered saline (20 mM Tris-HCl, 150 mM NaCl, pH 7.4 TBS) containing 1:100 Halt protease inhibitor cocktail (Thermo Fisher Scientific) and 1:100 phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich) were added to brain tissues at a 5:1 ratio and homogenized with Qiagen Tissue Lyser LT at 50 Hz for 5 min. Lysates were diluted according to the manufacturer’s protocol and centrifuged at 17,000 <italic>g</italic> at 4°C for 15 min. Supernatant was analyzed using a Nup62 ELISA (LSBio, #LS-F22196) according to the manufacturer’s protocol. Results are reported as ng/mL.</p></sec><sec id="s4-3-3"><title>Histology</title><p>Staining was performed as previously described (<xref ref-type="bibr" rid="bib21">Cherry et al., 2016</xref>). Briefly, tissue blocks of cortical samples were taken from Broadman area 8/9 for all cases. Tissues were embedded in paraffin and cut into 20-µm-thick sections. For chromogenic staining, sections were incubated overnight at 4°C with anti-NUP62 antibody. Sections were treated with biotinylated secondary antibodies and labeled with a 3-amino-9-ethylcarbazol HRP substrate kit (Vector Laboratories). Sections were counterstained with Gill’s hematoxylin (Vector Laboratories, #H-3401). For multiplex immunofluorescent images, sections were incubated overnight at 4°C with anti-NUP62 (BD Transduction Laboratories, #610497) and or anti-pTDP43 (Cosmo Bio, #NC0877946) antibodies. Fluorescent labeling was carried out using the PerkinElmer Opal 7-Color Automation IHC kit (#NEL801001KT), per manufacturer’s instructions. Sections were counterstained with DAPI.</p></sec></sec><sec id="s4-4"><title>Cell culture, transfection, and immunohistochemistry</title><p>HEK293T (#CRL-3216) cells were acquired from ATCC, was authenticated and tested negative for mycoplasma contamination. H293T cells were cultured on coverslips coated with poly-L-lysine (Sigma-Aldrich). Cells were transfected with either mRuby, NUP62-mRuby, HA-eGFP, Nup54-HA-eGFP, pEGFP-SF2/SRSF1 (Addgene, #17990), FLAG-NM23-H1/NME1 (Addgene, #25000), Frt-V5-HspB2 (Addgene, #63103), or mRFP-FKBP1A (Addgene, #67514) expression plasmids using TurboFect (Thermo Fisher Scientific), following the manufacturer’s instructions. Cells were washed and incubated with primary antibodies overnight: rabbit anti-TDP-43 (10782–2-AP), 1:1000 (Proteintech); or rat anti-phospho TDP-43 (MABN14), 1:1000 (Millipore, Sigma-Aldrich). Cells were washed and incubated with secondary antibodies: anti-rabbit Alexa Flour 647, 1:100 (Life Technologies, #1660844); anti-rat Alexa Flour 568 (Invitrogen, Cat # A-11077). Coverslips were mounted onto slides using Fluoroshield with DAPI (Sigma-Aldrich, #F6057). Cells were imaged with a NIKON A1 eclipse T<sub>i</sub> confocal microscope.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Data curation, Funding acquisition, Project administration, Resources, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Investigation, Methodology, Validation</p></fn><fn fn-type="con" id="con12"><p>Data curation, Formal analysis, Funding acquisition, Project administration, Resources</p></fn><fn fn-type="con" id="con13"><p>Data curation, Formal analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Data curation, Formal analysis, Funding acquisition, Methodology, Resources, Supervision, Validation, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Validation, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All of the animals were handled according to approved institutional animal care and using the approved protocol #21049041 by the University of Pittsburgh.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Table summary of the proteomic analysis and GO association of approximately 2000 proteins identified in TBI and control (non-TBI) condition including the fold changes and statistical significance.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67587-supp1-v1.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Summary of neuropathology cases (severe CTE and mild CTE) and controls.</title><p>Table reports all relevant information for the human sample used in the study including age, sex, phosphor TDP-43, dementia, sports played, number of years played, Braak stage (0–6), consortium to establish a registry for Alzheimer’s disease (CERAD) score (0–3), and CAA score (0–3).</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67587-supp2-v1.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>GO-ID and p-Values as well as GO associations for genes whose protein levels increase or decrease &gt; 1.6-fold.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67587-supp3-v1.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-67587-transrepform1-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amador-Ortiz</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>WL</given-names></name><name><surname>Ahmed</surname><given-names>Z</given-names></name><name><surname>Personett</surname><given-names>D</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Duara</surname><given-names>R</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Hutton</surname><given-names>ML</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease</article-title><source>Annals of Neurology</source><volume>61</volume><fpage>435</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1002/ana.21154</pub-id><pub-id pub-id-type="pmid">17469117</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>EN</given-names></name><name><surname>Gochenaur</surname><given-names>L</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Grant</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Watkins</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Pandey</surname><given-names>UB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Traumatic injury induces stress granule formation and enhances motor dysfunctions in ALS/FTD models</article-title><source>Human Molecular Genetics</source><volume>27</volume><fpage>1366</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy047</pub-id><pub-id pub-id-type="pmid">29432563</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Nonaka</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><name><surname>Tsuchiya</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Hashizume</surname><given-names>Y</given-names></name><name><surname>Oda</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</article-title><source>Biochemical and Biophysical Research Communications</source><volume>351</volume><fpage>602</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2006.10.093</pub-id><pub-id pub-id-type="pmid">17084815</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Mackenzie</surname><given-names>IRA</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Nonoka</surname><given-names>T</given-names></name><name><surname>Niizato</surname><given-names>K</given-names></name><name><surname>Tsuchiya</surname><given-names>K</given-names></name><name><surname>Iritani</surname><given-names>S</given-names></name><name><surname>Onaya</surname><given-names>M</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies</article-title><source>Acta Neuropathologica</source><volume>117</volume><fpage>125</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1007/s00401-008-0480-1</pub-id><pub-id pub-id-type="pmid">19139911</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>ES</given-names></name><name><surname>Ling</surname><given-names>SC</given-names></name><name><surname>Huelga</surname><given-names>SC</given-names></name><name><surname>Lagier-Tourenne</surname><given-names>C</given-names></name><name><surname>Polymenidou</surname><given-names>M</given-names></name><name><surname>Ditsworth</surname><given-names>D</given-names></name><name><surname>Kordasiewicz</surname><given-names>HB</given-names></name><name><surname>McAlonis-Downes</surname><given-names>M</given-names></name><name><surname>Platoshyn</surname><given-names>O</given-names></name><name><surname>Parone</surname><given-names>PA</given-names></name><name><surname>Da Cruz</surname><given-names>S</given-names></name><name><surname>Clutario</surname><given-names>KM</given-names></name><name><surname>Swing</surname><given-names>D</given-names></name><name><surname>Tessarollo</surname><given-names>L</given-names></name><name><surname>Marsala</surname><given-names>M</given-names></name><name><surname>Shaw</surname><given-names>CE</given-names></name><name><surname>Yeo</surname><given-names>GW</given-names></name><name><surname>Cleveland</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Als-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43</article-title><source>PNAS</source><volume>110</volume><fpage>E736</fpage><lpage>E745</lpage><pub-id pub-id-type="doi">10.1073/pnas.1222809110</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayala</surname><given-names>YM</given-names></name><name><surname>Zago</surname><given-names>P</given-names></name><name><surname>D'Ambrogio</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>Y-F</given-names></name><name><surname>Petrucelli</surname><given-names>L</given-names></name><name><surname>Buratti</surname><given-names>E</given-names></name><name><surname>Baralle</surname><given-names>FE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Structural determinants of the cellular localization and shuttling of TDP-43</article-title><source>Journal of Cell Science</source><volume>121</volume><fpage>3778</fpage><lpage>3785</lpage><pub-id pub-id-type="doi">10.1242/jcs.038950</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakthavachalu</surname><given-names>B</given-names></name><name><surname>Huelsmeier</surname><given-names>J</given-names></name><name><surname>Sudhakaran</surname><given-names>IP</given-names></name><name><surname>Hillebrand</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Petrauskas</surname><given-names>A</given-names></name><name><surname>Thiagarajan</surname><given-names>D</given-names></name><name><surname>Sankaranarayanan</surname><given-names>M</given-names></name><name><surname>Mizoue</surname><given-names>L</given-names></name><name><surname>Anderson</surname><given-names>EN</given-names></name><name><surname>Pandey</surname><given-names>UB</given-names></name><name><surname>Ross</surname><given-names>E</given-names></name><name><surname>VijayRaghavan</surname><given-names>K</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name><name><surname>Ramaswami</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rnp-granule assembly via ataxin-2 disordered domains is required for long-term memory and neurodegeneration</article-title><source>Neuron</source><volume>98</volume><fpage>754</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.04.032</pub-id><pub-id pub-id-type="pmid">29772202</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basel-Vanagaite</surname><given-names>L</given-names></name><name><surname>Muncher</surname><given-names>L</given-names></name><name><surname>Straussberg</surname><given-names>R</given-names></name><name><surname>Pasmanik-Chor</surname><given-names>M</given-names></name><name><surname>Yahav</surname><given-names>M</given-names></name><name><surname>Rainshtein</surname><given-names>L</given-names></name><name><surname>Walsh</surname><given-names>CA</given-names></name><name><surname>Magal</surname><given-names>N</given-names></name><name><surname>Taub</surname><given-names>E</given-names></name><name><surname>Drasinover</surname><given-names>V</given-names></name><name><surname>Shalev</surname><given-names>H</given-names></name><name><surname>Attia</surname><given-names>R</given-names></name><name><surname>Rechavi</surname><given-names>G</given-names></name><name><surname>Simon</surname><given-names>AJ</given-names></name><name><surname>Shohat</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mutated nup62 causes autosomal recessive infantile bilateral striatal necrosis</article-title><source>Annals of Neurology</source><volume>60</volume><fpage>214</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1002/ana.20902</pub-id><pub-id pub-id-type="pmid">16786527</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>UNIPROT: A worldwide hub of protein knowledge</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D506</fpage><lpage>D515</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1049</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bischoff</surname><given-names>FR</given-names></name><name><surname>Krebber</surname><given-names>H</given-names></name><name><surname>Kempf</surname><given-names>T</given-names></name><name><surname>Hermes</surname><given-names>I</given-names></name><name><surname>Ponstingl</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Human rangtpase-activating protein rangap1 is a homologue of yeast Rna1p involved in mrna processing and transport</article-title><source>PNAS</source><volume>92</volume><fpage>1749</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.5.1749</pub-id><pub-id pub-id-type="pmid">7878053</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The neuropathology and neurobiology of traumatic brain injury</article-title><source>Neuron</source><volume>76</volume><fpage>886</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.11.021</pub-id><pub-id pub-id-type="pmid">23217738</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boer</surname><given-names>J</given-names></name><name><surname>Bonten-Surtel</surname><given-names>J</given-names></name><name><surname>Grosveld</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Overexpression of the nucleoporin can/nup214 induces growth arrest, nucleocytoplasmic transport defects, and apoptosis</article-title><source>Molecular and Cellular Biology</source><volume>18</volume><fpage>1236</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1128/MCB.18.3.1236</pub-id><pub-id pub-id-type="pmid">9488438</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>JK</given-names></name><name><surname>Wang</surname><given-names>I-F</given-names></name><name><surname>Hung</surname><given-names>L</given-names></name><name><surname>Tarn</surname><given-names>W-Y</given-names></name><name><surname>Shen</surname><given-names>C-KJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Tdp-43 overexpression enhances exon 7 inclusion during the survival of motor neuron pre-mRNA splicing</article-title><source>Journal of Biological Chemistry</source><volume>283</volume><fpage>28852</fpage><lpage>28859</lpage><pub-id pub-id-type="doi">10.1074/jbc.M805376200</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyce</surname><given-names>M</given-names></name><name><surname>Carrico</surname><given-names>IS</given-names></name><name><surname>Ganguli</surname><given-names>AS</given-names></name><name><surname>Yu</surname><given-names>SH</given-names></name><name><surname>Hangauer</surname><given-names>MJ</given-names></name><name><surname>Hubbard</surname><given-names>SC</given-names></name><name><surname>Kohler</surname><given-names>JJ</given-names></name><name><surname>Bertozzi</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Metabolic cross-talk allows labeling of o-linked beta-n-acetylglucosamine-modified proteins via the n-acetylgalactosamine salvage pathway</article-title><source>PNAS</source><volume>108</volume><fpage>3141</fpage><lpage>3146</lpage><pub-id pub-id-type="doi">10.1073/pnas.1010045108</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buratti</surname><given-names>E</given-names></name><name><surname>Baralle</surname><given-names>FE</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR Exon 9</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>36337</fpage><lpage>36343</lpage><pub-id pub-id-type="doi">10.1074/jbc.M104236200</pub-id><pub-id pub-id-type="pmid">11470789</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabretta</surname><given-names>S</given-names></name><name><surname>Richard</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Emerging roles of disordered sequences in RNA-binding proteins</article-title><source>Trends in Biochemical Sciences</source><volume>40</volume><fpage>662</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2015.08.012</pub-id><pub-id pub-id-type="pmid">26481498</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantu</surname><given-names>D</given-names></name><name><surname>Croker</surname><given-names>D</given-names></name><name><surname>Tamir</surname><given-names>S</given-names></name><name><surname>Shacham</surname><given-names>S</given-names></name><name><surname>Dulla</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Using the selective inhibitor of nuclear export (SINE) compound KPT-350 to reduce cortical circuit hyperexcitability and interneuron cell loss in the controlled cortical impact (CCI) model of traumatic brain injury (TBI</article-title><source>Neurology</source><volume>86</volume><fpage>5</fpage><lpage>23</lpage></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>JC</given-names></name><name><surname>Morton</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>Drosophila</italic> lines with mutant and wild type human TDP-43 replacing the endogenous gene reveals phosphorylation and ubiquitination in mutant lines in the absence of viability or lifespan defects</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0180828</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0180828</pub-id><pub-id pub-id-type="pmid">28686708</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>NB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Chronic neurodegenerative consequences of traumatic brain injury</article-title><source>Restorative Neurology and Neuroscience</source><volume>32</volume><fpage>337</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.3233/RNN-130354</pub-id><pub-id pub-id-type="pmid">24398724</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Richard</surname><given-names>M</given-names></name><name><surname>Sandler</surname><given-names>DP</given-names></name><name><surname>Umbach</surname><given-names>DM</given-names></name><name><surname>Kamel</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Head injury and amyotrophic lateral sclerosis</article-title><source>American Journal of Epidemiology</source><volume>166</volume><fpage>810</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1093/aje/kwm153</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherry</surname><given-names>JD</given-names></name><name><surname>Tripodis</surname><given-names>Y</given-names></name><name><surname>Alvarez</surname><given-names>VE</given-names></name><name><surname>Huber</surname><given-names>B</given-names></name><name><surname>Kiernan</surname><given-names>PT</given-names></name><name><surname>Daneshvar</surname><given-names>DH</given-names></name><name><surname>Mez</surname><given-names>J</given-names></name><name><surname>Montenigro</surname><given-names>PH</given-names></name><name><surname>Solomon</surname><given-names>TM</given-names></name><name><surname>Alosco</surname><given-names>ML</given-names></name><name><surname>Stern</surname><given-names>RA</given-names></name><name><surname>McKee</surname><given-names>AC</given-names></name><name><surname>Stein</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy</article-title><source>Acta Neuropathologica Communications</source><volume>4</volume><elocation-id>112</elocation-id><pub-id pub-id-type="doi">10.1186/s40478-016-0382-8</pub-id><pub-id pub-id-type="pmid">27793189</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherry</surname><given-names>JD</given-names></name><name><surname>Stein</surname><given-names>TD</given-names></name><name><surname>Tripodis</surname><given-names>Y</given-names></name><name><surname>Alvarez</surname><given-names>VE</given-names></name><name><surname>Huber</surname><given-names>BR</given-names></name><name><surname>Au</surname><given-names>R</given-names></name><name><surname>Kiernan</surname><given-names>PT</given-names></name><name><surname>Daneshvar</surname><given-names>DH</given-names></name><name><surname>Mez</surname><given-names>J</given-names></name><name><surname>Solomon</surname><given-names>TM</given-names></name><name><surname>Alosco</surname><given-names>ML</given-names></name><name><surname>McKee</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer’s disease</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0185541</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0185541</pub-id><pub-id pub-id-type="pmid">28950005</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choksi</surname><given-names>DK</given-names></name><name><surname>Roy</surname><given-names>B</given-names></name><name><surname>Chatterjee</surname><given-names>S</given-names></name><name><surname>Yusuff</surname><given-names>T</given-names></name><name><surname>Bakhoum</surname><given-names>MF</given-names></name><name><surname>Sengupta</surname><given-names>U</given-names></name><name><surname>Ambegaokar</surname><given-names>S</given-names></name><name><surname>Kayed</surname><given-names>R</given-names></name><name><surname>Jackson</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TDP-43 phosphorylation by casein kinase iε promotes oligomerization and enhances toxicity in vivo</article-title><source>Human Molecular Genetics</source><volume>23</volume><fpage>1025</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddt498</pub-id><pub-id pub-id-type="pmid">24105464</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>CC</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Umoh</surname><given-names>ME</given-names></name><name><surname>Vaughan</surname><given-names>SW</given-names></name><name><surname>Lorenzini</surname><given-names>I</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Sayegh</surname><given-names>M</given-names></name><name><surname>Donlin-Asp</surname><given-names>PG</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Duong</surname><given-names>DM</given-names></name><name><surname>Seyfried</surname><given-names>NT</given-names></name><name><surname>Powers</surname><given-names>MA</given-names></name><name><surname>Kukar</surname><given-names>T</given-names></name><name><surname>Hales</surname><given-names>CM</given-names></name><name><surname>Gearing</surname><given-names>M</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Boylan</surname><given-names>KB</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Petrucelli</surname><given-names>L</given-names></name><name><surname>Sattler</surname><given-names>R</given-names></name><name><surname>Zarnescu</surname><given-names>DC</given-names></name><name><surname>Glass</surname><given-names>JD</given-names></name><name><surname>Rossoll</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD</article-title><source>Nature Neuroscience</source><volume>21</volume><fpage>228</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1038/s41593-017-0047-3</pub-id><pub-id pub-id-type="pmid">29311743</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conicella</surname><given-names>AE</given-names></name><name><surname>Zerze</surname><given-names>GH</given-names></name><name><surname>Mittal</surname><given-names>J</given-names></name><name><surname>Fawzi</surname><given-names>NL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ALS mutations disrupt phase separation mediated by α-helical structure in the TDP-43 low-complexity c-terminal domain</article-title><source>Structure</source><volume>24</volume><fpage>1537</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1016/j.str.2016.07.007</pub-id><pub-id pub-id-type="pmid">27545621</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>CN</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Odeh</surname><given-names>HM</given-names></name><name><surname>Gendron</surname><given-names>TF</given-names></name><name><surname>Jansen-West</surname><given-names>K</given-names></name><name><surname>Del Rosso</surname><given-names>G</given-names></name><name><surname>Yue</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Gomes</surname><given-names>E</given-names></name><name><surname>Tong</surname><given-names>J</given-names></name><name><surname>Daughrity</surname><given-names>LM</given-names></name><name><surname>Avendano</surname><given-names>NM</given-names></name><name><surname>Castanedes-Casey</surname><given-names>M</given-names></name><name><surname>Shao</surname><given-names>W</given-names></name><name><surname>Oskarsson</surname><given-names>B</given-names></name><name><surname>Tomassy</surname><given-names>GS</given-names></name><name><surname>McCampbell</surname><given-names>A</given-names></name><name><surname>Rigo</surname><given-names>F</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Shorter</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Petrucelli</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>C9orf72 poly aggr(gr)uces TDPaggregatinducestdp-43</article-title><source>Science Translational Medicine</source><volume>12</volume><elocation-id>eabb3774</elocation-id><pub-id pub-id-type="doi">10.1126/SCITRANSLMED.ABB3774</pub-id><pub-id pub-id-type="pmid">32878979</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaper</surname><given-names>DC</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Sutcliffe</surname><given-names>B</given-names></name><name><surname>Humphrey</surname><given-names>DM</given-names></name><name><surname>Elliott</surname><given-names>CJH</given-names></name><name><surname>Stepto</surname><given-names>A</given-names></name><name><surname>Ludlow</surname><given-names>ZN</given-names></name><name><surname>Vanden Broeck</surname><given-names>L</given-names></name><name><surname>Callaerts</surname><given-names>P</given-names></name><name><surname>Dermaut</surname><given-names>B</given-names></name><name><surname>Al-Chalabi</surname><given-names>A</given-names></name><name><surname>Shaw</surname><given-names>CE</given-names></name><name><surname>Robinson</surname><given-names>IM</given-names></name><name><surname>Hirth</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Loss and gain of <italic>Drosophila</italic> TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes</article-title><source>Human Molecular Genetics</source><volume>22</volume><fpage>1539</fpage><lpage>1557</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddt005</pub-id><pub-id pub-id-type="pmid">23307927</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickmanns</surname><given-names>A</given-names></name><name><surname>Kehlenbach</surname><given-names>RH</given-names></name><name><surname>Fahrenkrog</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nuclear pore complexes and nucleocytoplasmic transport: From structure to function to disease</article-title><source>International Review of Cell and Molecular Biology</source><volume>320</volume><fpage>171</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/bs.ircmb.2015.07.010</pub-id><pub-id pub-id-type="pmid">26614874</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Angelo</surname><given-names>MA</given-names></name><name><surname>Raices</surname><given-names>M</given-names></name><name><surname>Panowski</surname><given-names>SH</given-names></name><name><surname>Hetzer</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Age-dependent deterioration of nuclear pore complexes causes a loss of nuclear integrity in postmitotic cells</article-title><source>Cell</source><volume>136</volume><fpage>284</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.11.037</pub-id><pub-id pub-id-type="pmid">19167330</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eftekharzadeh</surname><given-names>B</given-names></name><name><surname>Daigle</surname><given-names>JG</given-names></name><name><surname>Kapinos</surname><given-names>LE</given-names></name><name><surname>Coyne</surname><given-names>A</given-names></name><name><surname>Schiantarelli</surname><given-names>J</given-names></name><name><surname>Carlomagno</surname><given-names>Y</given-names></name><name><surname>Cook</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>SJ</given-names></name><name><surname>Dujardin</surname><given-names>S</given-names></name><name><surname>Amaral</surname><given-names>AS</given-names></name><name><surname>Grima</surname><given-names>JC</given-names></name><name><surname>Bennett</surname><given-names>RE</given-names></name><name><surname>Tepper</surname><given-names>K</given-names></name><name><surname>DeTure</surname><given-names>M</given-names></name><name><surname>Vanderburg</surname><given-names>CR</given-names></name><name><surname>Corjuc</surname><given-names>BT</given-names></name><name><surname>DeVos</surname><given-names>SL</given-names></name><name><surname>Gonzalez</surname><given-names>JA</given-names></name><name><surname>Chew</surname><given-names>J</given-names></name><name><surname>Vidensky</surname><given-names>S</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name><name><surname>Mertens</surname><given-names>J</given-names></name><name><surname>Troncoso</surname><given-names>J</given-names></name><name><surname>Mandelkow</surname><given-names>E</given-names></name><name><surname>Salvatella</surname><given-names>X</given-names></name><name><surname>Lim</surname><given-names>RYH</given-names></name><name><surname>Petrucelli</surname><given-names>L</given-names></name><name><surname>Wegmann</surname><given-names>S</given-names></name><name><surname>Rothstein</surname><given-names>JD</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer’s Disease</article-title><source>Neuron</source><volume>99</volume><fpage>925</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.07.039</pub-id><pub-id pub-id-type="pmid">30189209</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fann</surname><given-names>JR</given-names></name><name><surname>Ribe</surname><given-names>AR</given-names></name><name><surname>Pedersen</surname><given-names>HS</given-names></name><name><surname>Fenger-Grøn</surname><given-names>M</given-names></name><name><surname>Christensen</surname><given-names>J</given-names></name><name><surname>Benros</surname><given-names>ME</given-names></name><name><surname>Vestergaard</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Long-Term risk of dementia among people with traumatic brain injury in Denmark: a population-based observational cohort study</article-title><source>The Lancet Psychiatry</source><volume>5</volume><fpage>424</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(18)30065-8</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Floch</surname><given-names>AG</given-names></name><name><surname>Palancade</surname><given-names>B</given-names></name><name><surname>Doye</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Fifty years of nuclear pores and nucleocytoplasmic transport studies: Multiple tools revealing complex rules</article-title><source>Methods in Cell Biology</source><volume>122</volume><fpage>1</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-417160-2.00001-1</pub-id><pub-id pub-id-type="pmid">24857723</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname><given-names>RC</given-names></name><name><surname>Yaffe</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Epidemiology of mild traumatic brain injury and neurodegenerative disease</article-title><source>Molecular and Cellular Neuroscience</source><volume>66</volume><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2015.03.001</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasset-Rosa</surname><given-names>F</given-names></name><name><surname>Chillon-Marinas</surname><given-names>C</given-names></name><name><surname>Goginashvili</surname><given-names>A</given-names></name><name><surname>Atwal</surname><given-names>RS</given-names></name><name><surname>Artates</surname><given-names>JW</given-names></name><name><surname>Tabet</surname><given-names>R</given-names></name><name><surname>Wheeler</surname><given-names>VC</given-names></name><name><surname>Bang</surname><given-names>AG</given-names></name><name><surname>Cleveland</surname><given-names>DW</given-names></name><name><surname>Lagier-Tourenne</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Polyglutamine-expanded huntingtin exacerbates age-related disruption of nuclear integrity and nucleocytoplasmic transport</article-title><source>Neuron</source><volume>94</volume><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.03.027</pub-id><pub-id pub-id-type="pmid">28384474</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasset-Rosa</surname><given-names>F</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Melamed</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Shorter</surname><given-names>J</given-names></name><name><surname>Da Cruz</surname><given-names>S</given-names></name><name><surname>Cleveland</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cytoplasmic tdp-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear tdp-43, and cell death</article-title><source>Neuron</source><volume>102</volume><fpage>339</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2019.02.038</pub-id><pub-id pub-id-type="pmid">30853299</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gleixner</surname><given-names>A</given-names></name><name><surname>Verdone</surname><given-names>BM</given-names></name><name><surname>Otte</surname><given-names>C</given-names></name><name><surname>Ramesh</surname><given-names>N</given-names></name><name><surname>Gale</surname><given-names>J</given-names></name><name><surname>Mauna</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>J</given-names></name><name><surname>Copley</surname><given-names>K</given-names></name><name><surname>Daley</surname><given-names>E</given-names></name><name><surname>Ortega</surname><given-names>J</given-names></name><name><surname>Cicardi</surname><given-names>M</given-names></name><name><surname>Kiskinis</surname><given-names>E</given-names></name><name><surname>Kofler</surname><given-names>J</given-names></name><name><surname>Pandey</surname><given-names>U</given-names></name><name><surname>Trotti</surname><given-names>D</given-names></name><name><surname>Donnelly</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>NUP62 is recruited to pathological condensates and promotes tdp-43 insolubility in c9orf72 and sporadic ALS/FTD</article-title><source>Research Square</source><volume>8</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.21203/rs.3.rs-144654/v1</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gloster</surname><given-names>TM</given-names></name><name><surname>Zandberg</surname><given-names>WF</given-names></name><name><surname>Heinonen</surname><given-names>JE</given-names></name><name><surname>Shen</surname><given-names>DL</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Vocadlo</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hijacking a biosynthetic pathway yields a glycosyltransferase inhibitor within cells</article-title><source>Nature Chemical Biology</source><volume>7</volume><fpage>174</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1038/nchembio.520</pub-id><pub-id pub-id-type="pmid">21258330</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>SM</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Oakes</surname><given-names>D</given-names></name><name><surname>Bhudhikanok</surname><given-names>GS</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Langston</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Head injury and Parkinson’s disease risk in twins</article-title><source>Annals of Neurology</source><volume>60</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1002/ana.20882</pub-id><pub-id pub-id-type="pmid">16718702</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grima</surname><given-names>JC</given-names></name><name><surname>Daigle</surname><given-names>JG</given-names></name><name><surname>Arbez</surname><given-names>N</given-names></name><name><surname>Cunningham</surname><given-names>KC</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Ochaba</surname><given-names>J</given-names></name><name><surname>Geater</surname><given-names>C</given-names></name><name><surname>Morozko</surname><given-names>E</given-names></name><name><surname>Stocksdale</surname><given-names>J</given-names></name><name><surname>Glatzer</surname><given-names>JC</given-names></name><name><surname>Pham</surname><given-names>JT</given-names></name><name><surname>Ahmed</surname><given-names>I</given-names></name><name><surname>Peng</surname><given-names>Q</given-names></name><name><surname>Wadhwa</surname><given-names>H</given-names></name><name><surname>Pletnikova</surname><given-names>O</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name><name><surname>Duan</surname><given-names>W</given-names></name><name><surname>Snyder</surname><given-names>SH</given-names></name><name><surname>Ranum</surname><given-names>LPW</given-names></name><name><surname>Thompson</surname><given-names>LM</given-names></name><name><surname>Lloyd</surname><given-names>TE</given-names></name><name><surname>Ross</surname><given-names>CA</given-names></name><name><surname>Rothstein</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mutant huntingtin disrupts the nuclear pore complex</article-title><source>Neuron</source><volume>94</volume><fpage>93</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.03.023</pub-id><pub-id pub-id-type="pmid">28384479</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>MA</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Marion</surname><given-names>SA</given-names></name><name><surname>Tsui</surname><given-names>JKC</given-names></name><name><surname>Teschke</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Head injuries and Parkinson’s disease in a case-control study</article-title><source>Occupational and Environmental Medicine</source><volume>70</volume><fpage>839</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1136/oemed-2013-101444</pub-id><pub-id pub-id-type="pmid">24142978</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hetzer</surname><given-names>M</given-names></name><name><surname>Gruss</surname><given-names>OJ</given-names></name><name><surname>Mattaj</surname><given-names>IW</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The Ran gtpase as a marker of chromosome position in spindle formation and nuclear envelope assembly</article-title><source>Nature Cell Biology</source><volume>4</volume><fpage>E177</fpage><lpage>E184</lpage><pub-id pub-id-type="doi">10.1038/ncb0702-e177</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>GD</given-names></name><name><surname>Snow</surname><given-names>CM</given-names></name><name><surname>Senior</surname><given-names>A</given-names></name><name><surname>Haltiwanger</surname><given-names>RS</given-names></name><name><surname>Gerace</surname><given-names>L</given-names></name><name><surname>Hart</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Nuclear pore complex glycoproteins contain cytoplasmically disposed o-linked n-acetylglucosamine</article-title><source>The Journal of Cell Biology</source><volume>104</volume><fpage>1157</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1083/jcb.104.5.1157</pub-id><pub-id pub-id-type="pmid">3571327</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Li</surname><given-names>PC</given-names></name><name><surname>Liliang</surname><given-names>PC</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>KW</given-names></name><name><surname>Chang</surname><given-names>LC</given-names></name><name><surname>Shiu</surname><given-names>LY</given-names></name><name><surname>Chen</surname><given-names>MF</given-names></name><name><surname>Sun</surname><given-names>YT</given-names></name><name><surname>Wang</surname><given-names>HK</given-names></name><name><surname>kuang</surname><given-names>WH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tdp-43 proteolysis is associated with astrocyte reactivity after traumatic brain injury in rodents</article-title><source>Journal of Neuroimmunology</source><volume>313</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2017.10.011</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutten</surname><given-names>S</given-names></name><name><surname>Dormann</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Nucleocytoplasmic transport defects in neurodegeneration - Cause or consequence?</article-title><source>Seminars in Cell &amp; Developmental Biology</source><volume>99</volume><fpage>151</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2019.05.020</pub-id><pub-id pub-id-type="pmid">31152789</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Wheeler</surname><given-names>JR</given-names></name><name><surname>Walters</surname><given-names>RW</given-names></name><name><surname>Agrawal</surname><given-names>A</given-names></name><name><surname>Barsic</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ATPase-Modulated stress granules contain a diverse proteome and substructure</article-title><source>Cell</source><volume>164</volume><fpage>487</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.12.038</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>K</given-names></name><name><surname>Sanchez-Garcia</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Khare</surname><given-names>S</given-names></name><name><surname>Mathur</surname><given-names>K</given-names></name><name><surname>Graze</surname><given-names>RM</given-names></name><name><surname>Hahn</surname><given-names>DA</given-names></name><name><surname>McIntyre</surname><given-names>LM</given-names></name><name><surname>Rincon-Limas</surname><given-names>DE</given-names></name><name><surname>Fernandez-Funez</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Purification of transcripts and metabolites from <italic>Drosophila</italic> heads</article-title><source>Journal of Visualized Experiments</source><elocation-id>e50245</elocation-id><pub-id pub-id-type="doi">10.3791/50245</pub-id><pub-id pub-id-type="pmid">23524378</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>BS</given-names></name><name><surname>Snead</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>McCaffery</surname><given-names>JM</given-names></name><name><surname>Shorter</surname><given-names>J</given-names></name><name><surname>Gitler</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Tdp-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity</article-title><source>The Journal of Biological Chemistry</source><volume>284</volume><fpage>20329</fpage><lpage>20339</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.010264</pub-id><pub-id pub-id-type="pmid">19465477</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzenberger</surname><given-names>RJ</given-names></name><name><surname>Loewen</surname><given-names>CA</given-names></name><name><surname>Wassarman</surname><given-names>DR</given-names></name><name><surname>Petersen</surname><given-names>AJ</given-names></name><name><surname>Ganetzky</surname><given-names>B</given-names></name><name><surname>Wassarman</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A <italic>Drosophila</italic> model of closed head traumatic brain injury</article-title><source>PNAS</source><volume>110</volume><fpage>E4152</fpage><lpage>E4159</lpage><pub-id pub-id-type="doi">10.1073/pnas.1316895110</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzenberger</surname><given-names>RJ</given-names></name><name><surname>Loewen</surname><given-names>CA</given-names></name><name><surname>Bockstruck</surname><given-names>RT</given-names></name><name><surname>Woods</surname><given-names>MA</given-names></name><name><surname>Ganetzky</surname><given-names>B</given-names></name><name><surname>Ganetky</surname><given-names>B</given-names></name><name><surname>Wassarman</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A method to Inflict closed head traumatic brain injury in <italic>Drosophila</italic></article-title><source>Journal of Visualized Experiments</source><elocation-id>e52905</elocation-id><pub-id pub-id-type="doi">10.3791/52905</pub-id><pub-id pub-id-type="pmid">26168076</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kedersha</surname><given-names>N</given-names></name><name><surname>Ivanov</surname><given-names>P</given-names></name><name><surname>Anderson</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Stress granules and cell signaling: More than just a passing phase?</article-title><source>Trends in Biochemical Sciences</source><volume>38</volume><fpage>494</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2013.07.004</pub-id><pub-id pub-id-type="pmid">24029419</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusano</surname><given-names>A</given-names></name><name><surname>Staber</surname><given-names>C</given-names></name><name><surname>Ganetzky</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Nuclear mislocalization of enzymatically active Rangap causes segregation distortion in <italic>Drosophila</italic></article-title><source>Developmental Cell</source><volume>1</volume><fpage>351</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/S1534-5807(01)00042-9</pub-id><pub-id pub-id-type="pmid">11702947</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lattante</surname><given-names>S</given-names></name><name><surname>Rouleau</surname><given-names>GA</given-names></name><name><surname>Kabashi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Tardbp and FUS mutations associated with amyotrophic lateral sclerosis: summary and update</article-title><source>Human Mutation</source><volume>34</volume><fpage>812</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1002/humu.22319</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Kohler</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Glycosylation of the nuclear pore</article-title><source>Traffic</source><volume>15</volume><fpage>347</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1111/tra.12150</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>DH</given-names></name><name><surname>Hoelz</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The structure of the nuclear pore complex (an update)</article-title><source>Annual Review of Biochemistry</source><volume>88</volume><fpage>725</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-062917-011901</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>SC</given-names></name><name><surname>Polymenidou</surname><given-names>M</given-names></name><name><surname>Cleveland</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis</article-title><source>Neuron</source><volume>79</volume><fpage>416</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.07.033</pub-id><pub-id pub-id-type="pmid">23931993</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lye</surname><given-names>TC</given-names></name><name><surname>Shores</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Traumatic brain injury as a risk factor for Alzheimer’s disease: a review</article-title><source>Neuropsychology Review</source><volume>10</volume><fpage>115</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1023/A:1009068804787</pub-id><pub-id pub-id-type="pmid">10937919</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Management of Concussion/mTBI Working Group</collab></person-group><year iso-8601-date="2009">2009</year><article-title>VA/DOD clinical practice guideline for management of concussion/mild traumatic brain injury</article-title><source>Journal of Rehabilitation Research and Development</source><volume>46</volume><fpage>CP1</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2005.05.008</pub-id><pub-id pub-id-type="pmid">20108447</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>JR</given-names></name><name><surname>Gleixner</surname><given-names>AM</given-names></name><name><surname>Mauna</surname><given-names>JC</given-names></name><name><surname>Gomes</surname><given-names>E</given-names></name><name><surname>DeChellis-Marks</surname><given-names>MR</given-names></name><name><surname>Needham</surname><given-names>PG</given-names></name><name><surname>Copley</surname><given-names>KE</given-names></name><name><surname>Hurtle</surname><given-names>B</given-names></name><name><surname>Portz</surname><given-names>B</given-names></name><name><surname>Pyles</surname><given-names>NJ</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Calder</surname><given-names>CB</given-names></name><name><surname>Wills</surname><given-names>ZP</given-names></name><name><surname>Pandey</surname><given-names>UB</given-names></name><name><surname>Kofler</surname><given-names>JK</given-names></name><name><surname>Brodsky</surname><given-names>JL</given-names></name><name><surname>Thathiah</surname><given-names>A</given-names></name><name><surname>Shorter</surname><given-names>J</given-names></name><name><surname>Donnelly</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>RNA binding antagonizes neurotoxic phase transitions of TDP-43</article-title><source>Neuron</source><volume>102</volume><fpage>321</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2019.01.048</pub-id><pub-id pub-id-type="pmid">30826182</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGurk</surname><given-names>L</given-names></name><name><surname>Gomes</surname><given-names>E</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Mojsilovic-Petrovic</surname><given-names>J</given-names></name><name><surname>Tran</surname><given-names>V</given-names></name><name><surname>Kalb</surname><given-names>RG</given-names></name><name><surname>Shorter</surname><given-names>J</given-names></name><name><surname>Bonini</surname><given-names>NM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Poly prevents pat(adp-ribopreventseparapatholphaseDP-43 sepofn proTDPbyiquid depromotiliquidtredemiandanulstressizgranule</article-title><source>Molecular Cell</source><volume>71</volume><fpage>703</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.07.002</pub-id><pub-id pub-id-type="pmid">30100264</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKee</surname><given-names>AC</given-names></name><name><surname>Gavett</surname><given-names>BE</given-names></name><name><surname>Stern</surname><given-names>RA</given-names></name><name><surname>Nowinski</surname><given-names>CJ</given-names></name><name><surname>Cantu</surname><given-names>RC</given-names></name><name><surname>Kowall</surname><given-names>NW</given-names></name><name><surname>Perl</surname><given-names>DP</given-names></name><name><surname>Hedley-Whyte</surname><given-names>ET</given-names></name><name><surname>Price</surname><given-names>B</given-names></name><name><surname>Sullivan</surname><given-names>C</given-names></name><name><surname>Morin</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>H-S</given-names></name><name><surname>Kubilus</surname><given-names>CA</given-names></name><name><surname>Daneshvar</surname><given-names>DH</given-names></name><name><surname>Wulff</surname><given-names>M</given-names></name><name><surname>Budson</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy</article-title><source>Journal of Neuropathology and Experimental Neurology</source><volume>69</volume><fpage>918</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e3181ee7d85</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKee</surname><given-names>AC</given-names></name><name><surname>Stern</surname><given-names>RA</given-names></name><name><surname>Nowinski</surname><given-names>CJ</given-names></name><name><surname>Stein</surname><given-names>TD</given-names></name><name><surname>Alvarez</surname><given-names>VE</given-names></name><name><surname>Daneshvar</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>H-S</given-names></name><name><surname>Wojtowicz</surname><given-names>SM</given-names></name><name><surname>Hall</surname><given-names>G</given-names></name><name><surname>Baugh</surname><given-names>CM</given-names></name><name><surname>Riley</surname><given-names>DO</given-names></name><name><surname>Kubilus</surname><given-names>CA</given-names></name><name><surname>Cormier</surname><given-names>KA</given-names></name><name><surname>Jacobs</surname><given-names>MA</given-names></name><name><surname>Martin</surname><given-names>BR</given-names></name><name><surname>Abraham</surname><given-names>CR</given-names></name><name><surname>Ikezu</surname><given-names>T</given-names></name><name><surname>Reichard</surname><given-names>RR</given-names></name><name><surname>Wolozin</surname><given-names>BL</given-names></name><name><surname>Budson</surname><given-names>AE</given-names></name><name><surname>Goldstein</surname><given-names>LE</given-names></name><name><surname>Kowall</surname><given-names>NW</given-names></name><name><surname>Cantu</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The spectrum of disease in chronic traumatic encephalopathy</article-title><source>Brain</source><volume>136</volume><fpage>43</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1093/brain/aws307</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKee</surname><given-names>AC</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Folkerth</surname><given-names>RD</given-names></name><name><surname>Keene</surname><given-names>CD</given-names></name><name><surname>Litvan</surname><given-names>I</given-names></name><name><surname>Perl</surname><given-names>DP</given-names></name><name><surname>Stein</surname><given-names>TD</given-names></name><name><surname>Vonsattel</surname><given-names>J-P</given-names></name><name><surname>Stewart</surname><given-names>W</given-names></name><name><surname>Tripodis</surname><given-names>Y</given-names></name><name><surname>Crary</surname><given-names>JF</given-names></name><name><surname>Bieniek</surname><given-names>KF</given-names></name><name><surname>Dams-O’Connor</surname><given-names>K</given-names></name><name><surname>Alvarez</surname><given-names>VE</given-names></name><name><surname>Gordon</surname><given-names>WA</given-names></name><collab>TBI/CTE group</collab></person-group><year iso-8601-date="2016">2016</year><article-title>The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy</article-title><source>Acta Neuropathologica</source><volume>131</volume><fpage>75</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1007/s00401-015-1515-z</pub-id><pub-id pub-id-type="pmid">26667418</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mckee</surname><given-names>AC</given-names></name><name><surname>Abdolmohammadi</surname><given-names>B</given-names></name><name><surname>Stein</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The neuropathology of chronic traumatic encephalopathy</article-title><source>Brain Pathology</source><volume>158</volume><fpage>297</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-63954-7.00028-8</pub-id><pub-id pub-id-type="pmid">30482357</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mez</surname><given-names>J</given-names></name><name><surname>Solomon</surname><given-names>TM</given-names></name><name><surname>Daneshvar</surname><given-names>DH</given-names></name><name><surname>Murphy</surname><given-names>L</given-names></name><name><surname>Kiernan</surname><given-names>PT</given-names></name><name><surname>Montenigro</surname><given-names>PH</given-names></name><name><surname>Kriegel</surname><given-names>J</given-names></name><name><surname>Abdolmohammadi</surname><given-names>B</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Babcock</surname><given-names>KJ</given-names></name><name><surname>Adams</surname><given-names>JW</given-names></name><name><surname>Bourlas</surname><given-names>AP</given-names></name><name><surname>Papadopoulos</surname><given-names>Z</given-names></name><name><surname>McHale</surname><given-names>L</given-names></name><name><surname>Ardaugh</surname><given-names>BM</given-names></name><name><surname>Martin</surname><given-names>BR</given-names></name><name><surname>Dixon</surname><given-names>D</given-names></name><name><surname>Nowinski</surname><given-names>CJ</given-names></name><name><surname>Chaisson</surname><given-names>C</given-names></name><name><surname>Alvarez</surname><given-names>VE</given-names></name><name><surname>Tripodis</surname><given-names>Y</given-names></name><name><surname>Stein</surname><given-names>TD</given-names></name><name><surname>Goldstein</surname><given-names>LE</given-names></name><name><surname>Katz</surname><given-names>DI</given-names></name><name><surname>Kowall</surname><given-names>NW</given-names></name><name><surname>Cantu</surname><given-names>RC</given-names></name><name><surname>Stern</surname><given-names>RA</given-names></name><name><surname>McKee</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Assessing clinicopathological correlation in chronic traumatic encephalopathy: Rationale and methods for the unite study</article-title><source>Alzheimer’s Research &amp; Therapy</source><volume>7</volume><elocation-id>62</elocation-id><pub-id pub-id-type="doi">10.1186/s13195-015-0148-8</pub-id><pub-id pub-id-type="pmid">26455775</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molliex</surname><given-names>A</given-names></name><name><surname>Temirov</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Coughlin</surname><given-names>M</given-names></name><name><surname>Kanagaraj</surname><given-names>AP</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Mittag</surname><given-names>T</given-names></name><name><surname>Taylor</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization</article-title><source>Cell</source><volume>163</volume><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.09.015</pub-id><pub-id pub-id-type="pmid">26406374</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>T</given-names></name><name><surname>Qamar</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>JQ</given-names></name><name><surname>Schierle</surname><given-names>GSK</given-names></name><name><surname>Rees</surname><given-names>E</given-names></name><name><surname>Miyashita</surname><given-names>A</given-names></name><name><surname>Costa</surname><given-names>AR</given-names></name><name><surname>Dodd</surname><given-names>RB</given-names></name><name><surname>Chan</surname><given-names>FTS</given-names></name><name><surname>Michel</surname><given-names>CH</given-names></name><name><surname>Kronenberg-Versteeg</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>SP</given-names></name><name><surname>Wakutani</surname><given-names>Y</given-names></name><name><surname>Meadows</surname><given-names>W</given-names></name><name><surname>Ferry</surname><given-names>RR</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Tartaglia</surname><given-names>GG</given-names></name><name><surname>Favrin</surname><given-names>G</given-names></name><name><surname>Lin</surname><given-names>WL</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Zhen</surname><given-names>M</given-names></name><name><surname>Ron</surname><given-names>D</given-names></name><name><surname>Schmitt-Ulms</surname><given-names>G</given-names></name><name><surname>Fraser</surname><given-names>PE</given-names></name><name><surname>Shneider</surname><given-names>NA</given-names></name><name><surname>Holt</surname><given-names>C</given-names></name><name><surname>Vendruscolo</surname><given-names>M</given-names></name><name><surname>Kaminski</surname><given-names>CF</given-names></name><name><surname>St George-Hyslop</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Als/ftd mutation-induced phase transition of FUS liquid droplets and reversible hydrogels into irreversible hydrogels impairs RNP granule function</article-title><source>Neuron</source><volume>88</volume><fpage>678</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.10.030</pub-id><pub-id pub-id-type="pmid">26526393</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Sampathu</surname><given-names>DM</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Truax</surname><given-names>AC</given-names></name><name><surname>Micsenyi</surname><given-names>MC</given-names></name><name><surname>Chou</surname><given-names>TT</given-names></name><name><surname>Bruce</surname><given-names>J</given-names></name><name><surname>Schuck</surname><given-names>T</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>CM</given-names></name><name><surname>McCluskey</surname><given-names>LF</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Feiden</surname><given-names>W</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>V-Y</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</article-title><source>Science</source><volume>314</volume><fpage>130</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1126/science.1134108</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nofrini</surname><given-names>V</given-names></name><name><surname>Di Giacomo</surname><given-names>D</given-names></name><name><surname>Mecucci</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Nucleoporin genes in human diseases</article-title><source>European Journal of Human Genetics</source><volume>24</volume><fpage>1388</fpage><lpage>1395</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2016.25</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Old</surname><given-names>WM</given-names></name><name><surname>Meyer-Arendt</surname><given-names>K</given-names></name><name><surname>Aveline-Wolf</surname><given-names>L</given-names></name><name><surname>Pierce</surname><given-names>KG</given-names></name><name><surname>Mendoza</surname><given-names>A</given-names></name><name><surname>Sevinsky</surname><given-names>JR</given-names></name><name><surname>Resing</surname><given-names>KA</given-names></name><name><surname>Ahn</surname><given-names>NG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Comparison of label-free methods for quantifying human proteins by shotgun proteomics</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>4</volume><fpage>1487</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1074/mcp.M500084-MCP200</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omalu</surname><given-names>BI</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name><name><surname>Minster</surname><given-names>RL</given-names></name><name><surname>Kamboh</surname><given-names>MI</given-names></name><name><surname>Hamilton</surname><given-names>RL</given-names></name><name><surname>Wecht</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Chronic traumatic encephalopathy in a National Football League player</article-title><source>Neurosurgery</source><volume>57</volume><fpage>128</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1227/01.NEU.0000163407.92769.ED</pub-id><pub-id pub-id-type="pmid">15987548</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omalu</surname><given-names>BI</given-names></name><name><surname>Fitzsimmons</surname><given-names>RP</given-names></name><name><surname>Hammers</surname><given-names>J</given-names></name><name><surname>Bailes</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Chronic traumatic encephalopathy in a professional american wrestler</article-title><source>Journal of Forensic Nursing</source><volume>6</volume><fpage>130</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1111/j.1939-3938.2010.01078.x</pub-id><pub-id pub-id-type="pmid">21175533</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osterwalder</surname><given-names>T</given-names></name><name><surname>Yoon</surname><given-names>KS</given-names></name><name><surname>White</surname><given-names>BH</given-names></name><name><surname>Keshishian</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>A conditional tissue-specific transgene expression system using inducible GAL4</article-title><source>PNAS</source><volume>98</volume><fpage>12596</fpage><lpage>12601</lpage><pub-id pub-id-type="doi">10.1073/pnas.221303298</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>HO</given-names></name><name><surname>Jawerth</surname><given-names>L</given-names></name><name><surname>Maharana</surname><given-names>S</given-names></name><name><surname>Jahnel</surname><given-names>M</given-names></name><name><surname>Hein</surname><given-names>MY</given-names></name><name><surname>Stoynov</surname><given-names>S</given-names></name><name><surname>Mahamid</surname><given-names>J</given-names></name><name><surname>Saha</surname><given-names>S</given-names></name><name><surname>Franzmann</surname><given-names>TM</given-names></name><name><surname>Pozniakovski</surname><given-names>A</given-names></name><name><surname>Poser</surname><given-names>I</given-names></name><name><surname>Maghelli</surname><given-names>N</given-names></name><name><surname>Royer</surname><given-names>LA</given-names></name><name><surname>Weigert</surname><given-names>M</given-names></name><name><surname>Myers</surname><given-names>EW</given-names></name><name><surname>Grill</surname><given-names>S</given-names></name><name><surname>Drechsel</surname><given-names>D</given-names></name><name><surname>Hyman</surname><given-names>AA</given-names></name><name><surname>Alberti</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A liquid-to-solid phase transition of the ALS protein fus accelerated by disease mutation</article-title><source>Cell</source><volume>162</volume><fpage>1066</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.07.047</pub-id><pub-id pub-id-type="pmid">26317470</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>TL</given-names></name><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Weibull</surname><given-names>CE</given-names></name><name><surname>Sandler</surname><given-names>DP</given-names></name><name><surname>Kamel</surname><given-names>F</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Severe head injury and amyotrophic lateral sclerosis</article-title><source>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</source><volume>14</volume><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.3109/21678421.2012.754043</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polymenidou</surname><given-names>M</given-names></name><name><surname>Lagier-Tourenne</surname><given-names>C</given-names></name><name><surname>Hutt</surname><given-names>KR</given-names></name><name><surname>Bennett</surname><given-names>CF</given-names></name><name><surname>Cleveland</surname><given-names>DW</given-names></name><name><surname>Yeo</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Misregulated RNA processing in amyotrophic lateral sclerosis</article-title><source>Brain Research</source><volume>1462</volume><fpage>3</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2012.02.059</pub-id><pub-id pub-id-type="pmid">22444279</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pujol</surname><given-names>G</given-names></name><name><surname>Söderqvist</surname><given-names>H</given-names></name><name><surname>Radu</surname><given-names>A</given-names></name><name><surname>Pujol</surname><given-names>G</given-names></name><name><surname>Söderqvist</surname><given-names>H</given-names></name><name><surname>Radu</surname><given-names>A</given-names></name><name><surname>Pujol</surname><given-names>G</given-names></name><name><surname>SöderqvistRadu</surname><given-names>HH</given-names></name><name><surname>Pujol</surname><given-names>G</given-names></name><name><surname>Söderqvist</surname><given-names>H</given-names></name><name><surname>Radu</surname><given-names>A</given-names></name><name><surname>Pujol</surname><given-names>G</given-names></name><name><surname>Söderqvist</surname><given-names>H</given-names></name><name><surname>Radu</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Age-associated reduction of nuclear protein import in human fibroblasts</article-title><source>Biochemical and Biophysical Research Communications</source><volume>294</volume><fpage>354</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(02)00492-8</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>P</given-names></name><name><surname>Xylourgidis</surname><given-names>N</given-names></name><name><surname>Sabri</surname><given-names>N</given-names></name><name><surname>Uv</surname><given-names>A</given-names></name><name><surname>Fornerod</surname><given-names>M</given-names></name><name><surname>Samakovlis</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The <italic>Drosophila</italic> nucleoporin DNup88 localizes DNup214 and CRM1 on the nuclear envelope and attenuates NES-mediated nuclear export</article-title><source>Journal of Cell Biology</source><volume>163</volume><fpage>701</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1083/jcb.200304046</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>R</given-names></name><name><surname>Smoot</surname><given-names>ME</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Ruscheinski</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>PL</given-names></name><name><surname>Lotia</surname><given-names>S</given-names></name><name><surname>Pico</surname><given-names>AR</given-names></name><name><surname>Bader</surname><given-names>GD</given-names></name><name><surname>Ideker</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A travel guide to cytoscape plugins</article-title><source>Nature Methods</source><volume>9</volume><fpage>1069</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2212</pub-id><pub-id pub-id-type="pmid">23132118</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Aungst</surname><given-names>S</given-names></name><name><surname>Sabirzhanov</surname><given-names>B</given-names></name><name><surname>Faden</surname><given-names>AI</given-names></name><name><surname>Lipinski</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Impaired autophagy flux is associated with neuronal cell death after traumatic brain injury</article-title><source>Autophagy</source><volume>10</volume><fpage>2208</fpage><lpage>2222</lpage><pub-id pub-id-type="doi">10.4161/15548627.2014.981787</pub-id><pub-id pub-id-type="pmid">25484084</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schachtrup</surname><given-names>C</given-names></name><name><surname>Ryu</surname><given-names>JK</given-names></name><name><surname>Mammadzada</surname><given-names>K</given-names></name><name><surname>Khan</surname><given-names>AS</given-names></name><name><surname>Carlton</surname><given-names>PM</given-names></name><name><surname>Perez</surname><given-names>A</given-names></name><name><surname>Christian</surname><given-names>F</given-names></name><name><surname>Le Moan</surname><given-names>N</given-names></name><name><surname>Vagena</surname><given-names>E</given-names></name><name><surname>Baeza-Raja</surname><given-names>B</given-names></name><name><surname>Rafalski</surname><given-names>V</given-names></name><name><surname>Chan</surname><given-names>JP</given-names></name><name><surname>Nitschke</surname><given-names>R</given-names></name><name><surname>Houslay</surname><given-names>MD</given-names></name><name><surname>Ellisman</surname><given-names>MH</given-names></name><name><surname>Wyss-Coray</surname><given-names>T</given-names></name><name><surname>Palop</surname><given-names>JJ</given-names></name><name><surname>Akassoglou</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nuclear pore complex remodeling by p75(NTR) cleavage controls TGF-β signaling and astrocyte functions</article-title><source>Nature Neuroscience</source><volume>18</volume><fpage>1077</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1038/nn.4054</pub-id><pub-id pub-id-type="pmid">26120963</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmittgen</surname><given-names>TD</given-names></name><name><surname>Livak</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Analyzing real-time PCR data by the comparative C met(T</article-title><source>Nature Protocols</source><volume>3</volume><fpage>1101</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.73</pub-id><pub-id pub-id-type="pmid">18546601</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivanandam</surname><given-names>TM</given-names></name><name><surname>Thakur</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Traumatic brain injury: A risk factor for Alzheimer’s disease</article-title><source>Neuroscience and Biobehavioral Reviews</source><volume>36</volume><fpage>1376</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2012.02.013</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solmaz</surname><given-names>SR</given-names></name><name><surname>Chauhan</surname><given-names>R</given-names></name><name><surname>Blobel</surname><given-names>G</given-names></name><name><surname>Melčák</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Molecular architecture of the transport channel of the nuclear pore complex</article-title><source>Cell</source><volume>147</volume><fpage>590</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.09.034</pub-id><pub-id pub-id-type="pmid">22036567</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sozda</surname><given-names>CN</given-names></name><name><surname>Hoffman</surname><given-names>AN</given-names></name><name><surname>Olsen</surname><given-names>AS</given-names></name><name><surname>Cheng</surname><given-names>JP</given-names></name><name><surname>Zafonte</surname><given-names>RD</given-names></name><name><surname>Kline</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Empirical comparison of typical and atypical environmental enrichment paradigms on functional and histological outcome after experimental traumatic brain injury</article-title><source>Journal of Neurotrauma</source><volume>27</volume><fpage>1047</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1089/neu.2010.1313</pub-id><pub-id pub-id-type="pmid">20334496</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>RA</given-names></name><name><surname>Riley</surname><given-names>DO</given-names></name><name><surname>Daneshvar</surname><given-names>DH</given-names></name><name><surname>Nowinski</surname><given-names>CJ</given-names></name><name><surname>Cantu</surname><given-names>RC</given-names></name><name><surname>McKee</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Long-term consequences of repetitive brain trauma: Chronic traumatic encephalopathy</article-title><source>The Journal of Injury, Function, and Rehabilitation</source><volume>3</volume><fpage>S460</fpage><lpage>S467</lpage><pub-id pub-id-type="doi">10.1016/j.pmrj.2011.08.008</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tajiri</surname><given-names>N</given-names></name><name><surname>Peña</surname><given-names>DL</given-names></name><name><surname>Acosta</surname><given-names>SA</given-names></name><name><surname>Kaneko</surname><given-names>Y</given-names></name><name><surname>Tamir</surname><given-names>S</given-names></name><name><surname>Landesman</surname><given-names>Y</given-names></name><name><surname>Carlson</surname><given-names>R</given-names></name><name><surname>Shacham</surname><given-names>S</given-names></name><name><surname>Borlongan</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A nuclear attack on traumatic brain injury: Sequestration of cell death in the nucleus</article-title><source>CNS Neuroscience &amp; Therapeutics</source><volume>22</volume><fpage>306</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1111/cns.12501</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamir</surname><given-names>S</given-names></name><name><surname>Cochran</surname><given-names>S</given-names></name><name><surname>Ruan</surname><given-names>K</given-names></name><name><surname>Wilhelm</surname><given-names>M</given-names></name><name><surname>Rothstein</surname><given-names>J</given-names></name><name><surname>Hayes</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Shacham</surname><given-names>S</given-names></name><name><surname>Grima</surname><given-names>J</given-names></name><name><surname>Lloyd</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>KPT-350 reduces neurodegeneration and rescues aberrant nucleocytoplasmic transport in <italic>Drosophila</italic> model of C9orf72 ALS/FTD</article-title><source>Journal of the Neurological Sciences</source><volume>381</volume><elocation-id>715</elocation-id><pub-id pub-id-type="doi">10.1016/j.jns.2017.08.2015</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>XL</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Brady</surname><given-names>RD</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Llanos</surname><given-names>R</given-names></name><name><surname>Cheung</surname><given-names>S</given-names></name><name><surname>Wright</surname><given-names>DK</given-names></name><name><surname>Casillas-Espinosa</surname><given-names>PM</given-names></name><name><surname>Sashindranath</surname><given-names>M</given-names></name><name><surname>O’Brien</surname><given-names>TJ</given-names></name><name><surname>McDonald</surname><given-names>SJ</given-names></name><name><surname>Turner</surname><given-names>BJ</given-names></name><name><surname>Shultz</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Transactive response Dna-binding protein 43 abnormalities after traumatic brain injury</article-title><source>Journal of Neurotrauma</source><volume>5</volume><fpage>12</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1089/neu.2017.5491</pub-id><pub-id pub-id-type="pmid">29901412</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>KM</given-names></name><name><surname>Saint-Hilaire</surname><given-names>MH</given-names></name><name><surname>Sudarsky</surname><given-names>L</given-names></name><name><surname>Simon</surname><given-names>DK</given-names></name><name><surname>Hersh</surname><given-names>B</given-names></name><name><surname>Sparrow</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Weisskopf</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Head injury at early ages is associated with risk of Parkinson’s disease</article-title><source>Parkinsonism &amp; Related Disorders</source><volume>23</volume><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2015.12.005</pub-id><pub-id pub-id-type="pmid">26725141</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyanova</surname><given-names>S</given-names></name><name><surname>Temu</surname><given-names>T</given-names></name><name><surname>Carlson</surname><given-names>A</given-names></name><name><surname>Sinitcyn</surname><given-names>P</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Cox</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Visualization of LC-MS/MS proteomics data in Maxquant</article-title><source>Proteomics</source><volume>15</volume><fpage>1453</fpage><lpage>1456</lpage><pub-id pub-id-type="doi">10.1002/pmic.201400449</pub-id><pub-id pub-id-type="pmid">25644178</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tylicka</surname><given-names>M</given-names></name><name><surname>Matuszczak</surname><given-names>E</given-names></name><name><surname>Dębek</surname><given-names>W</given-names></name><name><surname>Hermanowicz</surname><given-names>A</given-names></name><name><surname>Ostrowska</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Circulating proteasome activity following mild head injury in children</article-title><source>Child’s Nervous System</source><volume>30</volume><fpage>1191</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1007/s00381-014-2409-4</pub-id><pub-id pub-id-type="pmid">24700339</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uryu</surname><given-names>K</given-names></name><name><surname>Nakashima-Yasuda</surname><given-names>H</given-names></name><name><surname>Forman</surname><given-names>MS</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Clark</surname><given-names>CM</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>Lee</surname><given-names>VM-Y</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies</article-title><source>Journal of Neuropathology &amp; Experimental Neurology</source><volume>67</volume><fpage>555</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e31817713b5</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Deursen</surname><given-names>J</given-names></name><name><surname>Boer</surname><given-names>J</given-names></name><name><surname>Kasper</surname><given-names>L</given-names></name><name><surname>Grosveld</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>G2 arrest and impaired nucleocytoplasmic transport in mouse embryos lacking the proto-oncogene can/nup214</article-title><source>The EMBO Journal</source><volume>15</volume><fpage>5574</fpage><lpage>5583</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1996.tb00942.x</pub-id><pub-id pub-id-type="pmid">8896451</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanacore</surname><given-names>N</given-names></name><name><surname>Binazzi</surname><given-names>A</given-names></name><name><surname>Bottazzi</surname><given-names>M</given-names></name><name><surname>Belli</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Amyotrophic lateral sclerosis in an Italian professional soccer player</article-title><source>Parkinsonism &amp; Related Disorders</source><volume>12</volume><fpage>327</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2005.11.007</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HK</given-names></name><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Liliang</surname><given-names>PC</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>HJ</given-names></name><name><surname>Li</surname><given-names>YC</given-names></name><name><surname>Tsai</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Traumatic brain injury causes frontotemporal dementia and tdp-43 proteolysis</article-title><source>Neuroscience</source><volume>300</volume><fpage>94</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.05.013</pub-id><pub-id pub-id-type="pmid">25982564</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiesner</surname><given-names>D</given-names></name><name><surname>Tar</surname><given-names>L</given-names></name><name><surname>Linkus</surname><given-names>B</given-names></name><name><surname>Chandrasekar</surname><given-names>A</given-names></name><name><surname>Olde Heuvel</surname><given-names>F</given-names></name><name><surname>Dupuis</surname><given-names>L</given-names></name><name><surname>Tsao</surname><given-names>W</given-names></name><name><surname>Wong</surname><given-names>PC</given-names></name><name><surname>Ludolph</surname><given-names>A</given-names></name><name><surname>Roselli</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Reversible induction of TDP-43 granules in cortical neurons after traumatic injury</article-title><source>Experimental Neurology</source><volume>299</volume><fpage>15</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2017.09.011</pub-id><pub-id pub-id-type="pmid">28941811</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wisniewski</surname><given-names>JR</given-names></name><name><surname>Zougman</surname><given-names>A</given-names></name><name><surname>Nagaraj</surname><given-names>N</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Universal sample preparation method for proteome analysis</article-title><source>Nature Methods</source><volume>6</volume><fpage>359</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1322</pub-id><pub-id pub-id-type="pmid">19377485</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Kasper</surname><given-names>LH</given-names></name><name><surname>Mantcheva</surname><given-names>RT</given-names></name><name><surname>Mantchev</surname><given-names>GT</given-names></name><name><surname>Springett</surname><given-names>MJ</given-names></name><name><surname>van Deursen</surname><given-names>JMA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Disruption of the FG nucleoporin nup98 causes selective changes in nuclear pore complex stoichiometry and function</article-title><source>PNAS</source><volume>98</volume><fpage>3191</fpage><lpage>3196</lpage><pub-id pub-id-type="doi">10.1073/pnas.051631598</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Mahmood</surname><given-names>A</given-names></name><name><surname>Chopp</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Animal models of traumatic brain injury</article-title><source>Nature Reviews. Neuroscience</source><volume>14</volume><fpage>128</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1038/nrn3407</pub-id><pub-id pub-id-type="pmid">23329160</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>McCabe</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Alterations of cerebral cortex and hippocampal proteasome subunit expression and function in a traumatic brain injury rat model</article-title><source>Journal of Neurochemistry</source><volume>104</volume><fpage>353</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.04970.x</pub-id><pub-id pub-id-type="pmid">17944870</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaninotto</surname><given-names>ALC</given-names></name><name><surname>Costa</surname><given-names>BT</given-names></name><name><surname>Ferreira</surname><given-names>IS</given-names></name><name><surname>French</surname><given-names>M</given-names></name><name><surname>Paiva</surname><given-names>WS</given-names></name><name><surname>Fregni</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Traumatic brain injury</article-title><source>Neuromethods</source><volume>139</volume><fpage>1</fpage><lpage>3</lpage></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>XJ</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Ning</surname><given-names>YL</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>ZA</given-names></name><name><surname>Chen</surname><given-names>JF</given-names></name><name><surname>Zhou</surname><given-names>YG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Impaired autophagic flux is associated with the severity of trauma and the role of A2AR in brain cells after traumatic brain injury</article-title><source>Cell Death &amp; Disease</source><volume>9</volume><elocation-id>252</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-018-0316-4</pub-id><pub-id pub-id-type="pmid">29449536</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Y-F</surname><given-names>X</given-names></name><name><surname>Cook</surname><given-names>C</given-names></name><name><surname>Gendron</surname><given-names>TF</given-names></name><name><surname>Roettges</surname><given-names>P</given-names></name><name><surname>Link</surname><given-names>CD</given-names></name><name><surname>Lin</surname><given-names>WL</given-names></name><name><surname>Tong</surname><given-names>J</given-names></name><name><surname>Castanedes-Casey</surname><given-names>M</given-names></name><name><surname>Ash</surname><given-names>P</given-names></name><name><surname>Gass</surname><given-names>J</given-names></name><name><surname>Rangachari</surname><given-names>V</given-names></name><name><surname>Buratti</surname><given-names>E</given-names></name><name><surname>Baralle</surname><given-names>F</given-names></name><name><surname>Golde</surname><given-names>TE</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Petrucelli</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Aberrant cleavage of tdp-43 enhances aggregation and cellular toxicity</article-title><source>PNAS</source><volume>106</volume><fpage>7607</fpage><lpage>7612</lpage><pub-id pub-id-type="doi">10.1073/pnas.0900688106</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Donnelly</surname><given-names>CJ</given-names></name><name><surname>Haeusler</surname><given-names>AR</given-names></name><name><surname>Grima</surname><given-names>JC</given-names></name><name><surname>Machamer</surname><given-names>JB</given-names></name><name><surname>Steinwald</surname><given-names>P</given-names></name><name><surname>Daley</surname><given-names>EL</given-names></name><name><surname>Miller</surname><given-names>SJ</given-names></name><name><surname>Cunningham</surname><given-names>KM</given-names></name><name><surname>Vidensky</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>MA</given-names></name><name><surname>Hong</surname><given-names>I</given-names></name><name><surname>Chiu</surname><given-names>SL</given-names></name><name><surname>Huganir</surname><given-names>RL</given-names></name><name><surname>Ostrow</surname><given-names>LW</given-names></name><name><surname>Matunis</surname><given-names>MJ</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Sattler</surname><given-names>R</given-names></name><name><surname>Lloyd</surname><given-names>TE</given-names></name><name><surname>Rothstein</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The C9ORF72 repeat expansion disrupts nucleocytoplasmic transport</article-title><source>Nature</source><volume>525</volume><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/nature14973</pub-id><pub-id pub-id-type="pmid">26308891</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Daigle</surname><given-names>JG</given-names></name><name><surname>Cunningham</surname><given-names>KM</given-names></name><name><surname>Coyne</surname><given-names>AN</given-names></name><name><surname>Ruan</surname><given-names>K</given-names></name><name><surname>Grima</surname><given-names>JC</given-names></name><name><surname>Bowen</surname><given-names>KE</given-names></name><name><surname>Wadhwa</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Rigo</surname><given-names>F</given-names></name><name><surname>Taylor</surname><given-names>JP</given-names></name><name><surname>Gitler</surname><given-names>AD</given-names></name><name><surname>Rothstein</surname><given-names>JD</given-names></name><name><surname>Lloyd</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Stress granule assembly disrupts nucleocytoplasmic transport</article-title><source>Cell</source><volume>173</volume><fpage>958</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.025</pub-id><pub-id pub-id-type="pmid">29628143</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>TW</given-names></name><name><surname>Madden</surname><given-names>Z</given-names></name><name><surname>Yuzwa</surname><given-names>SA</given-names></name><name><surname>Murray</surname><given-names>K</given-names></name><name><surname>Cecioni</surname><given-names>S</given-names></name><name><surname>Zachara</surname><given-names>N</given-names></name><name><surname>Vocadlo</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Post-translational o-glcnacylation is essential for nuclear pore integrity and maintenance of the pore selectivity filter</article-title><source>Journal of Molecular Cell Biology</source><volume>8</volume><fpage>2</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1093/jmcb/mjv033</pub-id><pub-id pub-id-type="pmid">26031751</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67587.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Verstreken</surname><given-names>Patrik</given-names></name><role>Reviewing Editor</role><aff><institution>KU Leuven</institution><country>Belgium</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Yamamoto</surname><given-names>Shinya</given-names></name><role>Reviewer</role><aff><institution>Baylor College of Medicine</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Anderson and colleagues use a traumatic brain injury (TBI) model fruit fly to understand the molecular pathogenesis of this disease. They identify proteins that are altered upon TBI, including that Nucleoporins (Nups) are upregulated and this is associated with the aggregation of TDP-43, a protein implicated in neurodegeneration. These findings were confirmed in a TBI rat model and in samples from patients who suffered from TBI. The findings provide molecular insight into TBI pathogenesis and identify a promising therapeutic pathway.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Traumatic injury results in functional impairments in nucleocytoplasmic transport and leads to TDP-43 pathology&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Huda Zoghbi as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Shinya Yamamoto (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>As you will see from the reviews below, and from our subsequent discussion, we were enthusiastic about the paper. The reviewers ask a number of questions that are listed below, but there are two items we all agreed on that we hope you will be able to address, possibly by including new experiments or by textual changes:</p><p>1. You currently do not directly demonstrate the stability of Nups. We suggest to either reword the text or include a pulse-chase experiment to study the stability of Nups;</p><p>2. Clearly discuss the two possible models i.e. TDP-43 aggregation leads to Nup alterations or vice versa; or include experiments that clarify this relationship.</p><p><italic>Reviewer #2:</italic></p><p>Anderson and colleagues investigated the mechanisms underlying toxicity during traumatic brain injury (TBI), which is emerging as a risk factor in several neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis (ALS) and chronic traumatic encephalopathy (CTE). They propose deficits in nucleocytoplasmic transport accompanied by TDP-43 pathology to be critical to TBI-induced damage. Starting from a proteomic analysis of brains from a TBI <italic>Drosophila</italic> model previously reported by the team (Anderson et al., 2018 HMG), the authors identify that the majority of the proteins with altered expression (361 proteins) are significantly upregulated, among which nearly half of the 30 known components of the nucleopore complex (NPC) -which the study focuses on. The authors report that repeated trauma provokes aberrant localization and aggregation of specific components of the NPC (including Nup62) in multiple TBI models including <italic>Drosophila</italic>, human cell line, rats, and ultimately in postmortem autopsied brains from CTE patients. Using a functional GFP-reporter assay they demonstrate that TBI impairs active nucleocytoplasmic transport and that pharmacological inhibition of nuclear export improves nuclear/cytoplasmic transport the GFP reporter as well as the fly eclosion deficits caused by TBI.</p><p>The team had previously reported that TBI recapitulates TDP-43 pathology in <italic>Drosophila</italic> (Anderson et al., 2018 HMG). Here, the authors report that increased expression of nucleoporins (Nups) including Nup62 in a human cell line (Hek) and in flies induces TDP-43 mislocalization/aggregation, motor impairments and reduced survival, thus leading to the proposal that TBI induced-NPC deficits may provoke TDP-43 pathology.</p><p>The authors convincingly demonstrate that TBI provokes morphological and functional alterations in NPC and nucleocytoplasmic transport, which can be partially improved by pharmacological inhibition of nuclear export thus providing mechanistic insight with potential therapeutic avenue. That being said, there are some aspects that need to be clarified to fully support all claims.</p><p>1. In figure 1 the authors conclude that trauma increases stability of Nup214, as increased accumulation of Nup214 is observed (by WB) with time of post-traumatic injury. However, the authors also report that mRNA levels are increased and the time course provided does not allow to fully exclude that Nup enhanced levels may occur predominantly at the transcriptional level (rather than at the protein level due to reduced turnover and/or increased stability as claimed by the authors). To substantiate the authors' conclusion on the effects of enhanced stability, pulse-chase/cycloheximide experiments should be considered.</p><p>Strengthening such evidence on stability is even more critical given this is in contrast with previously published studies describing a loss (or reduction) rather than increase of NPC components during neurodegenerative processes (Coyne et al., 2020 Neuron; Chou et al. 2017 Nat Neurosc) or aging (D'Angelo et al., 2009 Cell).</p><p>2. In their original study describing the TBI <italic>Drosophila</italic> model (Anderson et al. 2018 HMG) the authors had proposed that repetitive trauma induces TDP-43 mislocalization and stress granule formation. Here the authors suggest that TDP-43 pathology may be caused by TBI-induced NPC deficits as cautiously stated &quot;TBI leads to NCT defects, which potentially mediate the TDP-43 pathology in CTE&quot;. Given the ample evidence demonstrating that TDP-43 demixing/aggregation induces (in vitro and in vivo) NPC deficits with possible sequestration of some NPC components together with TDP-43 aggregates (Chou et al., 2017 Nat Neuros, Ditsworth et al. 2017 Acta Neuropath, Zhang et al., 2018 Cell, Gasset-Rosa et al. 2019 Neuron), nucleocytoplasmic transport deficits could thus be a consequence of cytoplasmic TDP-43 pathology, rather than the cause. It would be of interest to test whether targeting the NPC rescues/prevents TDP-43 pathology using siRNA-mediated silencing of Nups or pharmacological inhibition, as the authors did to show modest improvement in survival or eclosion, respectively. Providing such evidence could help convincingly determine whether NPC deficits cause TDP-43 pathology in CTE.</p><p>3. Line 123: 361 proteins were significantly found to be associated with TBI. Were these consistently found to be impaired with all replicates? The criteria used to select those 361 should be described. This would ascertain their relevance.</p><p>4. Figure 2: The sophisticated TBI rat model where trauma seems to be induced unilaterally and provokes TDP-43 pathology in the ipsilateral hemisphere could provide a unique system to test whether TDP-43 aggregates spread with time within the nervous system. It would be of interest to analyze the contralateral side and assess where TDP-43 pathology is also eventually recapitulated.</p><p>5. Figure 3 provides elegant evidence for functional rescue of NPT deficits using pharmacological inhibition (using KPT-compound derivatives). Was survival or TDP-43 pathology also improved?</p><p>6. There are differences between images shown in Figure 2A: not all cells (stained with Dapi) are Nup positive in the control flies (while it appears to be the case in the TBI larvae). What could be the reason? Are there different cell types represented in control versus TBI?</p><p>7. Figure 2B: NPC signal is not consistent between figure 2A and figure 2B (which appears very dotty in the latter), albeit it should be similar: can the authors clarify this discrepancy?</p><p>8. Figure 6: the increased intensity of Nup62 IHC signal reported in TBE patients is not fully consistent with that shown by immunofluorescence. Hence the overall IHC background signal is much higher in the patient tissues compared to the single control shown. Including additional controls would strengthen the data.</p><p>9, There are some problems with the references. For example: reference 45 (line 121) is not correct here, it should be reference 47. Similarly, on page 134, the references stating that &quot;NPC associated with neurodegenerative&quot; are not correctly cited. They should include Chou et al., 2018; Ditsworth et al. 2017, Zhang et al., Coyne et al., 2020 Neuron, Gasset-Rosa et al., 2019…</p><p>10. Figure 2H: the main section of the text refers to arrows/arrowheads that should point at RanGAP1 abnormal staining but they are missing in the figure itself.</p><p>11. Line 235: figure citation is not correct. It should be figure 3G (and not Figure 5G).</p><p><italic>Reviewer #3:</italic></p><p>In this study, Anderson and colleagues present data showing that traumatic brain injury (TBI) in <italic>Drosophila</italic> upregulates expression of Nucleoporins (Nups) that in turn impacts nucleocytoplasmic transport (NCT) by taking an untargeted proteomics approach. The authors further explore the effect of Nup upregulation on the aggregation of TDP-43 (TDPH), a protein whose aggregates are a hallmark of several neurodegenerative diseases; importantly chronic traumatic encephalopathy (CTE), a disease that affects those who play high contact sports such as American football. The authors provide convincing data showing that TBI increases Nup expression and affects (likely-pathological) TDP43 aggregation not just in <italic>Drosophila</italic> but consistently in a rat model. They also include data from patient samples to show that increased expression of NUP62 and TDP-43.</p><p>Overall, the data presented are very compelling and demonstrative of the power of a multi-species approach (<italic>Drosophila</italic>, rat and human) to explore disease related biology that is translatable and consistent across multiple systems.</p><p>1. Line 150 and 414: Here, the authors claim they measured the &quot;Nup214 protein stability&quot;. Also in the discussion, they state &quot;In support, our data showed the Nup214 stability and turnover is impaired by repeated traumatic injury in fly brains. It is possible that the slow turnover of Nup214 might be due to dysfunction in protein clearance pathways (e.g. autophagy).&quot; However, what they are doing here is a simple western blot at different time points post-TBI, and it is difficult to tease out differences in protein stability from mRNA/protein synthesis using this strategy. If the authors really want to claim that this is altering protein turnover, one should perform a western upon stopping translation (e.g. cycloheximide application) to claim that the changes that they see are indeed due to alterations in protein stability (not sure how feasible this is in their experimental setting in vivo). Otherwise, they need to do some sort of pulse labeling and tracing experiment. Note that they show that mRNA level of Nup214 (shown as Nup-214 in Fig1I) does increase in adults and larva (Fig1I, K). Hence, both increase in transcription and translation or mRNA stability may all contribute to the increase in Nup214 protein in addition to increased protein stability. If it is difficult to perform these experiments to concretely say that there is a defect in protein stability, the authors should reword their text to say they observe an alteration in &quot;Nup214 protein levels&quot; and not strongly state there is a defect in proteostasis of Nup214 since they don't have direct evidence.</p><p>2. Based on the authors model, TBI causes upregulation of certain Nups, which in turn causes TDP-43 aggregation, which then causes neurodegeneration. While the data presented in this paper supports this model, it is also possible that TBI first causes TDP-43 aggregation, which then causes upregulation/aggregation of Nups which then leads to neurodegeneration. I feel the second model is not discussed here and cannot be ruled out since certain experiments are lacking to prefer the first model over the second model. The difference of the two model is whether TDP-43 is upstream or downstream of Nup. For example, if one over-expresses TDP-43 in the absence of TBI, what happens to Nup expression and localization? Can one suppress the short lifespan and motor phenotype caused by over-expressing certain Nup by simultaneously knocking down TDP-43? It is possible both Model 1 and 2 are both correct, and in this case this may suggest that TDP-43 and Nups can regulate each other, causing a vicious cycle in TBI pathogenesis.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67587.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>As you will see from the reviews below, and from our subsequent discussion, we were enthusiastic about the paper. The reviewers ask a number of questions that are listed below, but there are two items we all agreed on that we hope you will be able to address, possibly by including new experiments or by textual changes:</p><p>1. You currently do not directly demonstrate the stability of Nups. We suggest to either reword the text or include a pulse-chase experiment to study the stability of Nups;</p></disp-quote><p>The reviewer made a great point, and we fully agree that a pulse-chase assay would help in clarifying the stability of Nups. We thought about doing a pulse-chase experiment in our fly model of traumatic brain injury (TBI). However, Cycloheximide treatment in <italic>Drosophila</italic> at larval or adult stages leads to lethality (Marco et al., Toxicology Letters, 1982). Moreover, the animal’s post-traumatic injury become symptomatic (Anderson et al., HMG 2018) and we suspect that treating them with cycloheximide would make their phenotypes obviously worst (even lethal) as reported previously, making it difficult to perform this assay in vivo. Therefore, we are rewording our statement about the stability of Nups.</p><p>This section now reads “We next asked if trauma alters endogenous nucleoporin protein levels overtime. To address this, we measured Nup214 protein levels in trauma and control larval and adult brains. We performed time-course analysis on larval (0, 2, 4, and 6 hours) or adult (0, 2, 4, 24, and 72 hours) animals’ post-injury to assess Nup214 protein level by Western blot analysis. Interestingly, we found that Nup214 protein levels remain upregulated in both larval and adult brains over the time point examined (Figure 1P-S), suggesting that trauma probably disrupts Nup214 levels and possibly turnover in vivo.”</p><disp-quote content-type="editor-comment"><p>2. Clearly discuss the two possible models i.e. TDP-43 aggregation leads to Nup alterations or vice versa; or include experiments that clarify this relationship.</p></disp-quote><p>This is another great point that the reviewer 3 made. In collaboration with Dr. Christopher Donnelly (senior author), we have a manuscript under review that defined the relationship between TDP-43 aggregation and Nup62 sequestration in iPSC motor neurons, HEK293T cells, and ALS patient postmortem tissues. In order to publicly share our unpublished data while under review, we uploaded our collaborative manuscript titled “Nup62 is recruited to pathological condensates and promotes TDP-43 insolubility in C9orf72 and sporadic ALS/FTLD” on Research Square site (Gleixner et al.,). Here is a link. https://www.researchsquare.com/article/rs<sup>-1</sup>44654/v1</p><p>Briefly, in our collaborative manuscript (Gleixner et al., 2021 PREPRINT), we report how TDP43 promotes nuclear depletion and cytoplasmic sequestration of Nup62 in ALS/FTD patient iPSC neurons. We found that formation of TDP-43 containing stress granules promotes the nuclear loss and sequestration of Nup62 in vitro and in vivo. Our data suggests that cytoplasmic Nup62 and TDP-43 interactions are pathological in nature and result in insoluble assemblies in both familial and sporadic ALS/FTD postmortem brain tissues (Gleixner et al., 2021 preprint). More importantly, cytoplasmic Nup62 droplets interaction through the NLS likely alter cytoplasmic TDP-43 phase transition resulting in insoluble inclusions. In addition to this, a recent study has shown that aggregated and pathogenic mutations in TDP-43 promote the sequestration and mislocalization of nucleoporins in mouse primary cortical neurons, human fibroblasts and induced pluripotent stem cell–derived neurons (Chou et al., 2018 Nature Neuroscience). Importantly, nuclear pore pathology has been observed in brain tissue in cases of sporadic ALS and those carrying pathogenic mutations in TDP-43 and C9orf72 (Chou et al., 2018; Cook et al., 2020).</p><p>Altogether, the abovementioned studies demonstrate the role of TDP-43 in sequestering nucleoporins in sporadic and familial forms of human neurodegenerative diseases. We are including details about both papers in the Discussion section of our manuscript. This section the discussion now reads:</p><p>“Recent data from our and Dr. Donnelly’s lab have demonstrated that cytoplasmic Nup62 droplets exhibit characteristics of proteins that undergo liquid-liquid phase separation, and it is likely that these interaction through the classical NLS promotes deleterious phase transition of cytoplasmic TDP-43 causing it to mature into insoluble inclusions (Gleixner et al., 2021 PREPRINT), providing a mechanism for how Nups might promote TDP-43 pathology in traumatic injury. […] Moreover, the synergistic effects of both mechanisms cannot be ruled out as cause of neurodegeneration in traumatic injury.”</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>[…] The authors convincingly demonstrate that TBI provokes morphological and functional alterations in NPC and nucleocytoplasmic transport, which can be partially improved by pharmacological inhibition of nuclear export thus providing mechanistic insight with potential therapeutic avenue. That being said, there are some aspects that need to be clarified to fully support all claims.</p><p>1. In figure 1 the authors conclude that trauma increases stability of Nup214, as increased accumulation of Nup214 is observed (by WB) with time of post-traumatic injury. However, the authors also report that mRNA levels are increased and the time course provided does not allow to fully exclude that Nup enhanced levels may occur predominantly at the transcriptional level (rather than at the protein level due to reduced turnover and/or increased stability as claimed by the authors). To substantiate the authors' conclusion on the effects of enhanced stability, pulse-chase/cycloheximide experiments should be considered.</p><p>Strengthening such evidence on stability is even more critical given this is in contrast with previously published studies describing a loss (or reduction) rather than increase of NPC components during neurodegenerative processes (Coyne et al., 2020 Neuron; Chou et al. 2017 Nat Neurosc) or aging (D'Angelo et al., 2009 Cell).</p></disp-quote><p>Please see our response (1 and 2) to the essential comments where we addressed these issues.</p><disp-quote content-type="editor-comment"><p>2. In their original study describing the TBI <italic>Drosophila</italic> model (Anderson et al. 2018 HMG) the authors had proposed that repetitive trauma induces TDP-43 mislocalization and stress granule formation. Here the authors suggest that TDP-43 pathology may be caused by TBI-induced NPC deficits as cautiously stated &quot;TBI leads to NCT defects, which potentially mediate the TDP-43 pathology in CTE&quot;. Given the ample evidence demonstrating that TDP-43 demixing/aggregation induces (in vitro and in vivo) NPC deficits with possible sequestration of some NPC components together with TDP-43 aggregates (Chou et al., 2017 Nat Neuros, Ditsworth et al. 2017 Acta Neuropath, Zhang et al., 2018 Cell, Gasset-Rosa et al. 2019 Neuron), nucleocytoplasmic transport deficits could thus be a consequence of cytoplasmic TDP-43 pathology, rather than the cause. It would be of interest to test whether targeting the NPC rescues/prevents TDP-43 pathology using siRNA-mediated silencing of Nups or pharmacological inhibition, as the authors did to show modest improvement in survival or eclosion, respectively. Providing such evidence could help convincingly determine whether NPC deficits cause TDP-43 pathology in CTE.</p></disp-quote><p>As suggested by the reviewer, we fed adult <italic>Drosophila</italic> KPT-350 (0.05mM and 0.5mM or DMSO) for 10 days and found dose-dependent reduction in Tbph aggregation and have incorporate this new data in (Supplementary Figure 4).</p><disp-quote content-type="editor-comment"><p>3. Line 123: 361 proteins were significantly found to be associated with TBI. Were these consistently found to be impaired with all replicates? The criteria used to select those 361 should be described. This would ascertain their relevance.</p></disp-quote><p>The 361 genes are just those whose p-value between TBI and non-TBI is ≤ 0.05. When we did both &gt;1.6-fold up or down and p≤0.05, there were 246 genes that were altered and present “TBI Proteome”. The GO analysis accepted all genes changed &gt;1.6-fold and p ≤ 0.1 to get enough genes to do GO analysis on. These genes were consistently observed in all replicates. We are including these details in the methodology section.</p><disp-quote content-type="editor-comment"><p>4. Figure 2: The sophisticated TBI rat model where trauma seems to be induced unilaterally and provokes TDP-43 pathology in the ipsilateral hemisphere could provide a unique system to test whether TDP-43 aggregates spread with time within the nervous system. It would be of interest to analyze the contralateral side and assess where TDP-43 pathology is also eventually recapitulated.</p></disp-quote><p>We agree with the reviewer. Further studies in the TBI rat model are ongoing and we plan to examine propagation, aggregation and spreading of TDP-43 pathology in different parts of the rat brain over time. It is going to take us several months to perform and analyze these assays in a rodent model. This is beyond the scope of our current manuscript.</p><disp-quote content-type="editor-comment"><p>5. Figure 3 provides elegant evidence for functional rescue of NPT deficits using pharmacological inhibition (using KPT-compound derivatives). Was survival or TDP-43 pathology also improved?</p></disp-quote><p>We agree with the reviewer. Further studies in the TBI rat model are ongoing and we plan to examine propagation, aggregation and spreading of TDP-43 pathology in different parts of the rat brain over time. It is going to take us several months to perform and analyze these assays in a rodent model. This is beyond the scope of our current manuscript.</p><disp-quote content-type="editor-comment"><p>6. There are differences between images shown in Figure 2A: not all cells (stained with Dapi) are Nup positive in the control flies (while it appears to be the case in the TBI larvae). What could be the reason? Are there different cell types represented in control versus TBI?</p></disp-quote><p>All cells stained with DAPI are Nup positive in Figure 2A. Careful analysis of Figure 2A control image will show that the DAPI signals are surrounded by Nup staining albeit the signal is lower in some of the cells. This might be because of antibody penetration issues (technical). We hope the reviewer can appreciate the effort in acquiring these images, as it is difficult to get Nup antibody that stain <italic>Drosophila</italic> tissues uniformly. Furthermore, even within the same <italic>Drosophila</italic> brain tissue there can be some level of variation in the staining pattern of NPC. Hence, we quantify abnormal NPC staining pattern (Figure 2B) in cells located specifically along the midline of the VNC because these cells showed robust and consistent NPC staining.</p><disp-quote content-type="editor-comment"><p>7. Figure 2B: NPC signal is not consistent between figure 2A and figure 2B (which appears very dotty in the latter), albeit it should be similar: can the authors clarify this discrepancy?</p></disp-quote><p>We believe that the reviewer is referring to Figure 2A and 2C. The two images are different in that Figure 2A is only stained with NPC marker Mab414 (imaged in the 568 channel), while Figure 2C is stained with both Mab414 (488 channel, green) and Tbph (568 channel, red) which seems to cause minor alteration in the NPC signal. We hope the reviewer can appreciate that although there was minor effect on the signal when double labeling with Mab414 and Tbph antibodies was done, the abnormal NPC morphology are consistent and still present in Figure 2B</p><p>(inset).</p><disp-quote content-type="editor-comment"><p>8. Figure 6: the increased intensity of Nup62 IHC signal reported in TBE patients is not fully consistent with that shown by immunofluorescence. Hence the overall IHC background signal is much higher in the patient tissues compared to the single control shown. Including additional controls would strengthen the data.</p></disp-quote><p>We are including additional high quality IHC images of two controls in our revised manuscript (please see Supplementary Figure 12).</p><disp-quote content-type="editor-comment"><p>9, There are some problems with the references. For example: reference 45 (line 121) is not correct here, it should be reference 47. Similarly, on page 134, the references stating that &quot;NPC associated with neurodegenerative&quot; are not correctly cited. They should include Chou et al., 2018; Ditsworth et al. 2017, Zhang et al., Coyne et al., 2020 Neuron, Gasset-Rosa et al., 2019…</p></disp-quote><p>We apologize for this error. We have checked every reference carefully and corrected them.</p><disp-quote content-type="editor-comment"><p>10. Figure 2H: the main section of the text refers to arrows/arrowheads that should point at RanGAP1 abnormal staining but they are missing in the figure itself.</p></disp-quote><p>We have added the arrows/arrowheads in the figure. Thanks for pointing out this mistake.</p><disp-quote content-type="editor-comment"><p>11. Line 235: figure citation is not correct. It should be figure 3G (and not Figure 5G).</p></disp-quote><p>We have corrected the figure citation.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>[…] 1. Line 150 and 414: Here, the authors claim they measured the &quot;Nup214 protein stability&quot;. Also in the discussion, they state &quot;In support, our data showed the Nup214 stability and turnover is impaired by repeated traumatic injury in fly brains. It is possible that the slow turnover of Nup214 might be due to dysfunction in protein clearance pathways (e.g. autophagy).&quot; However, what they are doing here is a simple western blot at different time points post-TBI, and it is difficult to tease out differences in protein stability from mRNA/protein synthesis using this strategy. If the authors really want to claim that this is altering protein turnover, one should perform a western upon stopping translation (e.g. cycloheximide application) to claim that the changes that they see are indeed due to alterations in protein stability (not sure how feasible this is in their experimental setting in vivo). Otherwise, they need to do some sort of pulse labeling and tracing experiment. Note that they show that mRNA level of Nup214 (shown as Nup-214 in Fig1I) does increase in adults and larva (Fig1I, K). Hence, both increase in transcription and translation or mRNA stability may all contribute to the increase in Nup214 protein in addition to increased protein stability. If it is difficult to perform these experiments to concretely say that there is a defect in protein stability, the authors should reword their text to say they observe an alteration in &quot;Nup214 protein levels&quot; and not strongly state there is a defect in proteostasis of Nup214 since they don't have direct evidence.</p></disp-quote><p>We have addressed this issue in more details in the “essential comment” section</p><p>(comment 1). We agree with the reviewer and we are re-wording our statement about the Nup62 protein stability and toning it down. Specifically, we have removed the word “stability” and replaced it with “Nup214 protein levels” as suggested by the reviewer.</p><p>Due to technological obstacles, we are unable to perform a pulse chase experiment in vivo. We agree that the Nup214 mRNA levels are also increased suggesting that both TBI impacts nucleoporins at transcription and translational levels. We have added a statement addressing both possibilities in the discussion (see response to comment #15).</p><disp-quote content-type="editor-comment"><p>2. Based on the authors model, TBI causes upregulation of certain Nups, which in turn causes TDP-43 aggregation, which then causes neurodegeneration. While the data presented in this paper supports this model, it is also possible that TBI first causes TDP-43 aggregation, which then causes upregulation/aggregation of Nups which then leads to neurodegeneration. I feel the second model is not discussed here and cannot be ruled out since certain experiments are lacking to prefer the first model over the second model. The difference of the two model is whether TDP-43 is upstream or downstream of Nup. For example, if one over-expresses TDP-43 in the absence of TBI, what happens to Nup expression and localization? Can one suppress the short lifespan and motor phenotype caused by over-expressing certain Nup by simultaneously knocking down TDP-43? It is possible both Model 1 and 2 are both correct, and in this case this may suggest that TDP-43 and Nups can regulate each other, causing a vicious cycle in TBI pathogenesis.</p></disp-quote><p>The reviewer made a valid point. We remain unbiased and open about both models.</p><p>It has been previously reported that overexpression of a C-terminal fragment of TDP-43 (TDP43-CTF) itself in primary cortical neurons perturbed Nup98 localization and distribution. This is further evident from mAb414 staining showing that TDP43-CTF overexpression is sufficient to cause FG Nup pathology (Chou et al., 2018). These findings suggesting a cascade of events due to defects in nucleocytoplasmic transport processes. We plan to follow up on the experiments that the reviewer suggested to directly assess which mechanism(s) are involved and which model is more relevant to TBI-mediated neurodegeneration. We are including statements about both models in the Discussion section (see response to essential comment #2).</p></body></sub-article></article>